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Abstract  
Glioblastoma multiforme (GBM) is a malignant tumour of astrocytes in the brain 
which accounts for approximately one third of all tumours in the nervous system. 
Despite the availability of chemotherapy, the median survival rate for all patients is 
between 15 to 24 months. Temozolomide (TMZ) and carmustine (BCNU) are the 
most common chemotherapeutic agents used in combination with radiotherapy or 
surgery to treat GBM. The overexpression of PrP
c
 in GBM has been reported and its 
involvement in the resistance to alkylating agents (TMZ and BCNU) was speculated. 
The exact role of PrP
c 
in GBM, i.e. how it is affected by chemotherapeutic agents and 
small molecules, needs to be further investigated. 
In this work, the effect of TMZ and BCNU on PrP
c
 was evaluated using U87 
glioblastoma cell line. The results showed that 24 h treatment with TMZ or BCNU 
followed by 48 h resting gave the highest level of G2/M cells (about 84%) when 
compared with untreated cells. The upregulations of p53 and p21 are believed to be 
the key cause for this increment. PRNP gene is also upregulated in TMZ or BCNU 
treated U87 cells for 24 h treatment followed by 48 h resting and this may contribute 
to the resistance these cells towards the treatments due to the cytoprotective effect of 
this protein despite less PrP
c
 is detected at protein level. Some of these findings are in 
agreement while others are opposite to those previously reported. 
The resistance to chemotherapy is considered as one of the main limitations for the 
effective treatment of cancer, especially for GBM. PRNP gene in U87 cell line was 
silenced to determine cell proliferation and chemoresistance. A decrease of 80% in 
PrP
c
 level was obtained after 48 h of treatment with transfection reagents. 
Additionally, the level of the PrP
c
 knockdown was retained 5 days post-knockdown. 
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- XIII - 
 
Silencing of the PRNP gene in glioblastoma cell line U87 reduces cell proliferation in 
a time-dependent manner. In addition, positive cells with proliferation marker ki67 
were significantly decreased in knockdown cells after 5 days. This implies that PrP
c
 
contributes to the malignance of the cancer cells. It was also found that there was no 
significant reduction in cell proliferation in response to TMZ or BCNU in knockdown 
cells and p21 is upregulated in TMZ or BCNU knockdown cells. Therefore, silencing 
PRNP gene may impact the function of p21 which contributes to the resistance to 
alkylating agents TMZ and BCNU.  
In an attempt to sensitise U87 cells to TMZ, the combination treatment of MG132 
with TMZ did not improve the apoptosis rate and no accumulative effect was 
observed. High concentration of MG132 increased the level of PrP
c
 in U87 cells after 
a short incubation time.  
The level of PrP
c
 was also evaluated in U87 cells treated with the compounds (FAPi) 
which inhibit the Fancony Anaemia (FA) pathway by reduction of FANCD2 using 
high content imaging by ImageXpress Micro. These compounds did not affect the 
level of PrP
c
 in these cells with or without combination with TMZ or BCNU showing 
that these FAPi are target specific.  
Several novel families of heteroaromatic compounds (30 compounds) previous shown 
to be cytotoxic to embryonic carcinoma cells (NT2) were screened on U87 cells and 
eight of them were found to be inhibit the proliferation of the cells. The compound 
175 that belongs to the acridine family induced apoptosis for U87 cells. It also arrests 
U87 cells in G2/M and upregulate p53 and p21 proteins which are regulatory for cell 
cycle. That may open the door to examine more acridine compounds as anti-
glioblastoma agents.    
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SD Standard deviation  
siRNA Small interfering RNA 
SMAC Second mitochondrial protein 
SOD Superoxide dismutase 
SOD1 Superoxide dismutase 1 
SSC Side scatter 
STI1 Stress inducible protein 1 
TBS Tris buffer saline  
TBS-T Tris buffer saline with triton  
TMZ Temozolomide  
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TP53 Tumour protein p53 
TRAIL TNF-related apoptosis-inducing ligand 
Ub Monoubiquitin  
UPR Unfolded protein response 
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Chapter 1: Introduction and Literature Review  
1.1 Introduction 
 
Glioblastoma multiforme (GBM) or Grade IV astrocytoma is a primary malignant 
brain tumour that can afflict most glial cells. It is an aggressive, and fatal disease, 
accounting for about one third of all tumours in the nervous system
1
. The median 
survival rate of this type of cancer is very short (up to two years). GBM affects a large 
number of heterogeneous brain cells and is more aggressive, angiogenic, genetically 
unstable and chemotherapeutic-resistant tumour than other types of astrocytomas. 
Radiotherapy followed by temozolomide (TMZ) is a current standard treatment 
regimen for GBMs after a surgical operation
2
. However, resistance evolves rapidly 
during the treatment and the cause for the resistance is poorly understood which 
results in ineffective treatment and poor prognosis. Therefore, further research is 
required in the area. 
Although the exact biological role of cellular prion protein (PrP
c
) remains enigmatic, 
many studies have revealed that PrP
c
 is involved in various cellular functions, 
including oxidative stress, apoptosis, cell migration, cell-cell signalling, regulation of 
the immune system, proliferation and copper metabolism etc. This mix of functions 
would suggest that PrP
c 





. Comincini and co-workers have shown that tissue samples from 
GBM tumours exhibit a high level of PrP
c
 expression compared to other grades of 
brain tumour
5
. TMZ induces cell cycle arrest in the G2/M phase, but it is has been 
noticed in vitro that TMZ-resistant GBM cells exhibit an upregulation of PRNP 
expression at this phase of the cell cycle
6
.  
Chapter 1: Introduction and Literature Review 
- 2 - 
 
One of the important issues concerning cancer treatment is chemoresistance since this 





 is thought to be involved in chemotherapeutic resistance for many 
types of cancers
8
, and this poses the question: what is the effect of PrP
c
 on the 
resistance of GBM cells treated with alkylating agents? 
Recently, proteasome inhibitors have been used to treat cancers such as multiple 
myeloma and are under examination for other types
9
 because the ubiquitin 
proteasomal pathway has a crucial role for proteolysis of most intracellular proteins 
and regulation of many cellular processes such as the differentiation, apoptosis and 
the cell cycle. In addition, the proteasome is responsible for the regulation of tumour 
suppressors, cell cycle regulators and transcription factors which are closely related to 
cancer development
10
. The proteasome inhibitor MG132, for example, is a peptide 
aldehyde that suppresses the growth of many kinds of tumours by arresting the cells in 
G2/M and inducing apoptosis
11
. MG132 reduces the aggressiveness of glioma cells by 
inhibiting their proliferation and promoting apoptosis
12,13
. Besides the effect of 
MG132 on apoptosis of glioblastoma cells, it has been found that the PrP
c
 expression 
level is increased in neuron cells N2a and N2a-PrP when treated with MG132
14
 as 
will be described in Section 5.1 of Chapter 5 of this thesis. Despite the effect of 
MG132 on glioma cells, its effect on these cells when used in combination with TMZ 
has not been investigated.  PrP
c
 level in U87 cells treated with MG132 also needs to 
be assessed.      
The Fanconi anaemia (FA) pathway is a DNA repair pathway and often responds to 
DNA damage, replication arrest and other disruptions which are produced by 
alkylating agents such as TMZ and carmustine (BCNU)
15
. Interestingly, as 
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chemotherapeutic agents, TMZ and BCNU have been shown to stimulate the FA 
pathway by upregulating of FANCD2. Inhibition of the FA pathway by silencing the 
key part of this pathway (FANCD2) has therefore been found to improve cell 
sensitivity to TMZ and BCNU
16
. Recently, Abhijit et al. revealed that FANCD2 
expression is upregulated in GBM compared to normal brain tissue and other grades 
of astrocytoma. The combination of some small molecules with TMZ or BCNU, 
therefore, served to sensitise glioblastoma cells to these treatments by inhibiting the 
FA pathway
17
. In previous work from our group (unpublished data), many novel small 
molecules were examined and shown to inhibit the FA pathway. We assume that such 
molecules may also affect the level of PrP
c
 in U87 cells because it has also previously 
been suggested that amide scaffolds can lower the level of PrP
c
 in T98G glioblastoma 
cells
18
 (this will be detailed in chapter 6).       
In this thesis, we hypothesised that the treatment of U87 cells with alkylating agents 
TMZ and BCNU might influence the prion protein expression level as a result of the 
accumulation of cells in G2/M and this effect might induce the resistance to these 
agents. Therefore, we first looked at the expression of PrP
c
 and its gene in different 
phases of the cell cycle in U87 cells treated with TMZ or BCNU. Silencing of PRNP 
gene was performed to study the effect of PrP
c
 on the sensitivity of U87 cells to TMZ 
and BCNU treatments. We then examine the impact of the MG132 proteasomal 
inhibitor on the level of PrP
c
 in U87 cells and the apoptotic effect of the MG132-TMZ 
combination on these cells. The possible efficacy of the novel drug combinations that 
inhibited the FA pathway was also assessed to determine the PrP
c
 level in U87. The 
potential anticancer effect of other novel small molecules was also screened here to 
evaluate their cytotoxicity on U87 cells. 
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1.2 Review of literature  
 
Through the literature survey, the possible links between the cellular prion protein 
(PrP
c
) in cancers, including GBM, and the challenges associated with the resistance of 
glioblastoma cells to the chemotherapies (TMZ and BCNU) commonly used to treat 
this aggressive and often fatal disease can be established. The overexpression of PrP
c
 
in GBM has been identified in many studies as well as its involvement in 
underpinning resistance to alkylating agents due to interaction with apoptotic 
pathways. The possibility of the resistance could be attributed to the accumulation of 
cells in G2/M phase, and PrP
c
 and its gene may have different expression in the G1 
phase compared to the G2/M phase. Specifically, the upregulation of PrP
c
 may protect 
GBM cells due to the cytoprotective effect of this protein. 
Within the cell cycle, the G2/M phase represents the response to DNA damage 
induced by various stimuli and is a vitally important staging point to ensure that cells 
do not trigger mitosis until damaged DNA is sufficiently repaired. p53 plays a crucial 
role in DNA repair and can regulate the cell cycle with its transcriptional target p21 
and arrest the cells in G2/M.  
The molecular mechanisms of PrP
c
’s involvement in the response of GBM cells to 
chemotherapy have yet to be investigated. Work in this area is promising and may 
provide significant improvements in how GBM cells respond to chemotherapeutic 
treatments. We hypothesised that treatment of U87 cells, as a model of glioblastoma, 
with alkylating agents TMZ and BCNU will result in the upregulation of prion protein 
due to the accumulation of cells in G2/M. This upregulation may induce resistance 
toward these treatments. Furthermore, the silencing of the PRNP gene may sensitise 
U87 cells against TMZ or BCNU. We also speculated that the combination of small 
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molecules with TMZ or BCNU could inhibit the expression of PrP
c
 in U87 cells. The 
following chapters of this thesis will outline a series of investigations, as described in 
section (1.2.8).   
1.2.1 Programmed cell death and cancer 
 
Programmed cell death is a process referring to the normal biological fate of the cell 
which is carried out by either apoptosis, autophagy or programmed necrosis to keep a 
balance between the living and dead cells. The apoptosis can be triggered by several 
biochemical and morphological changes such as nuclei shrinking, DNA fragmentation 
and condensation, and loss of cell-cell adhesion or extracellular matrix adhesion
19
. 
Autophagy occurs in response to cellular stress resulting from the lack of nutrients or 
growth factors
20
. It plays an important role in the preservation of tissue homeostasis 
and administrates many physiological processes such as cell differentiation, starvation, 
cell death and survival
21
. In addition to apoptosis and autophagy, programmed 
necrosis has recently identified as programmed cell death characterised by swelling, 
organelle dysfunction and cell lysis
22
. Disruption of any these regulatory mechanisms 
will in general result in cancer, including GBM. 
It is known that cancer can cause various alterations in cell signalling pathways which 
occur as a result of gene mutation
23
. Apoptosis serves to maintain a healthy body 
system by removing old cells. There are two main pathways inducing apoptosis: the 




The extrinsic pathway is activated by death receptors such as tumour necrosis factor 
(TNF) receptors: DR4 (TRAIL-R1), DR5 (TRAIL-R2), TNF-R1, Fas, DR3 and DR625. 
These receptors bind their related extracellular ligands. Fas binds to its receptor when 
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exposed to death stimuli, such as DNA damage and drugs, to form the Fas/Fas-L 
complex. This complex then recruits Fas-Associated protein with Death Domain 
(FADD) and pro-caspases 8,10 to form the death-inducing signalling complex (DISC) 
as an initiator to activate caspase 8, which in turn triggers the activation of caspases 3, 
6 and 7
26
. In addition, p53 can transactivate multiple other death receptors, such as 
DR5 and Fas, through its downstream effect, which is activated in response to DNA 
damage
27
. Moreover, BH3 interacting-domain death agonist (Bid) is activated by the 
active caspase-8. Bid triggers Bax and Bak (pro-apoptotic factors)
28
 and leads to the 
continuation of the intrinsic apoptotic pathway (Figure 1-1).  
The intrinsic pathway, meanwhile, is regulated by mitochondrial pro-enzymes. 
Upregulation of oncogenes or DNA damage DNA can stimulate this pathway
29
. In 
addition, other factors can also stimulate the intrinsic pathway such as growth factor 
deficiency, excess Ca
2+
 and DNA damage molecules
30
. Furthermore, Bcl-2 family 
proteins play an effective role in the mitochondrial pathway through permeabilisation 
of the mitochondrial membrane. The activation of mitochondria is regulated by either 
Bcl-2 pro-apoptotic proteins or Bcl-2 anti-apoptotic proteins
31
. According to several 
studies, these proteins are upregulated in different kinds of cancer
32
. Bax and Bak as a 
pro-apoptotic multi domain BH3 are necessary for mitochondrial apoptosis which 
activates mitochondria to release cytochrome c
33
. Cytochrome c is released from the 
mitochondria and then binds to apoptotic protease-activating factor 1 (Apaf 1) and 
procaspase 9 to form the apoptosome. The apoptosome triggers the signalling of 
caspases which are implicated  in apoptosis, such as caspase 3
34
. Additionally, the 
pro-apoptotic proteins Bim, Bid and Bad activate Bax/Bak signalling, which is 
activated by p53
35
, and this may be inhibited via anti-apoptotic proteins Bcl-2, Bcl-
XL, and Mcl-1
36
. As a tumour suppressor factor p53 has a crucial role in 
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mitochondrial apoptosis through its activation of Bax
37
. Bcl-2 suppresses 
mitochondrial apoptosis by inhibiting transcription of Bax and Bak
38
 (Figure 1-1).  
 




Autophagy is an evolutionarily catabolic process which occurs under different 
circumstances such as extra or intracellular stress. In this physiological process, the 
cells recycle excess cytoplasmic components via lysosomal degradation, which is 
regulated by some autophagy-related genes
39
.   In cancer, autophagy faces a challenge 
of whether to protect live cells or to promote cell death. It has been reported that the 
activity of autophagy protects malignant cells in the early stages of cancer. In contrast, 
autophagy can decrease the effect of cancer by promoting pro-autophagic genes and 
suppressing anti-autophagic genes. The autophagic pathway is promoted and 
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regulated by different cytosolic pathways including LC3, p53, mTORC1/C2, Beclin-1, 
Bcl-2 and PI3K (Class III and I)
40
. 
It has been reported that some forms of necrosis, such as necroptosis, are regulated in 
various cells under normal physiological conditions
22
. During this specific cell death 
process, the components of the cell are released into the extracellular region due to a 
result of cell membrane damage. This can stimulate immune cells and trigger an 
inflammatory response. The malignant tumour may provoke topical inflammation via 
this type of cell death. The activation of programmed necrosis may also participate in 
the reduction of cancer, however
41
. It should be noted that the discovery of the key 
markers of necrotic cell death, such as receptor-interacting protein kinases (RIPKs), 
opens the door to the development of more sophisticated theories of programmed 
necrosis.   
1.2.2 The cell cycle and cancer 
 
In eukaryotic cells, the cell cycle consists of a series of events across four phases: gap 
one or growth 1 (G1), synthesis (S), gap two or growth 2 (G2) and mitosis (M)
42
. In 
G1, the transcription and translation processes increase to produce cellular proteins 
which are important for DNA synthesis. In addition, the number of organelles such as 
ribosomes and mitochondria, also increase in preparation for pre-mitosis steps. This 
phase occupies the longest period in the cell cycle. In the S phase, DNA is 
disentangled and duplicated. The replication of DNA is considered a major event in 
the S phase. Subsequently, during the G2 phase, the cell grows in preparation for cell 
mitosis. The G2/M checkpoint is stimulated, and the cell will be arrested should DNA 
damage occur in this phase
43
. G2 / M is essential for eukaryotic cells to ensure that 
they do not undergo mitosis before any DNA damage is repaired
44
. Before cell 
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division, the chromosomes are separated, and cytokinesis divides organelles and the 
cell membrane into two equal parts. The mitotic (M) phase in animal cells is defined 
by the action of both mitosis and cytokinesis
45
. Generally, the division in eukaryotic 
cells is grouped into two main stages: interphase (G1, S and G2 phase) and mitosis (M 





Figure (1-2): Cell cycle in a eukaryotic cell.  
It has been reported that in cancer cells the cell cycle is always decontrolled, 
potentially promoting abnormal cell proliferation and division
47
. The checkpoints in 
the cell cycle are therefore considered to be good targets for the development of many 
treatments for cancers due to their potential to inhibit cell progression. One treatment 
strategy is to control these checkpoints and disrupt the process of cell division. 
Subsequently, this action activates apoptosis
48
. For instance, 5-fluorouracil inhibits 
DNA replication and taxol has an effect on microtubules, and these drugs are 
currently first-line treatments for breast and colorectal cancer, respectively
49
. These 
treatments are limited, however, in that they are toxic when delivered in high doses
50
.    
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1.2.3 Glioblastoma Multiforme (GBM) 
 
According to the World Health Organization (WHO), astrocytomas can be classified 
into four grades in the following (ascending) order of severity.  
Grade I is a low grade and very slow-growing tumour which commonly occurs in 
childhood. It can often be cured with surgical resection alone.  
Grade II is a low grade and slow-growing tumour that often recurs and develops into a 
higher grade malignant tumour (grade III and IV). Patients with a Grade II tumour 
have a median survival rate of up to 15 years. 
Grade III is a high-grade malignant tumour including anaplastic astrocytoma, 
anaplastic ependymoma, anaplastic oligodendroglioma and anaplastic 
oligoastrocytoma. It has high mitotic activity and may be transformed to grade IV. 
Patients with a Grade III tumour have a survival rate of up to 10 years. 
Grade IV or glioblastoma multiforme (GBM) is more aggressive than grade III, and it 
spreads to other portions of the brain rapidly. The median survival rate of GBM is 
between 15 to 24 months, depending on the prognosis and treatment regimen
51
. 
GBM or grade IV astrocytoma form about half of all gliomas and is a common type of 
offensive malignant tumour
1
. Bastien and collaborators further categorised GBMs into 
primary/de novo or secondary depending on the clinical history of patients. 
Primary/de novo GBMs are the most common type, accounting for about 90%-95% of 
all GBMs, and they are more aggressive, with the tumour progressing than with 
secondary GBMs. Patients with primary glioblastoma are diagnosed without clinical 
or histological evidence of precursor lesions. Secondary GBMs represent about 5%-
10% of the total GBMs and are commonly developed from low-grade astrocytomas 
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(Grade II or III)
1,52
. Although GBMs are often aggressive, they do not normally 




Computed tomography (CT or CAT) scan and magnetic resonance imaging (MRI) are 
sophisticated imaging systems which can accurately localise GBMs
52
. From 
pathological, histological and physiological perspectives, all GBMs display clear 
clinical manifestations, including abnormal proliferation, a decrease in apoptosis, 




As with most other types of cancers, the exact aetiology of GBM is unclear, but it is 
known that risk factors for GBM include exposure to ionising radiation and some rare 
genetic disorders
51
. Nonetheless, GBM shares some common underlying molecular 
events with all other cancers, as detailed below.  
1.2.4 GBM and programmed cell death 
 
In the glioblastoma cells, it was found that there are many regulators for apoptotic and 
homeostatic processes leading to them being over-expressed, mutated or methylated. 
For example, the Bcl-2 protein family, p53, growth factor receptors such as 
phosphoinositide-3 kinase (PI3K)/Akt, mammalian target of rapamycin (mTOR), and 
the TNFR family are all implicated in GBM cell death and survival
55
. 
The expression of the Bcl-2 protein family, whether pro- or anti-apoptotic proteins, is 
inconsistent in patients with different grades of astrocytoma. Krajewski et al. showed 
that the level of the pro-apoptotic proteins was lower in glioblastoma than other 
grades of gliomas
56
, while the expression of Bcl-2 positively correlated with the 
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survival period of patients, regardless of astrocytoma grade
57
. Moreover, in vitro 
studies revealed that cell death is induced in glioblastoma cells by gossypol (an 
extract from the cotton plant), both alone and in combination with temozolomide 
(TMZ). Gossypol binds to Bcl-2 and induces cell death in glioblastoma cells
58
. 
Overall, in U87, MZ-54 and U343 glioblastoma cells, autophagy may be induced by 
gossypol and gossypol-TMZ increases the sensitivity of these cells to TMZ
59
. 
Another set of studies have focused on micro RNA (miRNA), a small RNA that binds 
to complementary sequences of mRNA, inhibiting the translation of mRNA. Of 
particular interest is miRNA21. It has been shown that when this is overexpressed in 
GBM cells, it appears to induce resistance to TMZ by reducing the ratio of Bax/Bcl-
2
60
. Furthermore, it has been found that silencing of miRNA-21 promotes caspase-
induced cell death
61
. Likewise, GBM cells transfected with miRNA-153 also seemed 
to induce cell death through inhibition of Bcl-2. 
The p53 that is encoded by the TP53 gene also has an important role in apoptosis and 
cell cycle regulation
62
. Indeed, according to the Cancer Genome Atlas Research 
Network, the signalling of p53 is altered in 87% of all GBM patients.
63
 Ohgaki et al. 
showed that TP53 mutations frequently occur in GBM and that de novo GBM has 
fewer of these mutations than secondary GBM, 28% to 65%, respectively
64
.  
It has also been reported that growth factors such as epidermal growth factor receptor 
(EGFR), phosphatidylinositol 3-kinases (PI3K/AKT) and mammalian target of 
rapamycin (mTOR) are involved in facilitating apoptosis in glioblastoma cells.  For 
example, inhibition of  PI3K/Akt and mTOR improve survival rates in patients with 
glioblastoma
65
. Similarly, the inhibition of EGFR/mTOR promoted cell death and 
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During apoptosis of cells, TNF-related apoptosis-inducing ligand (TRAIL) binds to 
the death receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2). Although TRAIL binds 
three other types of TRAIL receptors, these do not induce an apoptotic signal in 
human cells
67
. Grund et al. found that DR5 was highly expressed in grade II gliomas 
compared with grade III and that the expression of DR5 correlated with the survival 
time of glioma pateints
68
. Consequently, DR5 is suggested to be the key constituent of 
TRAIL receptors that mediates cell death signalling in human glioma cells
69
. In 
glioblastoma cells, TRAIL inhibitors cause an intrinsic resistance to apoptosis that 
may result from the low expression of caspase 8, high levels of TRAIL-R3 and 
TRAIL-R4, or increasing the expression of TRAIL inhibitors
70
. Many cancer cell 
types, including glioblastoma, have been found to be resistant to the apoptotic stimuli 
of TRAIL. To combat this, the combination of TRAIL with small molecules has been 




1.2.5 Human Prion protein  
 
Over the last few decades, the prion protein has attracted much attention due to its 
role in neurodegenerative diseases, including transmissible spongiform 
encephalopathies (TSE) and Alzheimer’s disease
72
. The term “prion” was introduced 
by Stanley B. Prusiner in 1982 to describe a small proteinaceous infectious particle 
which causes TSE
73
. The prion protein has two isoforms, a normal cellular isoform 
(PrP
c
) and an abnormal infectious isoform (PrP
Sc
) (the superscript Sc refers to scrapie). 
These two isoforms share the same primary sequences but differ in their secondary 
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. The human PrP
c
 is encoded by the PRNP gene which is 
located on the short arm of chromosome 20
74,75
. As well as PrP
c
, there are two other 
members of the prion protein family, Doppal and Shadoo, encoded by PRND, and 
Shadoo/SPRN genes respectively in mammals
76
. In this study, the focus will be on 
PrP
c
 because of its role in many types of cancer. 
1.2.5.1 The structure of human cellular prion protein (PrPc) 
PrP
c
 is a cellular healthy isoform that exists in many organisms. The immature human 
PrP
c
, as a precursor protein, consists of 253 amino acids with a molecular weight of 
approximately 35-36 kDa. PrP
c
 consists of a signalling sequence (1-22), an 
unstructured N-terminal domain (23-113), a hydrophobic region (113-135), a 
structured C-terminal domain (113-232) and GPI-anchor sequence (232-253), as 




 is synthesised in the rough endoplasmic reticulum (ER) 
and glycosylated in the Golgi apparatus where several post-translational modifications 
take place. It is then transferred to the plasma membrane and attaches to lipid rafts, 
membrane microdomains enriched in cholesterol and sphingolipids, via a GPI 
(glycosylphosphatidylinositol) anchor
78,79
, although a small amount of the 
unglycosylated proteins remain in the cytoplasm of the cell
80
. This intracellular 





 is converted from immature to mature form (208 amino acids, 
from 23 to 231) during protein translocation and maturation to the extracellular side of 
the cell membrane, where the immature PrP
c
 loses the signal peptides in the N- and C-
terminals
82
. The median half-life of PrP
c
 is approximately five hours. It is then 
internalised to the cytoplasm through a caveola-dependent mechanism and broken 
down in the endolysosome compartment83,75.  
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The signal peptide at the N-terminal guides the PrP into the ER, where it is co-
translationally transported and synthesised
84
. The N-terminal region consists of four 
octapeptide repeats that have a high affinity to copper ions,
85
 implying that PrP
c
 could 
be involved in copper metabolism
75
. Another study has suggested that there is a 
functional interaction between PrP
c
 and zinc ions via electrostatic interaction
86
. 
Indeed, the formation of a Zn
2+
-PrP complex is seen in many PrP mutations of 
inherited prion diseases
87
. The N-terminal polybasic region and octapeptide repeats in 
PrP
c
 is also believed to be involved in Zn
+2




The hydrophobic region ( ̴ 113-135) connecting the N and C domains is the most 
reserved sequence motif of PrP
c
 in all species known
89
. A hydrophobic sequence may 
serve as a transmembrane domain in some isoforms of the prion protein
75
 and is 
involved in misfolding, oligomerisation and intracellular retention of mutant PrP
90
. 
The C-terminal domain of PrP
c
 consists of three α-helices (α1, α2 and α3), and two 
short antiparallel β-strands (β1 and β2)
89
. It connects to a single sequence for 
membrane attachment via a GPI-anchor
82,77
. The α2 and α3 form the bulk of the 
globular domain and are covalently bridged via a disulphide bond between Cys179 
and Cys214. Two N-linked glycans are also attached at 181 and 197. 
The stability of the human PrP
c
 structure has been attributed to the salt bridges and H-
bonding interactions found between α3-α1 and β2-α2-α3. These interactions drive the 
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Figure (1-3): Human PrP structure (Immature PrP
c
), [consists of 253 amino acids, including a signal 
peptide (1–22), four octapeptide repeats, a hydrophobic domain (113–135), a disulphide bond between 
Cys179 and Cys 214, two glycosidic bonds at positions 181 and 197 and a GPI-anchor (232 – 254)]. 





 is converted into PrP
Sc







 have an identical primary structure, the 
secondary structure of PrP
Sc
 consists of β-sheet instead of α-helices. The structural 
details of  PrP
Sc
 are very limited because this protein and its truncated variant (PrP 27-
30, amino acids ̴ 90-231) are insoluble, resistant to protease and have a strong 
tendency to aggregate
75
. Cryo-electron microscopy and X-ray diffraction at 19.2 Aᵒ, 
however, have shown that the structure of PrP
Sc
 may exist as a four-rung β-solenoid, 
although this result is subject to validation using higher-resolution imaging
91
.  
1.2.5.2 The functions of prion protein  
Varying levels of expression of PrP
c
 have been found in many human cells from 
different parts of the body, such as the brain, nervous system, heart, liver, kidneys and 
lymphoid tissue
3,92
. Although the precise function PrP
c
 is not fully understood, studies 
have suggested its involvement in various cellular functions, including copper 
regulation, protection against oxidative stress, anti-apoptosis, cell signalling, 
proliferation and others. Some of these will be briefly described in the following 
sections.  
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1.2.5.2.1 PrPc and copper regulation 
It has been suggested that PrP
c
 could play a role in the metabolism of copper; that it 
could serve as a recycling receptor for copper ion which in turn overrates the 
endocytosis of PrP
c93
. Brown and collaborators revealed that copper binds with the 
octapeptide repeat region of the N-terminal in five to six positions
94
, but that only two 
of these have higher affinity binding to copper ions
95
. Such high-affinity bindings are 
necessary to facilitate PrP
c
 endocytosis via clathrin-mediated pits
96
. In addition, 
studies of mouse neuroblastoma N2a and the human microglia C13-NJ cells have 
revealed that PrP
c
-copper stimulates the endocytosis of PrP
c
 via a caveolin-dependent 
pathway
97
. Cerebellar cells from PrP
c
 knockout mice contain approximately one-fifth 
of the copper ions of cerebellar cells in wild-type mice. This result suggested that PrP
c
 
may play an important role in copper binding to proteins in the brain
94
. Moreover, the 
copper concentration was reduced by nearly 50% in synaptosomal fractions isolated 
from PrP knockout mice compared to wild type mice
98
.  
1.2.5.2.2 PrPc and oxidative stress  
Many studies have reported that oxidative stress causes upregulation of PrP
c
 
expression in many studies
76
. Watt et al. demonstrated that PrP plays a vital role in 





 maintains oxidative stress-related homeostasis through the PrP-copper complex 
which upregulates superoxide dismutase (SOD)
100





 cells improves cell viability by upregulating SOD, eliminating the superoxide 
anion, and preventing apoptosis mediated by caspase 3/9
101
. The oxidative stress 
markers were significantly increased in brain lysates of PrPc knockout mice compared 
to wild type mice
102,103
. In addition, in an in vivo study, the octarepeat region of PrP
c
 
plays an effective role in reducing copper neurotoxicity in hippocampal neurons
104
. 
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 with manganese protects neuronal cells against Mn-induced GSH 
depletion, ROS generation, caspase-3 activation and DNA fragmentation
105
. Besides, 
β-cleavage in the octapeptide repeat region of PrP
c
 is induced by oxidative stress in 
the presence of copper, and this cleavage produces an N2 fragment which is capable 
of reducing the intracellular ROS induced by serum deprivation in neuronal cells and 
neural stem cells (NSCs)
106,107
. It has also been suggested that PrP
c 
activates the base 
excision repair pathway in response to oxidative stress – mediating DNA damage by 




Despite these findings concerning the role of PrP
c
 in oxidative stress, not all results 
are consistent. For instance, in in vivo studies by Hutter et al. and Steinacker et al. 
suggest that PrP
c
 does not contribute to SOD activity in the spinal cord, spleen or 
brain
109,110
. Another study showed that N2a neuroblastoma cells were protected 
against oxidative stress induced by 3-morpholino synonimine hydrochloride in the 
presence of PrP
c
, but that the protein’s overexpression made N2a cells were more 
sensitive to hydrogen peroxide treatment
111
.   
1.2.5.2.3 PrP
c
 and Bcl-2 family proteins    
It has been shown that PrP
c
 plays an essential role in the survival and death of cells. 
Bcl-2 proteins play a central role in the regulation of cell apoptosis, and the Bcl-2 
homology domain 2 (BH2) is essential for the anti-apoptotic function of Bcl-2
112
. 
Octapeptide repeats of PrP
c
 are highly conserved and share some degree of similarity 
to the BH2 domain of Bcl-2 proteins. PrP
c
 is found to promote the survival of human 
primary neurons cells by protecting against Bax-mediated cell death
113
. The binding 
between PrP
c
 and Bcl-2 was confirmed by a yeast two-hybrid system, Bcl-2 can 
Chapter 1: Introduction and Literature Review 
- 19 - 
 




 increased the survival of mouse neuron cells 
by upregulation of Bcl-2 and downregulation of  Bax
115
. 
Roucou et al., meanwhile, used human neuron cells transfected with Bax plasmid 
and/or PrP plasmid to investigate the effect of PrP and Bax on apoptosis. The cells 
encoded with both Bax and PrP plasmid were protected from apoptosis whereas 
neuron cells injected with Bax plasmid only went into apoptosis
116
. Conversely, the 
inhibition of endogenous PrP by PrP antisense in neurons induces cell death mediated 
by Bax
113
. Studies on human primary neurons and breast cancer MCF-7 cells showed 
that PrP only protected cells from Bax-mediated apoptosis
117
. Since the role of PrP as 
an anti-apoptotic factor could be attributed to its interaction with pro-apoptotic 
proteins which mediated cell death, Westergard and collaborators suggested many 












Chapter 1: Introduction and Literature Review 










Figure (1-4): The proposed mechanism for PrP with Bax to suppression of apoptosis. The apoptosis 
pathways that occur under the action of Bax may be suppressed by PrP in many different ways. A: 
because of the location of PrP on the surface of the cell, it may interact with a putative transmembrane 
receptor and initiate a signal transduction cascade which represses Bax mitochondrial translocation, 
conformational change or oligomerisation. B: PrP in the cytoplasm may interact directly with Bax and 
produce similar effects. C: pro-apoptotic, BH3 only family may be prevented by PrP. D: PrP may 
accelerate the interaction of anti-apoptosis factors such as Bcl-xL and Bcl-2 with Bax. E: downstream 
events in the Bax activation pathway, such as cytochrome c release, activation of Apaf-1 and caspases 
may be inhibited via PrP. F: The function of Bax in the endoplasmic reticulum may be altered by PrP 
affecting the unfolded protein response (UPR) and intracellular calcium. Adapted from Westergard et 
al. with kind permission of Elsevier Group
118
.  
Indeed, Bax-mediated apoptosis involves a sequence of events: Bax conformational 
change, mitochondrial translocation and cytochrome c release which finally cause cell 
death. Roucou and collaborators have reported that through the activation of Bax, PrP
c
 
initially suppresses the conformational change event in breast cancer and neuronal cell 
lines and protects the cells against Bax-mediated apoptosis
119
. Furthermore, 
Westergard et al. mentioned that the conformational change of Bax in serum-free 
medium happened rapidly in PrP
-/-
 hippocampal neurons compared to cells expressing 
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. Another study showed that cytoplasmic PrP has minimal anti-Bax activity and 
is a predominant form of PrP with anti-Bax function in human neurons and MCF-7 
cells
120
. In addition, transfecting cytosolic PrP into neurons protected these cells from 
apoptosis mediated by Bax
116
. The above findings support the mechanisms A and B in 
Figure (1-4). 
Nevertheless, several studies have shown conflicting results regarding the effect of 
cytosolic PrP as an anti-Bax agent. Rambold et al. stated that cytosolic PrP is 
cytotoxic rather than cytoprotective in a number of cells
121
. Other studies on Chinese 
hamster ovary and green monkey kidney cells showed that insoluble PrP is produced 
in the cytosol, which is not affected by proteinase K in the same way as PrP
Sc122,14
. 
Furthermore, the accumulation of even small amounts of cytosolic PrP induced 
neuronal toxicity and caused massive damage in cerebral granule and glial cells in 
transgenic mice
123
. Overall, the interaction of PrP with Bax remains unclear. 
1.2.5.2.4 PrP
c 
and some signalling pathways   
Several studies have suggested that PrP is involved in transmembrane and 
intracellular signalling through interaction with signalling molecules such as Src 
family kinase, Fyn kinase124, stress-inducible protein (STI1)125,126, cyclic adenosine 




 and others. Some 
scholars have argued that the flexible structure of the N-terminal region in PrP
c
 may 
allow it to bond directly to other proteins
129
. These signalling pathways have been 
expected to be affected by PrP
c
 expression or cellular processes which are regulated 
by PrP
c76
. In the neuronal differentiation model 1C11, the interaction of PrP with the 
integral membrane protein caveolin activates P59Fyn signalling which regulates cell 
growth
130
. The interaction of STI1 with PrP has also been shown to induce the 
activation of the signalling pathway via mitogen-activated protein kinase (MAPK), 
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which is important in the development of neuron cells
131
. Chiarini et al. showed that 
PrP
c
-binding peptide stimulates cAMP/PKA and extracellular signal-related kinase 
(Erk) pathways, and partially protects cells from anisomycin-mediated apoptosis in 




 expression affects the activity of both 
PI3K-Akt and ERK1/2 signalling pathways, which have been reported to be involved 




. The activation of the 
PI3K-Akt pathway by PrP
c
 could also explain how PrP
c
 affects cell proliferation
134
. 
Chen et al. revealed that PrP
c
 increased neurite outgrowth and neuronal survival in 
mouse neuron cells resulting from the activation of the signal transduction pathways, 
PI3K/Akt, cAMP and MAPK
115
. It has also been found that PrP
c
 expression triggers 
Src family kinases Fyn /Yes and mediates cell adhesion
135
. 
On the other hand, the interaction of PrP
c
 with other proteins may be indirectly 
regulated by PrP
c
 since other signalling pathways also participate in this interaction
76
. 
For instance, although the PI3K-Akt pathway is assumed to enhance cell 
proliferation
128
, the expression of PrP
c
 may have contradictory effects on proliferation 
in different experimental models.  
1.2.5.2.5 PrP
c
 and cell proliferation  
Studies have revealed conflicting information about the role of PrP
c
 in the regulation 
of proliferating cells. Mice overexpressing PrP
c
 exhibit higher levels of cellular 
proliferation in the adult neurogenic region than wild type and knockout mice, but 
fewer proliferating cells were observed in the hippocampus of knockout mice 
compared to wild type and mice overexpressing PrP
c136
. Zhang et al. found that PrP
c
 
supported the self-renewal of hematopoietic stem cells (HSCs)
137
. Prion protein has 
been found to enhance the proliferation of neural stem cells (NSCs), whereas both the 
N1  and  N2  fragments of PrP
c
 appear to inhibit cellular growth
138
. Overexpression of 
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 has also been shown to increase cell proliferation in mouse neuroblastoma cells 
N2a
134
, the LS 174T colon adenocarcinoma cell line
139
 and cancer stem cells derived 
from GBM
140
. In contrast, the absence of PrP
c
 increased the proliferation of 
undifferentiated oligodendrocyte cells
141
. Moreover, Kim et al. showed that PrP-





decreased the proliferation rate of intestinal epithelial cells and has a dual function in 
the regulation of polarisation and proliferation of these cells
143
. As can be seen, the 
effects of PrP
c
 on cell proliferation depends on the type of cells.  
1.2.5.3 Prion protein and cancers 
Several lines of research have demonstrated that PrP
c
 may be implicated in cancers. 
While PrP
c
 appears to contribute to different functions of the cell, such as 
proliferation, differentiation, adhesion, migration, ion homeostasis, anti-apoptosis and 
transduction of the signal its exact function in cancer is unclear
3
. Various studies have 
observed PrP
c














It has been found that knocking out of PrP
c
 in cancer cells effectively inhibits the 
growth of cancer cells while, conversely, the overexpression of PrP
c
 enhances cell 
survival and/or proliferation
146
. The following sections will focus on the suggested 
roles of PrP
c
 in different types of cancer. 
1.2.5.3.1 PrPc and breast cancer  
Over the last decade, the role of PrP
c
 in breast cancer has been evaluated and 
elucidated
3
. Dery et al. revealed that endoplasmic reticulum stress positively regulates 
the level of PrP mRNA in MCF-7 cells. A positive correlation has also been seen 
between BiP mRNA and PrP mRNA levels in breast cancer cell lines and tissue
150
. 
Another study found that PrP
c
 has different expression levels in breast carcinoma cell 
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lines. The TNF-resistant1001 cell line expressed the PRNP gene seventeen times 
higher than the TNF-sensitive MCF7 cell line, and this appeared to revert TNF-
sensitivity to resistance in these cells
151
.  
Meslin et al. examined the relationship between PrP
c
 and TRAIL using breast cancer 
cell lines TRAIL-sensitive MCF-7, MCF-7/ADR (resistance to Adriamycin, ADR), 
and 2101 (resistance to TRAIL). They found that the PrP
c
 expression increased in 
both the resistant cell lines. TRAIL induced apoptosis when PrP
c
 was knocked down 
in these cells through caspases, Bid cleavage, Mcl-1 degradation, but not through 
TRAIL receptors. They also found that while knockdown PrP
c
 reduced the Bcl-2 level, 





 in MCF7/ADR cells interacts with P-glycoprotein (P-gp) to form 
PrP
c
/P-gp complex and this initiates the motility in these cells. Silencing PrP
c
 or 
blocking P-gp inhibits paclitaxel (P-gp substrate), inducing the migration in vitro. 
Furthermore, inhibition of the PrP
c
/P-gp complex induces cell apoptosis
153
. Using by 
tissue microarray, analysis of samples from 756 breast cancer patients revealed a 
negative relationship between PrP
c
 expression and sensitivity to adjuvant 
chemotherapy. This study showed that higher PrP
c
 expression is associated with ER-
negative breast cancer subsets, and these ER-negative/PrP
c
-positive patients were less 





another study, researchers reported the overexpression of PrP
c
 and CD44 (cell surface 
adhesion receptor) in MCF-7/ADR cells. When PrP
c
 or CD44 were inhibited Several 
cell functions were suppressed, such as migration, invasion and proliferation. In 
addition, in human breast cancer tissue, the interaction of PrPc and CD44 was found 
in the post-neoadjuvant-chemotherapy patients
155
. 
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On the other hand, Yu et al. revealed that the knockdown of PrP
c
 expression in MDA-
MB-435 breast cancer cells increased the cell death induced by serum deprivation 
medium and induced the resistance to doxorubicin and DNA-interacting 
chemotherapy drugs. Moreover, they found that silencing PrP
c 
had no significant 
effect on cell proliferation and colony formation
8
.  
1.2.5.3.2 PrPc and colorectal cancer  
PrP
c
 has been shown to play a role in the function of the cytoskeleton in epithelial 
cells. It interacts with cytoskeleton-associated proteins and some intracellular proteins 
such as spectrin, desmoglein 2, in Caco-2/TC7 (Colon adenocarcinoma cells). This 
interaction improves the cell-cell adhesion and proliferation and is necessary for cell 
polarisation and differentiation
143
. Furthermore, the knockdown of PrP
c
 inhibits the 
proliferation and survival rate in DLD-1 and SW480 colorectal cancer cells by 
disrupting the Fyn-HIF-2α pathway and downregulating glucose transporter 1 (Glut1). 
In addition, the injection of PRNP shRNA in mice reduced the growth of colorectal 
tumour
156
. Wit et al. showed that both Glut1 and PrP
c
 are increased through the 
progression of adenoma to carcinoma. Thus, they suggested that Glut1 and PrP
c
 could 




In tissue samples from colorectal cancer patients, the PRNP gene was upregulated in 
relapsed patients compared to non-relapsed patients. Moreover, PRNP expression was 
an independent prognostic factor for three-year survival in colorectal carcinoma 
patients
158
. Importantly, PrPc antibodies decreased the growth of HCT116 colon 
cancer cells and improved the activity of cancer treatments such as 5-FU, cisplatin, 
doxorubicin and irinotecan as well as reducing tumour growth in vivo
157,3
. Wang et al. 
revealed that PrP
c
 expression increased the motility of the colorectal carcinoma cell 
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line SW480 whereas knockdown of PrP
c
 in primary human colon adenocarcinoma 
LIM2405 cells inhibited cell migration. Within the same study, inhibition of PrP
c
 
reduced the metastasis in vivo
159
.  
1.2.5.3.3 PrP and pancreatic ductal adenocarcinoma (PDAC)  
Han et al. were the first to evaluate the gene expression level of PrP in different 
pancreatic ductal adenocarcinoma (PDAC) cell lines growing in tissue. Using cDNA 
microarray analysis, they found that PrP mRNA was upregulated in these cells
160
. 
Another study showed that PrP expression is a marker in different groups of patients 
with PDAC
148
. PrP was expressed, at varying levels, in seven PDAC cell lines
161
. 
Indeed, the PrP in cell lines of this cancer exists as pro-PrP (PrP retaining its GPI-
PSS)
161,162
. Li et al. demonstrated that pro-PrP GPI-PSS binds to FLNa, an actin-
binding protein that participates in the anchoring of membrane proteins and cell 
signalling. The knockdown of PrP expression disrupted protein-signalling and 
cytoskeletal organisation. It also decreased the proliferation and migration of  PDAC 
cells as well as the development of tumours in vivo
161
. A recent study by Yang et al. 
also showed that knockout of the PRNP gene in BxPC-3 and PDAC cells inhibited 
cell migration. They found that multiple gene irregularities in these cells contribute to 








is highly expressed in the gastric mucosa of patients with Helicobacter pylori 
infection
163
. This upregulation may result from hypergastrinemia, a high level of 
interleukin 1 beta-synthase and increasing prostaglandin E2
164
. Helicobacter pylori 




 expression was detected in both non-cancerous 
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and malignant gastric tissues
166
. Zhao et al. identified that the PRNP gene was one of 
the upregulated genes in SGC 7901/ADR cells and ADR resistant gastric 
adenocarcinoma cell line SGC7901, using a PCR-based subtractive hybridisation 
technique
167
.   
PrP
c
 was more highly expressed in SGC7901/ADR (resistant to ADR) cells than 
SGC7901 cells (sensitive to ADR). The PrP
c
 overexpression in SGC7901 cells 
increased the resistance to P-glycoprotein (P-gp)-related drugs, whereas inhibition of 
P-gp could partially reduce PrP
c
-mediated multidrug resistance (MDR) and induce 
apoptosis. PrP
c
 also inhibits ADR-mediated apoptosis by increasing Bcl-2 and 
suppressing Bax expression in gastric cancer cells
168
. Additionally, the over-
expression of PrP
c 
in the gastric cancer cells SGC7901 and AGS increased migration 
and proliferation via activation of PI3K/Akt and promoting G1/S transition by 
upregulation of Cyclin D1
169
. Liang and collaborators suggested that the PI3K/Akt 
pathway is implicated in PrP
c
-induced MDR (ADR and VCR, vincristine) in gastric 
adenocarcinoma cells and that inhibition of this pathway reduced the resistance 
exhibited in MDR-gastric cancer cells and decreased the level of P-gp
170
. Within the 
same research group, one octapeptide repeat deletion (1-OPRD) of PrP
c
 was found in 





OPRD) there was the same effect on MDR, cell invasiveness, adhesion or apoptosis 
but cell proliferation was mainly influenced by PrP
c
 (1-OPRD) compared to PrP
c
 due 
to the activation Cyclin 3 and Cyclin 1
171
. 
It has been shown that PrP
c
 is overexpressed in the tissue samples of patients with 
metastatic gastric cancers. PrP
c
 also promoted cancer metastasis in mice transfected 
by gastric cancer cell lines. These findings could be attributed to the role of the OPR-
containing N terminal domain of PrP
c
 which induces the invasiveness and metastasis 
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processes in gastric cancer cells
172
. Overall, these studies suggest that PrP
c
 and MGr1-
Ag/37LRP (upregulated protein in gastric cancer drug-resistant cells) may be 




1.2.5.3.5 PrP and other types of cancers  
The PrP
c
 expression level in normal skin cells is very low. When the skin in inflamed, 
however, PrP
c
 is strongly expressed in keratinocyte and infiltrating mononuclear 
cells
175
. Although the PrP
c
 is not detected in normal melanocytes, it is overexpressed 
in melanoma cells. In addition, an in vitro study showed that the PrP in M2 and A7 
melanoma cells is pro-PrP, which binds with FLNa in A7 cell lines. This binding 
significantly induces the migration of A7 cells. Inhibition of PrP significantly reduces 
the migration and invasion of A7 cells, however
176
.  
In prostate cancer, overexpression of PrP
c
 is found in prostate spheroids that are 
associated with ROS and the size of tumour spheroids
177
. High levels of expression of 
PrP
c
 have been identified in biopsies of prostate tumours, hepatic cancer and oral 
squamous cell carcinoma
3
. Another study has shown that PRNP is involved in 
osteosarcomas. In addition, the expression of this gene was upregulated in human 
osteosarcoma
149
. Conti et al. reported that PrP
c
 was detected in soft tissue sarcomas 
and it could be one of the novel biomarkers of this cancer. It was one of 16 proteins 
significantly increased in metastatic sera compared to non-metastatic sera
178
. A 
substantial body of evidence, therefore, supports the involvement of PrP
c
 in various 
cancers. 
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1.2.5.3.6 PrPc and Glioblastoma  
Various studies have shown that PrP
c
 is involved in astrocytoma and interacts with 
certain signalling pathways that contribute to multiple cellular functions. Comincini 
and co-workers evaluated the expression of the PRNP gene in astrocytomas, finding 
that PRNP is highly expressed in all tumour samples and astrocytoma cells
5
. In T89G 
glioblastoma cells, Kikuchi et al. found that the expression of PrP
c 
may be associated 
with the G1 phase of the cell cycle. The amount of PrP
c
 expression depends on the 
period of cell culture (in a time-dependent manner) with the protein level on Day 16 
being higher than that on Day 4 by about two fold
179
. 
Lopes et al. identified STI1 or protein as a cell surface ligand of PrP
c
 that activates 
several signal transduction pathways, some of which modulate the proliferation and 
cell death of neurons
180
. STI1 promotes the proliferation of the glioblastoma cell line 
A172 through the activation of Erk and PI3K pathways and does not affect normal 
astrocytes. The binding of PrP
c
 with STI1 may induce the proliferation of these 
cells
181
. Further study has demonstrated that both HOP (Hsp70-Hsp90 complex) and 
PrP
c
 are strongly expressed and that this positively correlates with high proliferation 
and low survival of glioblastoma patients compared to other astrocytoma grades or 
normal tissue samples. HOP interacts with PrP
c
 to increase the proliferation of GBM 
cells (U87 and U251) by activating the PI3K and Erk pathways. Inhibition of this 
binding, on the other hand, reduces the proliferation of GBM cells. Silencing PrP
c
 
decreases tumour growth and promotes the survival of mice with GBM
4
. In this 
context, PrP
c 
and HOP are co-localised and highly expressed in glioblastoma stem-
like cells (GSC). Proliferation and self-renewal of GSC cells appear to be affected by 
disruption to the binding of PrP
c
 with HOP: for example, exogenous HOP treatment 
(recombinant) induces the proliferation and self-renewal of GSC, depending on the 
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 level, whereas inhibition of HOP reduces the proliferation of these cells. 
Importantly, knockdown of PrP
c
 impairs cell migration and reduces cell adhesion, 
which confirms the important function of PrP
c
 on the cell surface
182
. In addition, the 
proliferation and migration of GBM95 glioblastoma cells have been shown to 
increase when cultured in microglia conditioned medium, due to the secretion STI1 by 
microglia cells. Remarkably, the anti-PrP
c
 antibody does not affect the proliferation of 
GBM95 cells with or without microglia conditioned medium
183
.  
Barbieri et al. studied the effect of PrP
c
 on the cell death of glioblastoma in vitro and 
in vivo. The results showed that silencing PrP
c
 using the antisense of the PRNP gene 
in T98G human glioblastoma cells induced autophagy by promoting LC3-II, Beclin 1 
expressions and Bcl-2 downregulation. Silencing PrP
c
 also reduced the size of the 
tumour in male mice
184
. In another study, knockdown of PrP
c
 in J889 human 




Zhuang and co-workers showed that PrP
c
 is upregulated in the G2/M cell phase in 
glioblastoma cells U87 and U251 treated with TMZ and that this could induce the 
resistance to TMZ. On the contrary, cells in phase G1/S displayed a lower level of 
PrP
c
 and the sensitivity to TMZ was promoted. Additionally, a flow cytometry assay 
showed a high rate of apoptosis in TMZ treated G1/S cells compared to G2/M cells
6
. 
The specific pro-apoptotic effector domain in cancers (SAC) has been identified in 
many cancer cells
186
. In cells treated with TMZ, PrP
c
 interacts with Par4 (response of 
prostate apoptosis 4) via SAC. This interaction induces an anti-apoptotic effect by 




Chapter 1: Introduction and Literature Review 
- 31 - 
 
1.2.6 Chemotherapeutics for GBM 
Clinical treatments for GBM face many difficulties due to the resistance of tumour 
cells, the hypersensitivity of brain tissues, the limited ability of brain cells to self-
repair and the permeability of drugs across the brain blood barrier
187
. Currently, the 
standard therapy for GBM patients is surgery followed by radiation and 
chemotherapy
188
. Alkylating agents, such as TMZ and BCNU, are the main treatments 
for malignant brain tumours, but while these have the ability to damage the DNA and 
promote cell death, the cytotoxic effects of these treatments are associated with the 
pathways of DNA repair
189
.  
The chemistry of TMZ as a prodrug is similar to imidazotetrazine compounds. TMZ 
is reduced in an alkaline or neutral medium to produce triazene 
methyltriazenoimidazole carboxamide (MTIC), which is then converted to 5-amino-
imidazole-4-carboxamide (AIC) and a methyldiazonium ion. The methyldiazonium 
ion is attacked by the nucleophile on DNA to form methylated DNA, preventing DNA 
replication and thereby triggering apoptosis (Figure 1-5). The majority of 
methylations can occur either on guanine-N7 or guanine-N3 site, accounting for 70% 
and 9% respectively. These N-methylations have no therapeutic value because the 
lesions are successfully treated with basic excision repair enzymes. The methylation 
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Figure (1-5): The mechanism of TMZ action  
The mechanism of action for the chloroethylating agent BCNU involves multiple 
steps. The first step is to chloroethylate the guanine in DNA (step 1 Figure 1-6), 
followed by a rearrangement step (step 2 Figure 1-6). Later, the C-O bond is cleaved 
and the methyl group either attacks the amino group of cytosine (step 3 Figure 1-6) to 
form DNA interstrand cross-link or is transferred to cysteine through the MGMT 
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Figure (1-6): The mechanism of BCNU action
191
 
According to clinical studies, TMZ in combination with radiotherapy is the 
cornerstone of treatment for glioblastoma patients when compared with radiotherapy 
alone, with survival rates of 14.6 months and 12.1 months respectively
193,194
. That 
said, resistance to TMZ is a major issue. O6-methylguanine DNA methyltransferase 
enzyme (MGMT) reduces the efficacy of TMZ by eliminating the damage wrought by 
the drug on the methyl groups within cell DNA
195
. Inhibition of the MGMT gene 
increases the response to the alkylating agent and extends the survival time, 
however
196,197
. Moreover, it has been shown that the activity of MGMT is diminished 
in peripheral mononuclear cells by TMZ, depending on the duration of treatment. In a 
clinical study, inhibition of the MGMT gene improves the survival time by 
approximately a further 6.2 months through increasing the activity of TMZ
198
. The 
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efficiency of TMZ might also depend on MGMT expression in stem-like cancer cells 
in GBM since it has been shown that GBM cancer stem cells that express MGMT 




In spite of the activity of the TMZ-radiotherapy combination in glioblastoma patients, 
the resistance of tumour cells, poor prognosis and limitations of treatment after 
recurrent malignancy have promoted researchers to look for different approaches to 
develop an alternative treatment. Different strategies have been followed to this end, 
including inhibition of the receptor tyrosine kinases, development of alternative drugs 
(e.g. etoposide, irinotecan and cisplatin), modifications of treatment delivery (such as 
BCNU wafers), increasing drug sensitivity by repression of MGMT, using gene 
therapy or improving immune techniques
200
.  
Expression of the eukaryotic elongation factor-2 kinase (EEF2K) reduces the efficacy 
of TMZ treatment in glioma cell lines and silencing of this protein increases the 
sensitivity of cells toward TMZ. The apoptosis which is mediated by alkylating agents 
is promoted further by inhibiting EEF2K. These findings have also been confirmed in 
vivo
201
. Moreover, it has been shown that p53 plays a significant role in chemotherapy 
resistance. Inhibition of p53 in U87 glioblastoma cell lines via the small molecule 
pifithrin-α also induces sensitivity to TMZ and BCNU treatments
202
. Based on studies 
in xenograft cells, it has been reported that reduced levels of MGMT lead to an 





 cells for about six hours and increases the sensitivity of these cells to 
BCNU therapy. The sensitivity of cells to alkylating chemotherapy depends on O
6
-
methylguanine deletion, however, and this is mediated by MGMT
189
. Xu et al. 
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discovered that the inhibition of CD44 receptor reduces tumour growth and improves 
the sensitivity of chemotherapeutics such as BCNU and TMZ in GBM pateints
203
.    
A BCNU wafer is a localised therapy that has the advantage of being able to bypass 
the blood-brain barrier to address the malignant tissue directly. The toxic effect that 
results from this treatment is decreased compared to other chemotherapeutic 
regimens
204
, and this localised BCNU wafer followed by TMZ treatment exhibits a 
better survival rate in some GBM patients
205
.  
1.2.7 GBM disease models  
In order to study cancer biology, disease aetiology and facilitate drug discovery, 
various models have been developed
206
. For GBM in particular, disease models can be 
classified into two main groups in preclinical in vivo and in vitro models. Current 
preclinical in vivo models are divided into two classes: syngeneic mouse GBM and 
xenografts. The establishment of syngeneic models are either by development the 
native glioblastoma cell lines via exposure to a certain risk factors such as radiation or 
chemical insult, or spontaneously through the genetic engineering to reproduce the 
tumour. Xenografts model are subdivided into two categories, including GBM cell-
line xenografts and patient-derived tissue xenografts
207
. GBM cell-line xenografts 
have high growth rate, but drawback includes that it possibly does not retain the 
histological feature of glioblastoma cells. The patient-derived xenografts are more 
efficient models because they retain the biological and genetic features of primary 
tumour
208
.      
In vitro culture models have been widely established for GBM research since the 
isolation and immortalization of cell lines were achieved. GBM is a fast-growing and 
the most aggressive primary malignant brain tumour. Off all the primary malignant 
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cancers, percentage of GBM patients is relatively small (1.35 % in the US)
209
. Hence, 
access primary cell to study this disease is limited, not to mention obtaining samples 
from the brain is fraught with difficulties and is usually not an option. Forty eight 
human glioblastoma cell lines have been developed and available from biobank
210
. 
Table (1-1) shows the commonly GBM cells used in research. U87 cell line is the 
most commonly used as a model cell line to study GBM and provided valuable 
knowledge in brain cancer research. Over the last three decades, U87 has the highest 
PubMed citation (more than 1900) compare to other commonly used glioblastoma cell 
models, U251 (more than 1100 citations) and T98G (more than 900 citations)
210
.  
Table (1-1): Commonly used cell lines in GBM studies, the information provided by 
ATCC and European Collection of Authenticated Cell Culture (ECACC). 
Name of the cell line The origin Morphology  
U87 Human brain-Male  Epithelial 
U251 Human brain-Male Astrocytoid 
T98G Human brain-Male Fibroblast  
A172 Human brain-Male Unknown 
U138  Human brain-Male Polygonal  
U118 Human brain-Male Mixed 
LN-18 Human brain-Male Epithelial 
LN-229 Human brain-Female  Epithelial 
U373 Human brain Astrocytoid 
 
Uppsala 87 Malignant  Glioma (U87-GM) or U87 is non-neuronal glial brain tumour 
cell line
209
. The male cell line has an epithelial morphology and was obtained from a 
patient of unknown age in 1966 in Uppsala University
211
. The currently available 
version of U78 is from the American Type Culture Collection (ATCC- HTB-14). It 
was reported as a grade IV glioma cell line derived from a 44-year old male caucasian 
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patient diagnosed with glioblastoma. The exact nature was reported by Allen et al, 
2016 from Uppsala University to be different from previous U87 glioblastoma cell 
lines used in their study
211
. In addition to that, ATCC in 2016 updated U87 as 
unknown age and likely glioblastoma. The genome of this cell line has been 
sequenced and found that 60 genes are mutated in the U87 cell line and are located in 
regions that are commonly deleted in GBMs
209
. U87 cell line has previously been 
used in many in vitro studies to investigate the involvement of prion protein in many 
processes such as apoptosis and proliferation of GBM
4,184,212
. Furthermore, previous 
work in the group used U87 cells in the screening of novel small molecules inhibitors 
for the FA pathway in search for sensitising agents for chemotherapies of GBM, TMZ 
and BCNU. Besides, most researchers rely on publicly available cell lines
211
. U87MG 
appears to be a more representative GBM cell line than others because its genomic 
features are a large number of chromosomal abnormalities, that can be typical of 
cancer cell lines and primary cancers
213
. Therefore, in the current study U87 cells 
were selected to investigate the role of PrP
c
 in GBM upon the treatment with TMZ 
and BCNU and identify the FAPi discovered in the previous work would have any 
impact on PrP
c
 pathway.  
1.2.8 Thesis aim and objectives   
PrP
c
 expression is implicated in many cancers, including GBM.  Although the role of 
PrP
c
 expression has been investigated in glioblastoma cells, the effect of GMB 
chemotherapeutic agents (i.e both TMZ and BCNU) on PrP
c
 expression has not been 
studied in depth. In addition, PrP
c
 expression level may influence on the proliferation 
of U87 cells and their resistance to alkylating agents. The main aim of this thesis was, 
therefore, to investigate the level of PrP
c
 expression in glioblastoma cell line U87 
treated with alkylating agents TMZ and BCNU and the effects of some small 
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molecules on its level. In addition, the effect of a collection of potential anticancer 
novel small molecules (30 compounds) on U87 were evaluated. To achieve these aims, 
the following tasks were addressed: 
 Since the level of PrPc expression has been suggested to be affected in different 
cell cycle phases, PRNP and PrP
c
 expressions in U87 cells treated with TMZ or 
BCNU were evaluated across the cell cycle. The following experiments were 
performed (Chapter 3).  
 Cell cycle analysis was used for U87 cells treated with cell cycle modulators, 
Aphidicolin and Nocadozole, that are known to arrest the cells in G1 and 
G2/M after 24h respectively. Additionally, U87 cells were treated with 
alkylating agents TMZ and BCNU, and the cell cycle was analysed at different 
time points using flow cytometry.   
 The regulators of the cell cycle, p53 and p21, were assessed to confirm the 
arrest at G2/M in response to alkylating agents.   
 The PRNP gene and PrPc protein expression levels in U87 treated with 
Aphidicolin, Nocodazole, TMZ or BCNU were evaluated using qPCR (for 
gene level), flow cytometry and western blot (for protein level). 
 The cell morphology of treated U87 cells was investigated using actin filament 
staining.  
 PrPc may play a role in the resistance to alkylating agents demonstrated by U87 
cells. We speculated that silencing the PRNP gene may affect the proliferation of 
U87 cells, whether treated or untreated with alkylating agents. To investigate this 
speculation the following objectives were carried out (Chapter 4). 
 Knockdown of the PRNP gene in U87 cells using PRNP siRNA.  
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 Evaluation of the knockdown level using qPCR, flow cytometry, western blot 
and immunocytochemistry (ICC). 
 Assessment of the effect of PRNP knockdown on cell proliferation using MTT 
and Alamar blue assay. Besides, the proliferation marker ki67 was quantified 
using ICC. 
 Evaluation of the proliferation of knockdown cells treated with TMZ or 
BCNU using MTT assay. 
 Estimation of the cell cycle phases and regulatory cell cycle proteins, p53 and 
p2, in knockdown U87 cells treated with alkylating agents.  
 Proteasome inhibitor MG132 decreases the degradation of PrPc in some neuron 
cells. It also promotes apoptosis in various cancer cells, including glioblastoma 
cells, as reviewed in the relevant chapter (chapter 5, section 5.1). It is assumed 
that proteasome inhibitor, MG132 could reduce the degradation of PrP
c
, hence 
increase the protein level in U87 cells. Furthermore, we expected that the 
combination of MG132 with TMZ may promote the apoptosis of U87 cells. Thus, 
the following steps were performed to test these speculations. (Chapter 5) 
 Evaluation of cell viability in U87 cells treated with MG132 and calculation of 
the IC50 using MTT assay. 
 Assessment of the PrPc expression level in the U87 cells treated with MG132 
using flow cytometry western blot and ICC.  
 Evaluation of cell proliferation and apoptosis in cells treated with MG132 and 
MG132/TMZ combination MTT and annexin V with PI assays, respectively. 
 Estimation of cell cycle phase and the level of p53 and p21 in U87 cells 
treated with MG132 or MG132/TMZ combination using flow cytometry and 
western blot assays, respectively.  
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 Many novel compounds (benzimidazole derivatives) were screened to assess the 
level of PrP
c
 expression in U87 cells. These compounds have been synthesised in 
previous work by this research group (Drs. Matthew Sellwood and Peng Hua) and 
have been shown to have the ability to inhibit the FA pathway by reducing 
FANCD2, the key part of FA pathway. These compounds may have a potential to 
decrease the level of PrP
c
 expression in U87 cells due to their ability to bind PrP
c
. 
We, therefore, hypothesised that these molecules may affect the PrP
c
 pathway. To 
test our hypothesis the following experiments were performed (Chapter 6).  
 Investigation of the effect of these molecules on cell viability in combination 
with TMZ or BCNU using MTT assay.  
 ICC by ImageXpress Micro as a high content screening assay was used to 
evaluate the level of PrP
c
 expression in treated cells with and without TMZ or 
BCNU combination.  
 In a further study, the efficacy of a collection of potential anticancer small 
molecules (30 compounds) on U87 was evaluated. These compounds were 
synthesised in previous work by this group. Due to the cytotoxic effect of these 
compounds on the NT2 stem cells, we expected that these compounds may 
promote cell death of U87 cells. To address this expectation, the following 
experiments were carried out (Chapter7). 
 Evaluation of cell viability in U87 cells treated with these compounds using MTT 
assay. 
 Assessment of the apoptosis in U87 cells treated with these molecules using 
Annexin V with PI. 
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 Evaluation of cell cycle phases and the level of p53 and p21 in cells treated with 
the compound/s that induced apoptosis using flow cytometry and western blot 
assays, respectively.  
 Evaluation of the effect of the compound/s that induced apoptosis on the level of 
PrP
c
 expression to determine whether this increases or reduces the level of this 
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Chapter 2: Materials and Methods 
2.1 Materials  
2.1.1 Reagents and Chemicals  
The reagents and chemicals used in this thesis are detailed in the following table.  
Table (2-1): List of chemicals and reagents 
Experiment  Chemical /reagent Source  
Cell culture Fetal Bovine Serum ThermoFisher 
Non-Essential Amino Acid Sigma Aldrich 
HBSS (1X) ThermoFisher 
Trypsin- 0.25 EDTA ThermoFisher 
Cell viability (MTT) Isopropanol Sigma Aldrich 
HCl VWR 
MTT (thiazolyl blue tetrazolium 
bromide)   
Sigma Aldrich 
Protein determination Bradford reagent Sigma Aldrich 
Western blot Tris-glycine-SDS buffer (10X) SLS 
Tris-glycine buffer (10X) SLS 
Colour plus protein marker Bio-Rad 
Tween 20 Sigma Aldrich 
Milk powder Sigma Aldrich 
BSA Sigma Aldrich 
Methanol Sigma Aldrich 
3F4 anti-prion antibody BioLegand 
p21 primary antibody Santa Cruz 
p53 primary antibody  Santa Cruz 
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Cell cycle  PI/RNase Staining ThermoFisher 
Ethanol  VWR 
FACS (protein 
expression) 
Tris-base  Fisher 
Sodium Chloride  Fisher 
Hydrochloric acid  VWR 
Sodium azide Sigma Aldrich 
4% Paraformaldehyde Alfa Aesar 
8H4 anti-prion antibody Sigma Aldrich 
Goat anti-mouse IgG -FITC Santa Cruz 
Donkey anti-mouse IgG Alexa 488 ThermoFisher 
Mouse mAb IgG Isotype control  Cell Signaling 
Treatments  DMSO Sigma Aldrich 
Aphidicolin Alfa-Aesar 
Nocodazole Sigma Aldrich 
TMZ Sigma Aldrich 
BCNU Sigma Aldrich 
 MG132 Sigma Aldrich 
Confocal microscopy   Ki67 primary antibody BD Pharm 
Alamar blue assay Resazurin Sodium Salt Sigma Aldrich 
siRNA Transfection  On-Target plus Human PRNP Dharmacon 
On-Target plus Non targeting Dharmacon 
DharmaFECT Transfection Reagent Dharmacon 
5X siRNA Buffer Dharmacon 
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2.1.2 Equipment and Apparatus 
In the following table, the equipment and apparatus used in the thesis are listed. 
Table (2-2): List of the equipment and apparatus 
Equipment/ Apparatus  Source  
Plate reader BIO-TEK 
Minicentrifuge  Eppendorf 
Centrifuge 5810 Eppendorf 
Incubator  NUAIRE 
Fume hood Labcaire 
Water bath VWR 
Dry bath Grant 
Nano drop  Thermo scientific 
Roller mixer Stuart scientific  
Flow cytometry (LSRII) BD Biosciences 
ImageXpress Micro Molecular Devices 
Hemocytometer  Sigma Aldrich 
Microscop  Olympus 
Mx3005P qPCR System Agilent Technologies  
Balance  METTLER TOLEDO 
LEICA SP5 microscope Leica 
Micropipette Eppendorf 
PVDF membrane (western blot) ThermoFisher 
Filter paper (western blot) Bio-Rad 
Precast gels Bio-Rad 
Transparencies USA 
Glass slide, size 25 mm × 75 mm Sigma Aldrich 
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2.1.3 Experimental Kits 
The commercial kits which were used in this study, are listed in the following table. 
Table (2-3): List of commercial kits 
Kit Source 
PureLink® RNA Mini Kit Invitrogen 
AMV First Strand cDNA synthesis  BioLabs  
PowerUp Sybr Green Master Mix Applied Biosystems  
PureLink® DNase Set Invitrogen  
FITC Annexin V Apoptosis Detection Kit 
with PI 
BioLegend 




2.2.1 Cell line and cell culture 
 
2.2.1.1 Cell line  
The cell culture-based experiments detailed throughout the thesis was performed 
using a glioblastoma cell line, U87. This cell line was kindly donated by Dr. Spencer 
Collis, University of Sheffield, Medical School.  
2.2.1.2 Thawing cells  
Upon retrieval from vapour-phase liquid nitrogen storage, the cryovial was placed 
immediately in a 37 °C water bath to rapidly thaw cells. After a sterile wipe with 70% 
ethanol, the contents of the vial were then transferred into a 15 ml centrifuge tube 
with warm culture medium. The tube was spun down at 1000 rpm for 5 minutes. After 
the supernatant was discarded, the cells were mixed well by pipetting with 10 ml of 
fresh medium and transferred into a T75 flask. The flask was incubated at 37 °C in the 
incubator. The medium was changed after 24 hours.  
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2.2.1.3 Cell culture medium 
Dulbecco’s modified eagles medium (DMEM) containing 4.5 g/L glucose, L-
glutamine (DMEM, D5796; 500ml; Lonza) and further supplemented with 10% of 
Fetal Bovine Serum (FBS) and 1% Non-Essential Amino Acid (NEAA) was used to 
culture the U87 cell line. The medium was stored at 4 ºC and warmed to 37 ºC in a 
water bath for at least 30 minutes prior to any experimentation.  
2.2.1.4 Cell subculturing 
The cells were split every 3-4 days using a T75 flask when the cells reached 70-80% 
confluence. The cells were washed with PBS (phosphate buffer saline) or HBSS 
(Hank's Balanced Salt Solution, 1X, thermoFisher) and then detached using 1 ml 
trypsin (Trypsin- 0.25 EDTA), following 1-2 minutes incubation at 37 ºC and 5% CO2. 
Nine ml of fresh warm medium was then added into the cells. After the cells were 
resuspended with a fresh medium by pipetting, 1-2 ml of cell suspension was 
transferred to a new T75 flask labelled with the number of cell passage and date. An 
appropriate amount of fresh medium (9 -10 ml) was then added to the flask and finally 
incubated in the humid incubator.   
2.2.1.5 Freezing of cells 
Once the cells were 70-80% confluent, they were detached from the flask by 
trypsinisation and re-suspended in a warm medium. The cells were counted and then 
spun down at 1000 rpm for 5 minutes. The supernatant was removed and the cells 
were resuspended with an appropriate volume of cryomedium (10% DMSO and 90% 
fresh medium). 1-2×10
6
 cells/ml were transferred into the cryovial that was labelled 
correctly with cell types, the number of passage, initial person’s name and date. The 
cryovial was placed in Mr Frosty freezing container to achieve a -1 °C every minute. 
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The container was then transferred into -80 ºC freezer overnight and for the long-term 
storage, the vials were placed in the vapor phase of liquid nitrogen.   
2.2.2 Cells Viability assay (MTT) 
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay was used 
to assess cell viability. 10 µl of MTT reagent (5mg/ml) was added to each well on a  
96-well plate and incubated for 2 hours at 37 °C. Then the medium was aspirated and 
60 μl of acidic isopropanol was added to each well. Finally, the absorbance of the 
sample was measured using a UV plate reader. The optical density was measured at 
570 nm with background subtraction at 690 nm. The viability of cells was figured 
according to the control by a percentage value.  
2.2.3 Cell cycle assay 
Cells were seeded in T25 flask or 6-well plate and left in the incubator to attach 
overnight. Cells were then treated according to the time and concentration of each 
type of treatment. After treatment, the cells were harvested by trypsin and 
resuspended with fresh medium. Later, the cells were transferred into Eppendorf tube 
and spun down at 2000 rpm for 5 minutes then the supernatant was decanted, and the 
pellets were resuspended with cold PBS to wash the cells. 100 µl of cold 70% ethanol 
were then added to the pellets and gently resuspended. The samples with 70% ethanol 
were incubated for 30 minutes at 4 °C. Before analysis by flow cytometry, the 
ethanol-suspended cells were centrifuged for 5 minutes at 2000 rpm, and then the 
ethanol was decanted thoroughly. The pellets were washed with cold PBS and then 
resuspended with 500 µl of propidium iodide (PI)/RNase staining solution. Each 
sample was analysed using 488 nm, 532 nm or similar excitation and the emission 
was collected using a long- pass filter blue 660/20 or equivalent. The population of 
cells was gated in forward scatter (FSC) and side scatter (SSC) to select a single cell 
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and avoid any cellular debris. The gates were then used to create histograms. These 
represent the number of single cells and DNA contents. The flow cytometry 
experiments were carried out at the Medical school, University of Sheffield. Special 
thanks go to Mrs Susan Clark for providing training sessions on LSRII flow 
cytometry machine to perform the current experiments.  
2.2.4 Real-time quantitative PCR assay  
 
2.2.4.1 RNA extraction  
RNA was extracted according to the instructions specified with PureLink RNA Mini 
kit (ambion by life technologies). After harvesting the cells, the culture medium was 
removed and the cells were washed with ice-cold PBS and spun down at 3500 rpm. 
The supernatant was removed and 0.3-0.6 ml of lysis buffer was added. The lysate 
was then passed through a disposable syringe with a needle gauge 18-21, 10 times. 
Following which, a similar volume of 70% ethanol was added to the sample and 
vortexed. The lysate was then transferred to a spin cartridge and centrifuged at 13400 
rpm for 15 seconds. The supernatant was discarded and 350µl of the wash buffer 1 
was added to the spin cartridge and then spun down again at 13400 rpm for 15 
seconds. The spin cartridge was washed by adding 80 µl of DNase solution (PureLink 
DNase, Invitrogen) and then centrifuged for 15 seconds at 13400 rpm. 350µl of the 
wash buffer 1 was then added to the spin cartridge and centrifuged for 15 seconds. 
This step was followed by washing the spin cartridge using 500 µl of the wash buffer 
2, twice, and then spun down for 1-2 minutes to dry the spin cartridge. The flow-
through was discarded and the spin cartridge was transferred into a new collection 
tube. This was followed by adding 30-100 µl of RNase-free water to the spin cartridge 
and incubated for 1 minute at room temperature to elute the RNA. The eluate (RNA) 
was collected by centrifugation for 2 minutes at 13400 rpm. This was stored at -80C°.       
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2.2.4.2 Synthesis of cDNA 
Complimentary of DNA (cDNA) was synthesized by using reverse transcriptase 
according to the instruction specified in AMV First Strand cDNA Synthesis Kit 
(BioLab). Briefly, 1-6 µl of total RNA (200-400 ng/ µl) was added to oligo primer 
d(T)23 and an appropriate amount of nuclease-free water to give a final volume 8 µl. 
The mixture was mixed thoroughly and incubated for 5 minutes at 70 °C. This step 
was followed by the addition of 10 µl and 2 µl of AMV Reaction Mix and AMV 
Enzyme Mix to each sample, respectively. 2 µl of nuclease-free water was added to 
the negative control tube instead of AMV Enzyme Mix. The samples, including the 
negative control tube, were then incubated for 1 hour at 42 °C. The samples were then 
incubated for 5 minutes at 80 °C. The product was diluted with nuclease-free water to 
50 µl. Finally, the samples were labelled correctly and stored at -20 °C.   
2.2.4.3 Primer design and real-time quantitative PCR 
PowerUp
TM
 SYBR Green Master Mix system (Applied Biosystem) was applied to 
express the PRNP gene. The primers of PRNP and a housekeeping gene GAPDH 
were designed and tested using NCBI program to target the specific gene of interest. 
The sequences of primers are listed in the table (2-4) below. All primers were 
purchased from Sigma-Aldrich and were dissolved in nuclease-free water as a stock 
of 100 µM. The stock was kept at -20 °C, and the concentration of each primer used 
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Table (2-4): The sequences of primers 
Primers Sequence 
PRNP Forward 5’-GGTGGTGTCTCACTCTTTCTTC-3’ 
PRNP Reverse 5’-CCAGCATCTCAGGTCTACTCTA-3’ 
GAPDH Forward 5’-CCCTTCATTGACCTCAACTACA-3’ 
GAPDH Reverse 5’-ATGACAAGCTTCCCGTTCTC-3’ 
 
The mixture of qPCR materials was made using 10 µl of SYBR GREEN Mix (2X), 
1µl each of template DNA, forward primer and reverse primer, and 7 µl of nuclease-
free water to give a total volume of 20 µl in each well. Experiment was performed in 
triplicates, using 3 different samples. The amplification was performed under thermal 
cycling conditions i.e. 1 cycle of 50 ºC for 2 minutes, 1 cycle 95 ºC for 2 minutes, 50 
cycles of 95 ºC for 15 seconds and 58 ºC for 1 minutes. This was applied using 
Agilant MX3005 qPCR machine, in a 96-well PCR-plate. The change of gene 
expression was calculated using ∆∆Ct method as detailed using the following 
equations:  
∆𝐶𝑡 (𝐶𝑜𝑛𝑡𝑟𝑜𝑙)  = 𝐶𝑡 (𝑇𝑎𝑟𝑔𝑒𝑡 𝑔𝑒𝑛𝑒) − 𝐶𝑡 (𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑔𝑒𝑛𝑒) 
∆𝐶𝑡 (𝑇𝑟𝑒𝑎𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒) = 𝐶𝑡(𝑇𝑎𝑟𝑔𝑒𝑡 𝑔𝑒𝑛𝑒) − 𝐶𝑡 (𝑅𝑒𝑓𝑒𝑟𝑒𝑐𝑒 𝑔𝑒𝑛𝑒) 
∆∆𝐶𝑡 = ∆𝐶𝑡 (𝑇𝑟𝑒𝑎𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒) − ∆𝐶𝑡 (𝐶𝑜𝑛𝑡𝑟𝑜𝑙) 
𝐹𝑜𝑙𝑑 𝐶ℎ𝑎𝑛𝑔𝑒 = 𝟐−∆∆𝑪𝒕  
         Where Ct: Threshold cycle 
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2.2.5 Quantification of protein expression by Western blotting 
 
2.2.5.1 Protein quantification 
After lysing the cells, protein concentration was calculated using the bicinchoninic 
acid (BCA) method. The protein level in the lysate was measured to determine the 
exact concentration of the sample that will be loaded in SDS-gel. The working reagent 
of BCA was prepared  by mixing 50 parts of BCA Reagent A with 1 part of BCA 
Reagent B. Serial dilutions of BSA were made (0.0, 0.1, 0.2, 0.4, 0.6, 0.8, 1.0 mg/ml). 
10 μl from either the lysate or BSA sample was added to each well. 200 μl of BCA 
warking reagent was then added to each well and then the 96-well plate was left for 
30 minutes in the incubator at 37 °C before the absorbance at 570 nm was read. The 
calibration curve was made from BSA samples to quantify the concentration of 
protein in the late using the formula (Figure 2-1). 
 
Figure (2-1): The standard curve for serial dilutions of BSA in RIPA buffer  
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2.2.5.2 Western blot assay 
U87 cells were seeded in 6-well plates at a density which was selected according to 
the duration of treatments (mentioned in each chapter of results). After the treatment 
period, cells were harvested by trypsin-EDTA. This step was followed by adding 
fresh medium, and the cells were resuspended and spun down at 1500 rpm for 5 
minutes. Cells were then washed twice with cold PBS and centrifuged at 1500 rpm for 
5 minutes. RIPA buffer with protease inhibitor was used to lyse the pellet in ice for 
25-30 minutes. The sample was spun down at 13400 rpm for 10 minutes. The lysate 
was collected and protein concentration was quantified by BCA method (section 
2.2.5.1). The sample was then diluted with RIPA buffer to obtain 40 μg as a total 
concentration. 40 μl of the sample was added to 10 μl of 5x loading buffer. The 
sample was then denatured at 95 °C for 5 minutes.  
After denaturation, 40 μl of the sample was loaded onto the precast gel. Initially, the 
samples were subjected to electrophoresis for 5 minutes at 300 V using 1x TGS buffer 
and the gel was run for further 30 minutes at 180 V. The ladder was also loaded to the 
gel. During this time the PVDF membrane was activated in 100 ml of methanol, and 
then a 100 ml of 10x TGM buffer and 800 ml double-distilled water were added to the 
100 ml of methanol to create 1x TGM buffer. The gel was transferred to a suitable 
container. The membrane, gel, filter paper and fibre pad were stacked in the order 
specified in Figure 2-2. 
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Figure (2-2):  The cassette of western blotting shows the order of the membrane, gel, filter paper and 




The cassette was transferred into the tank, and the sample was run for 30 minutes at 
400 mA. An ice pack was added to avoid overheating during the transfer process. 
After that, the membrane was exposed to a series of washes. First, the membrane 
washed for 15 minutes with TBS-T (Tris buffer saline, 0.1% Tween 20) and this was 
followed by blocking for 1 hour with 20 ml of 5% of non-fat milk in TBS-T. The 
membrane was then exposed to primary antibody depending on the type of protein at 
specific dilutions mentioned in the results chapter that was diluted with 5% non-fat 
milk in TBS-T overnight at 4°C.  
After overnight incubation, the membrane was washed three times for 5 minutes each 
with TBS-T to remove the remains of the primary antibody. The horseradish 
peroxidase-linked secondary antibody was then diluted by 1:4000 or 1:2000 in 1x 
TBS-T and incubated with the membrane for 1 hour at room temperature. The 
membrane was then washed once with TBS-T for 15 minutes and twice with TBS for 
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5 minutes, each. Finally, the membrane was exposed 3 minutes to ECL (Enhanced 
chemiluminescence) solution to allow imaging using Bio-Rad ChemiDoc system. 
2.2.6 Flow cytometry analysis: protein expression 
Protein expressing analysis was carried out according to the indirect flow cytometry 
protocol provided by Abcam. Briefly, cells were detached using the non-enzymatic 
dissociation solution. The cells then resuspended with fresh medium and transferred 
into Eppendorf tube (1-1.5x10
6
 cells) and spun down at 1500 rpm for 5 minutes. The 
medium was aspirated, and the cells washed by ice-cold PBS twice and then spun 
down again at 1500 rpm for 5 minutes. Cell viability was checked under a light 
microscope using trypan blue dye. Cells used in this assay were approximately 95% 
viable. The next steps depended upon the target (i.e. cell surface or cytosolic protein).  
2.2.6.1 Live cells (surface protein) flow cytometry 
Cells were resuspended with FACS buffer (PBS, 10% FBS, 1% sodium azide) and all 
samples were kept on ice. The pellets were washed with ice-cold PBS and centrifuged 
at 1500 rpm for 5 minutes. The primary antibody and/or isotype was diluted with 3% 
BSA. A 100 µl of primary or isotype antibody was added to each sample (with a 
population of 1x10
6 
cells) and then incubated in ice for 1h. Cells were then washed 
twice using ice-cold PBS and spun down at 1500 rpm for 5 minutes. Cells were then 
incubated with the secondary antibody for 45 mins on ice. Cells were then washed 
twice to remove any unbound secondary antibody. The samples were then 
resuspended in 300 µl ice-cold PBS and transferred into the flow cytometry tube. The 
samples were analysed at 488 nm, and the emission was collected using a long-pass 
filter blue 530/30. 
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2.2.6.2 Fixing and permeabilising cells (cytosolic protein) 
Cells were fixed using 4% paraformaldehyde for 10 minutes. The pellets were washed 
with ice cold PBS and centrifuged at 1500 rpm for 5 minutes. Cells were then 
permeabilised using 0.2% Triton 100x for 5 minutes and then spun down at 1500 rpm 
for 5 minutes. Following which triton was removed and blocked using 3% BSA (in 
PBS) for 30 minutes. The blocking reagent was then removed by centrifugation for 5 
minutes at 1500 rpm.  
The primary antibody and/or isotype were diluted with 3% BSA. 100 µl of primary or 
isotype antibody was added to each sample (containing ~1x10
6
 cells) and then 
incubated on ice for 1 hr. This was followed by incubation of secondary antibody for 
another hour and the finally, cells were washed two times using ice-cold PBS and 
then spun down at 1500 rpm for 5 minutes. Cells were washed twice to remove any 
remaining unbound antibodies. The samples then resuspended with 300 µl ice-cold 
PBS and transferred into a flow cytometry tube. The samples were analysed at a 
wavelength of 488nm, and the emission was collected using a long-pass filter blue 
530/30. 
2.2.7 ICC by Confocal Microscopy  
The coverslips were rinsed in 10 M nitric acid for 1h, then washed with distilled water 
three times and allowed to air dry.  Coverslips were autoclaved and stored in an 
incubator overnight to dry completely. The sterile coverslips were transferred into 24-
well plate and 500 µL poly-ornithin hydrobromide was added to each well for 40 
minutes at room temperature. They were washed three times using PBS.  
Cells were then seeded in a certain density according to the experiment in each 
chapter. Allowing time for attachment, cells were then treated with a specific 
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treatment depending on the type of the experiments. When the time of incubation was 
completed, the medium was removed, and cells were washed with PBS. Cells were 
then fixed with 4% paraformaldehyde for 10 minutes at room temperature. The 
fixative reagent was removed and cells were then washed two times to remove any 
remaining paraformaldehyde. PBS was then removed and cells were incubated for 1h 
with 500 µL blocking solution (1%BSA in PBS-T) at room temperature. Following 
which, the blocking solution was aspirated, and the cells were incubated with primary 
antibody overnight, the antibody was made up using 1%BSA with PBS-T. Next day, 
the primary antibody was removed and the cells washed three times with PBS-T, 5 
minutes each at room temperature. The secondary antibody was added to each well 
and then incubated for 1h at room temperature. After aspiration of the secondary 
antibody, the cells were washed twice with PBS-T and one time with PBS. Cells were 
then incubated with DAPI for 5 minutes and washed 3 times with PBS.  The 
coverslips were mounted with propyl galate onto a glass slide. The coverslips were 
sealed using transparent nail polish. The samples were imaged using a LEICA SP5 
microscope and using a 40x or 63x objective. The imagaing was performed in 
Sheffield Institute for Translational Neuroscience (SITraN), Sheffield University. I 
would like to express my special thanks to Dr. Cleide Souza for helping me to use the 
confocal microscopy. 
2.2.8 ICC screening assay 
Cells were seeded in 96-well plates from Greiner Bio-One Ltd, which had been 
treated with 100 μg/mL poly-ornithin hydrobromide. The seeding density 
depended on the period of the experiment. Next day, cells were treated with the FA 
pathway inhibitors (FAPi) compounds at a  concentration described in the methods; 
chapter 6. When the incubation time with the compounds finished, the medium was 
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aspirated and the wells were washed with PBS. Cells were then fixed by adding 50 
μl of 4% paraformaldehyde to each well for 10 minutes at room temperature. The 
cells then blocked with 1%BSA-T (1%BSA with 0.1% Triton 100x in PBS) for 1h 
at room temperature. Three times washes by TBS-T (0.1% Trioton in PBS), 5 
minutes each (50 μl for each well) were followed the incubation overnight at 4 ºC 
with primary antibody. Cells were then incubated with fluorescent secondary 
antibody (50 μl for each well) for 1h at room temperature. The wells were washed 
three times, twice with PBS-T and once with PBS, each for 5 minutes. This was 
followed by 5 minutes incubation with DAPI, and washes with 50 μl of PBS three 
times. Images were acquired using a Molecular Devices ImageXpress Micro 
microscope and at 20x objective. The figure below shows the ImageXpress Micro 
device. This experiment was carried out in the Department of Biomedical Science 
(BMS), Sheffield University. I appreciate Dr Stephen Brown’s help for the training 
session on ImagExpress Micro imaging system. 
 
Figure (2-3): ImageXpress Micro device 
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2.2.9 Transfection- siRNA delivery in U87 cells  
U87 cells were cultured in T25, 96-well plate, 6-well plate or 24-well plate. Next day 
the transfection reagent and siRNA were prepared and added. 5X siRNA buffer was 
diluted five times by adding RNase-free water. The target and non-target siRNA were 
then dissolved by adding a volume of siRNA buffer depending on the number of 
nanomoles of siRNA following the equation below to obtain 100µM as a stock 
solution. Later, the stock solution was diluted into 5µM by adding a 20x of siRNA 
buffer and this was aliquoted and stored at -20C˚. The DarmaFECT reagent and both 
siRNA (PRNP and non-target) were diluted in separated tube 10 times using the 
optimum medium and then was left 5 minutes at RT. Later, one volume of the 
DarmaFECT reagent was mixed with each siRNA, and they left 20 minutes at room 
temperature in the fume hood. The mixture was added to 5x of the fresh antibiotic-
free medium. Before treating the cells, the medium was aspirated from the attached 
cells, and the transfection reagent was poured onto the cells gently.     
𝑉 = 10 × 𝐶 
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To obtain the desired transfection condition, different concentrations of DarmaFECT 
were used to prepare the transfection medium. The optimum concentration of 
Darmafect was 0.08µl/5000cells. Besides, the optimum siRNA concentration was 50 
nM. After treating cells with transfection medium, the plate or flask was placed in the 
incubator at 37 °C for the desired period, i.e. 24h, 48h, 3days, 4days or 5days. The 
table below shows examples of siRNA and DarmaFECT volume (µl) in different cell 
densities and different total volumes (Table 2-5). 
Table (2-5): The examples of siRNA and DarmaFECT volume (µl) in different cell 
densities 
 
2.2.10 LDH assay 
Lactate dehydrogenase (LDH) is a cytotoxicity assay. U87 cells were seeded in a 96-
well plate at a certain density depending on the period of the experiment (see section 
4.2.6). The reagents for this assay were prepared according to the manufacturer’s 
instruction - Pierce LDH Cytotoxicity Assay Kit from Thermo Scientific.  The vial of 
Total volume (µl) Cell density 5µM siRNA (µl) DarmaFECT volume (µl) 
100 1000  1 0.02 
100 5000 1 0.08 
500 10000 5 0.16 
500 20000 5 0.32 
1000 25000 10 0.4 
1000 50000 10 0.8 
1500 25000 15 0.4 
1500 50000 15 0.8 
3000 100000 30 1.2 
3000 400000 30 6 
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the substrate (lyophilisate) was dissolved in 11.4 ml Mili-Q water in 15 ml centrifuge 
tube then mixed gently. The assay buffer vial (0.6 ml) was defrosted at room 
temperature then was added to the substrate to prepare the reaction mixture (RM). 
This mixture was aliquoted and stored at -20°C. 
The medium that was used for cell culture in this assay was phenol red-free medium 
with 5% serum to avoid any background activity. The wells during the seeding were 
divided into different parts including control (part 1 and 2) and treated as triplicate for 
each part. After the transfection with siRNA was performed, 10 µl of 10X Lysis 
Buffer was added to the control (part 1) and then incubated at 37°C, 5% CO2 for 45 
minutes to obtain the Maximum LDH Activity. Next, 50 µl of medium were 
transferred from each well to new 96-well plate. Later, 50 µl of RM was added to all 
wells. The plate was incubated 30 minutes at room temperature, protected from light. 
This step was followed by adding 50 µl of stopping reagent. To avoid any bubbles, 
the plate was centrifuged for 1 minute at 4000 rpm. Finally, the absorbance was 
measured using the plate reader at 490 nm with background subtraction at 680 nm. 
The following equation was applied to determine the percentage of cytotoxicity     
% Cytotoxicity = (Treated LDH activity – Spontaneous LDH activity)/(Maximum 
LDH activity – Spontaneous LDH activity) × 100 
Where Treated LDH activity is the absorbance of treated sample, Spontaneous LDH 
activity is the absorbance of control (part2), Maximum LDH activity is the absorbance 
of control (part1). 
2.2.11 Alamar Blue assay 
Cell proliferation for knockdown cells was analysed using Alamar blue assay. 
Resazurin Sodium Salt was dissolved in deionised water at 1 mM. To prepare a 
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working reagent of Alamar blue, one volume was diluted in 10 volumes of fresh 
medium.  
The cells were seeded in 24-well plate at different cell density depending on the 
period of incubation and then transfected with siRNA. After the incubation time, the 
medium was removed and 500 µl of working Alamar blue reagent was added into 
each well. The plate was then left 4h in the incubator at 37 °C. This step was followed 
by transferring 100 µl of working alamar blue reagent in triplicate from each well into 
96-well plate as shown in the figure below (Figure 2-4). The optical density was 
measured using plate reader spectrometry at 570 nm. The data was then calculated as 
a percentage to the absorbance of the control (untreated).   
 
Figure (2-4): The distribution of samples in 96-well plate used to performed cell viability assay by 
Alamar blue assay.   
2.2.12 Apoptosis assay 
Apoptosis assay for U87 cells was assessed with FITC Annexin V Apoptosis 
Detection Kit with PI (BioLegend), according to manufacturer recommendations. The 
cells were seeded in a 6-well plate at a certain time point according to the experiment. 
Cells were harvested using a non-enzymatic dissociation solution then washed twice 
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with cell staining buffer which was provided by BioLegend. Cells were resuspended 
in Annexin V Binding Buffer, 100 µl to each 300000-500000 cells. The suspension 
was transferred into FACS test tube by 100 µl in each tube. Five microliters of FITC 
Annexin V was added to each sample and mixed gently. 10 µl of Propidium Iodide 
solution (PI) was then added to each tube. The tube was mixed gently and incubated 
for 15 minutes at room temperature. 400 µl of Annexin V binding buffer was then 
added to each sample. The sample was transferred to flow cytometry and analysed 
using 488 nm excitation. The emission was collected using a long- pass filter blue 
620/20 for PI and blue 530/30 for FITC Annexin V.  
2.2.13 Statistical Analyses 
Data are displayed as mean ± SD and were statistically analysed by a GraphPad 
Prism 7 software, using t-test (to compare each tested group with the control) and 
one-way ANOVA with Tukey’s test (to compare between-groups and within-
groups differences). The experiments were repeated at least three times and the 
number of replicates (n) is mentioned in the legend of figures. The results are 
considered statistically significant when p-value is less than 0.05.     
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Chapter 3: Evaluation of PrPc and PRNP gene expression in different phases of the 
cell cycle and in U87 cells treated with TMZ or BCNU 
3.1 Introduction 
Currently, effective chemotherapies against glioblastoma are TMZ and BCNU, used 
alone or in combination with radiotherapy, but the chemoresistance of GBM cells 
remains one of the main problems. These genotoxic treatments induce DNA damage 
that activates DNA repair pathways and tumour suppressor p53
215
. Indeed, p53 is a 
transcriptional factor that activates its target genes in response to cellular stresses to 
prevent the proliferation of damaged cells by arresting the cell cycle and triggering 
apoptosis;
216
 a so-called DNA damage checkpoints
217
. It also transactivates p21, 
cyclin-dependent kinase (CDK) inhibitors, which induces cell cycle arrest through 
suppressing CDK4 and CDK6
216
. TMZ and BCNU have been shown to arrest the 
glioblastoma cells in G2/M, and this process delays the cells in order to allow more 
time to repair DNA damage induced by the alkylating agents. Thus, G2/M 
accumulation in these treated cells occurs due to upregulation of p53 and p21
202
.  
Several studies have reported that PrP
c
 is highly expressed in glioblastoma cells and 
that it appears to interact with many signalling pathways to protect the glioblastoma 
cells from the proapoptotic stimuli (reviewed in section 1.2.5.2). The behaviour of 
PrP
c
 in glioblastoma cells when they are treated with alkylating agents still needs to 
be elucidated, however. Indeed, to our knowledge, Zhuang et al. are the first 
researchers to have investigated the effect of TMZ on the expression of PrP
c
 in 
glioblastoma cells, which they measure by immunofluorescence and western blotting, 
as well as using array hybridization to assess the effect on levels of the PRNP gene. 
They found that PrP
c
 may induce the resistance to TMZ by upregulating PrP
c
 in the 
G2/M phase of the cell cycle. Similar studies have not been reported on BCNU, 
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however. Accordingly, in the present study, we evaluated PrP
c
 and its gene in U87 
cells treated with either TMZ or BCNU, using western blotting and flow cytometry 
(for protein quantification) and qPCR (for gene quantification) at different time points 
and cell cycle phases. The details are described in the next section (3.2)               
3.2 The aim 
The work in this chapter aimed to evaluate and compare PRNP and PrP
c
 levels in 
TMZ or BCNU treated U87 cells under the assumption that they may be upregulated 
in response to the accumulation at G2/M resulting from these treatments. The 
following objectives were addressed  
 The cell cycle will initially be analysed 24h after treatment with Aphidicolin 
and Nocodazole. These are cell-cycle modulators that are known to arrest the 
cell cycle at the G1 and G2/M phases, respectively. The purpose of this set of 
experiments is to validate the experimental design and to obtain G1 and G2/M 
cells. The second round of experiments was then undertaken in which U87 
cells were treated with the alkylating agents, TMZ and BCNU, and then 
analysed using flow cytometry to determine the percentage of cells in each 
phase of the cell cycle at different time points (6 h, 12 h and 24 h with and 
without incubation for 24h and 48h).    
 The regulatory cell cycle proteins p21 and p53 were then examined to confirm 
the arrest of the cell cycle at G2/M in response to the alkylating agents.   
 The PRNP gene level of cells arrested in G1 and G2/M phases by Aphidicolin 
and Nocodazole were assessed and the effect of TMZ or BCNU on PRNP 
gene in treated U87 cells at different time points (6h+48h, 24h and 24h+48h) 
was also examined using qPCR  
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 The impact of TMZ and BCNU on the PrPc level in treated U87 cells at 24h, 
6h+24h and 24h+48h were assessed by flow cytometry and western blotting.   
3.3 Methods 
3.3.1 Preparation of treatments 
DMSO was used as a co-solvent for all treatments and as a negative control for all 
experiments. MTT assay was used to determine the concentration of DMSO that 
could be tolerated in the cellular assay. It was observed that up to 0.5% DMSO in 
culture media had no effect on cell viability (see section 3.4.2.1), hence this 
concentration was used throughout the experiments. All compounds tested were 
dissolved in DMSO at 20x the working concentration. The alkylating agents, TMZ 
and BCNU, were prepared at 20 mM as a stock. The cell cycle synchronising agents, 
Aphidicolin and Nocodazole, meanwhile, were prepared at 2.96 mM and 0.2 mM, 
respectively. These stock solutions were divided into small aliquots and stored at -80 
ºC. These aliquots of stock solution were each diluted in ten times their volume of 
PBS to prepare a working solution. An appropriate volume of the working solution 
was taken and then further diluted with 20 times of fresh medium to obtain the 
required treatment concentration for cell culturing. 
3.3.2. Cell viability assay (MTT) 
3.3.2.1 Growth curve of U87 cells 
MTT assay was applied to determine the doubling time of U87. The cells were seeded 
in four 96-well plates at 4000 cells in each well. One plate was taken to measure the 
viability each day, i.e. cell viability was quantified for plate 1 on day 1; this procedure 
was repeated to quantify the viability of cells in plate 2, plate 3 and plate 4 on days 2, 
3 and 4, respectively. The absorbance of each well reflects the viability of cells.  
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3.3.2.2 MTT assay for treated cells 
To examine the efficacy of DMSO, alkylating agents and synchronised agents, the 
viability of the treated cells was assessed by MTT assay. U87 cells were harvested 
from a T75 flask using trypsin and then counted using a haemocytometer in 10 ml 
resuspended medium. The volume of cell suspension containing the desired number 
of cells (calculated according to the incubation time of the experiment and the total 
number of cells required for the number of 96-well plates) was transferred into a 
sterile 50 ml disposable basin. A volume of fresh medium sufficient for the number of 
plates to be used was added, and then 100 µl was transferred into each well of the 96-
well plates using a multichannel pipette. The plates were incubated overnight to allow 
the cells to attach. 
The next day, 5 µl of treatment was added to each well using a multichannel pipette. 
The controls for the cell viability assay, for DMSO and the other treatments, were 
PBS and 0.5% DMSO, respectively. The density of cells, concentration of treatments 
and incubation time are shown in the table (3-1). For comparison purposes, the 
concentrations and incubation periods used for TMZ and BCNU were the same as 
previously reported for U87 cells in the literature
6,202
. The concentration of 
Nocodazole and Aphidicolin used, and the incubation period, was also in the same 
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Table (3-1): Cell density and incubation time of treated cells in MTT assay. 
 
After incubation with these treatments for 24h, the MTT assay protocol (see section 
2.2.2) was followed to quantify the cell viability.   
3.3.3. Cell cycle assay by flow cytometry 
The cells were seeded in a T25 flask in different densities according to the incubation 
time. Table (3-2) below shows the seeding density at each time point to allow for the 
cells’ growth and to ensure 80-90% confluence was reached at the end of the 
incubation period. The cells were allowed to attach overnight and were then treated 
with 14.8 µM Aphidicolin, 1 µM Nocodazole, 100 µM TMZ or 100 µM BCNU. In 
the control group, the cells were treated with 0.5% DMSO in each experiment. Later, 
all samples were washed and the protocol for cell cycle analysis (see section 2.2.3) 
was followed in order to quantify the percentage of cells in each phase of the cell 
cycle. 
  
Treatment Cell density Concentration of treatment   Incubation time (h) 
DMSO 10000 0.05%, 0.1%, 0.5% or 1% 24 
TMZ 10000 25, 50 or 100 µM 24 
BCNU 10000 25, 50 or 100 µM 24 
Aphidicolin 10000 5, 10, or 14.8 µM  24 
Nocodazole 10000 0.125, 0.25, 0.5, 0.75 or 1 µM 24 
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Table (3-2): Seeding density of U87 cells in cell cycle experiments 
Time point (h) Seeding density 
6 0.7 x 10
6
 
12 0.7 x 10
6
 
24 0.5 x 10
6
 
6+24 0.5 x 10
6
 
6+48 0.4 x 10
6
 
12+24 0.5 x 10
6
 
12+48 0.4 x 10
6
 
24+24 0.4 x 10
6
 
24+48 0.3 x 106 
  
3.3.4. RT-qPCR 
RT-qPCR was performed to assess the level of the PRNP gene in the treated cells.  
The cells were harvested from a T75 flask and then cultured in 6-well plates at 
different densities depending on the incubation time. The cell densities and the 
incubation times of the cells are shown in table (3-3).  
Table (3-3): The incubation times and cell densities for RT-PCR experiment 
Incubation time Cell density Volume of medium (ml) 
24h 200000 2 
6+48h 150000 2 
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Different experimental groups were designed to quantify the effect of the treatments 
on the PRNP gene in the U87 cells, as follows:    
Experiment 1: This experiment included two parts. 
 The cells were treated with TMZ or BCNU for 6h and then left for 48h in 
fresh medium without treatment.  
 The cells were treated with Aphidicolin and Nocodazole for 24h. 
Experiment 2: The cells were incubated with TMZ or BCNU treatments for 24h. 
Experiment 3: The cells were treated 24h with TMZ or BCNU and incubated 48h in 
fresh medium.  
The diagram below shows the design of these experiments (Figure 3-1). 
 
Figure (3-1): A summary of the experimental designs showing the different time points and treatments.     
In each experiment, the cells were treated with TMZ, BCNU, Aphidicolin or 
Nocodazole by adding 100 µl of the working solution of these treatments in each well. 
The control was treated with 0.5% DMSO. After incubation with the treatment, the 
total RNA was extracted using a PureLink RNA Mini kit (Ambion by Life 
Technologies) (see section 2.2.4.1). RNA extractions were normalised using RNase 
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free water and then 1-6 µl of RNA extraction was used to synthesise cDNA according 
to the protocol described in section (2.2.4.2). PRNP gene expression was quantified 
using the PowerUpTM SYBR Green Master Mix system (Applied Biosystem) and the 
primers that were listed in section (2.2.4.3).  
3.3.5. Protein expression analysis by western blotting 
Western blot assay was carried out to investigate the levels of p21, p53 and PrP
c
 in the 
treated cells. For p21 and p53, the cells were seeded in a 6-well plate and then, after 
24h for attachment, were treated with 100 µM TMZ or BCNU for a further 24h. The 
medium was then replaced with fresh medium (i.e. without treatment) and the plates 
were left to incubate for 48h. The cells were then washed and harvested to obtain cell 
lysate. The procedure for western blotting was carried out according to the procedure 
described in section (2.2.5). The dilution factor for primary antibodies of p21 and p53 
was 1:500 in blocking solution (5% milk in TBS-T), as recommended by the Santa 
Cruz Biotechnology protocol, whereas the secondary antibody (Goat anti-mouse IgG 
antibody) was diluted 1:4000 in TBS-T.  
For PrP
c
 assessment, the cells were seeded and treated in the same way as described in 
section (3.3.4). When the incubation time was completed, the procedure for western 





 expression by flow cytometry  
To validate the results of the western blot analysis, the PrP
c 
expression in the treated 
cells was assessed by flow cytometry. The cells were cultured and treated after 
6h+48h, 24h and 24h+48h (as described in section 3.3.4). After the desired incubation 
time, all the samples were washed in PBS and then the protocol for flow cytometry 
was applied (see Section 2.2.6) to evaluate PrP
c
 level. The mean of the fluorescence 
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intensity (MFI) of each sample obtained by flow cytometry was normalised to the 
MFI of its isotype. 
3.4 Results 
3.4.1 U87 growth curve 
A growth curve was plotted to ensure that the cells used in the experiments were in 
the growth phase. This could also be used to estimate the number of cells in each 
experiment. The cells were cultured in the same density, and their viability was then 
measured on days 1, 2, 3 and 4 by MTT assay. According to the resulting cellular 
growth curve, the population doubled after approximately 30 hours. The population 
on days 3 and 4 then increased to be about twice that of days 2 and 3, respectively.  
(Figure 3-2)  
 
Figure (3-2): Growth curve for U87 cells over four days. The results represent mean ± SD for the 
octuplicate of three independent experiments, n=24.  
3.4.2 Cell viability of U87 cells  
The viability of the treated cells was assessed using the MTT assay. All displayed 
data were calculated as a percentage in respect to the untreated sample (control). 
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3.4.2.1 Cell viability of U87 in DMSO 
This experiment was performed to determine the concentration of DMSO that had no 
effect on the viability of U87 cells since DMSO was used as a co-solvent for the other 
treatments. The results of cell viability for various concentrations of DMSO (0.05%, 
0.1%, 0.5% and 1%) after 24h are shown in Figure (3-3). There was no great effect 
for DMSO concentrations of 0.05%, 0.1% and 0.5%, but a concentration of 1% 
DMSO resulted viability decreasing to 80.3%±4.2. It was therefore decided to 
dissolve all the treatment compounds in 0.5% DMSO for all subsequent experiments.  
 
Figure (3-3): Cell viability of U87 cells in different concentrations of DMSO. The bar chart represents 
the percentage of viable cells in comparison to control. All the data were performed in triplicate for 
four different experiments and the statistical analysis was by one-way ANOVA with Tukey’s test 
(n=12, **=p<0.01).    
3.4.2.2 Viability of U87 cells treated with TMZ and BCNU  
TMZ and BCNU were selected to treat U87 glioblastoma cells in this study in order to 
evaluate the PrP
c
 level. It was therefore important to evaluate the viability of U87 
cells when subjected to these treatments in order to determine the concentrations of 
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varying concentrations of TMZ or BCNU (25 µM, 50 µM, 100 µM) for 24h. The 
viability of the cells was calculated and normalised as a percentage in respect to the 
untreated control cells. Figure (3-4) shows that there were no significant variations in 
cell viability associated with any of the concentrations used. 100 µM was therefore 
used for the following experiments.    
 
Figure (3-4): The viability of U87 cells treated with a series of concentrations of TMZ and BCNU. The 
chart signifies the ratio of viable cells in comparison to the control. The data represent mean ± SD for 
the triplicate of three different experiments (n=9). The results were analysed using one-way ANOVA 
with Tukey’s test.  
3.4.2.3 Viability of U87 cells treated with Nocodazole and Aphidicolin  
Nocodazole and Aphidicolin were used to arrest U87 cells in the G2/M and G1 phases, 
respectively. The MTT assay was used to determine the appropriate concentrations of 
these agents. The cells were therefore treated with Nocodazole and Aphidicolin at 
different concentrations for 24h. It was found that 1 µM of Nocodazole significantly 
reduced cell viability to approximately 75% of that of the control group, while the 
cells with 14.8 µM (5 µg/ml) Aphidicolin displayed no significant change in the 
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subsequent experiments since it was found that lower concentrations were unable to 
arrest the cell cycle after 24h (data not shown). Regarding Aphidicolin, 14.8 µM was 
used in the subsequent experiments.  
 
Figure (3-5): Cell viability for U87 cells in synchronised agents. The bar charts represent mean ± SD 
of cell viability in respect to a series of concentrations of Nocodazole (A) and Aphidicolin (B). These 
experiments were repeated three times, and each conducted eight times (n=24). The data were analysed 
by one-way ANOVA with Tukey’s test (**=p<0.01).  
3.4.3 Cell cycle arrest 
3.4.3.1 Cell cycle arrest by Aphidicolin and Nocodazole 
To establish and optimise the assay, U87 cells were treated for 24h with the known 
cell cycle agents, Aphidicolin and Nocodazole to arrest the cells in the G1 and G2/M 
phases, respectively. The cell cycle synchronisation was performed using flow 
cytometry. The distribution of phases in the cell cycle changed after treatments with 
these compounds in comparison with untreated cells, as shown in Figure (3-6). It was 
found that around 83% of U87 cells were blocked in G1 when exposed to Aphidicolin 
(Figure 3-6, B). This result may be attributed to the blocking of DNA replication 
resulting from the inhibition of DNA polymerase by Aphidicolin
220
. Nocodazole, 
meanwhile, caused approximately 80% of the population of these cells to accumulate 
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in G2/M (Figure 3-6, C). This observation confirms that Nocodazole, a microtubule 





Figure (3-6): Cell cycle synchronisation of U87 cells by Nocodazole and Aphidicolin. The histograms 
show the cells which were synchronised by these treatments for 24h compared to the control (A). The 
bar charts illustrate the percentage of synchronised cells in each cell cycle phase with Aphidicolin (B) 
and Nocodazole (C). The results represent the mean ± SD for three independent experiments each in 
duplicate and all the data were analysed using t-test (n=6, *=p˂0.05, ****= p˂0.0001)     
3.4.3.2 Cell cycle analysis following treatment with TMZ and BCNU 
To assess the effect of alkylating agents on the cell cycle, U87 cells were treated with 
TMZ or BCNU at multiple time points (6h, 12h and 24h) with and without incubation 
for 24h and 48h. As can be seen from the histograms (Figure 3-7 A, C) and the bar 
charts (Figure 3-8 A), the cells that were exposed to TMZ displayed a gradual 
increase in G2/M arrest in a time-dependent manner compared to the control, 
recording the highest level (̴ 83%) at 24h+48h. With BCNU, meanwhile, the G2/M 
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cells increased dramatically when the period of treatment was extended from 12h to 
24h and then, on incubation, fluctuated to reach the highest level (̴ 83%) at 24h+48h 
(Figure 3-7 B, D and Figure 3-8 B). Indeed, cells with BCNU showed a similar cell 
cycle distribution as TMZ, except that at 12h, 24h, and likewise after incubation at 
6h+24h and 12h+24h, BCNU appeared more potent than TMZ in terms of arresting 
the cells in G2/M (Figure 3-8 C). These findings confirmed the results obtained by 
other studies, albeit with some variations. The distribution of the cell cycle for U87 
cells was previously shown to alter in response to TMZ or BCNU but to start to lose 
2N (DNA content) content after 12h exposure followed by 24h post-treatment, and 
this continued until 120h post-treatments
202
. Furthermore, another study showed that 
TMZ began accumulating cells in G2/M from 1 day to 10 days, after just 3h of 
treatment
221
. Generally, the arrest of cells by TMZ or BCNU can be ascribed to the 
induction of DNA damage, which serves to activate and accumulate p53 and p21
202
. 
Based on these results, three time points were selected to evaluate the level of PRNP 
and PrP
c
: 24h, 6h+48h and 24h+48h.  
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Figure (3-7): TMZ and BCNU induced cell synchronisation in the G2/M phase. Histograms shows that 
U87 cells were growth arrested following treatment with 100 µM of either TMZ or BCNU. A and C, 
U87 cells treated for 6, 12 and 24h with TMZ or BCNU, respectively. B and D, most of cells were 
arrested in G2/M when the cells were subsequently incubated without treatment for 24 and 48h.  
Chapter 3: Results section 1 
- 78 - 
 
 
Figure (3-8): The effect of alkylating agents on the U87 cell cycle. TMZ (A) and BCNU (B) increased 
cells in the G2/M phase according to the period of treatment and the incubation subsequent to treatment. 
(C) represents the comparisons of G2/M cells among the cells treated with TMZ or BCNU at different 
time points. These experiments were performed in duplicate and repeated three times (n=6). The data 
were statistically analysed as the mean ± SD; in this case using the t-test since we were comparing each 
phase of the cell cycle with its counterpart in the control (A and B) as well as between TMZ and BCNU 
(C) (n=6, *=p˂0.05, **= p˂ 0.01, ***=p˂0.001 ****= p˂0.0001).   
A 
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3.4.4 p21 and p53 expression increased in U87 cells treated by TMZ and BCNU  
As shown in the previous section (3.4.3.2), TMZ and BCNU arrest U87 cells in the 
G2/M phase; an effect attributed to the accumulation of p21 and p53 proteins that 
regulate the cell cycle. To confirm this, the expression of these proteins was evaluated 
for treated cells at 24h+48h. Our results show that p21 levels were significantly higher 
in the treated cells compared to the control group (about three times higher in respect 
to TMZ, and four times higher in respect to BCNU). (Figure 3-9, A). p53 also 
increased significantly in the treated cells, relative to untreated cells, as shown in 
(Figure 3-9, B) – about 2 to 1.5 folds in TMZ and BCNU respectively.  
 
Figure (3-9): p21 and p53 expression levels in TMZ or BCNU treated cells by western blot. 
Expressions of p21(A) and p53 (B) in U87 cells indicated that the expressions of both proteins were 
markedly increased in U87 treated with TMZ or BCNU for 24h+48h. The data were analysed as the 
mean ± SD using one-way ANOVA with Tukey’s test, for at least three independent experiments (n=3, 
**=p˂0.01, ***=p<0.001).  
Chapter 3: Results section 1 
- 80 - 
 
3.4.5 PRNP expression by qRT-PCR 
To determine whether U87 cell cultures exposed to 100 µM of TMZ or BCNU would 
change PRNP gene expression levels, the following experiments were designed, as 
mentioned in section (3.3.4): 
Experiment 1: The cells were treated with TMZ or BCNU for 6h and then left for 
48h without treatment. Another group of cells were treated with Aphidicolin or 
Nocodazole for 24h.  
Experiment 2: The cells were incubated with treatments (TMZ or BCNU) for 24h.  
Experiment 3: The cells were treated 24h with TMZ or BCNU and incubated 48h in 
fresh medium. 
The purpose of experiment 1 was to assess the effect of TMZ and BCNU on the gene 
expression. Furthermore, the correlation of the PRNP level in the G1 and G2/M 
phases was also investigated. The cells were treated for 24h with the synchronising 
agents Aphidicolin and Nocodazole in order to evaluate the expression of the PRNP 
gene in cells that arrested in G1 and G2/M, respectively. Figure (3-10 A) shows the 
influence of the above treatments on the mRNA expression level of PrP
c
. The PRNP 
gene expression was slightly increased when the cells were treated with TMZ or 
Nocodazole. This result revealed that the mRNA expression in the G2/M-arrested 
cells by TMZ or Nocodazole was increased when compared to the control. On the 
other hand, even though BCNU arrested the cells in the G2/M phase, the PRNP gene 
expression level was not affected. Furthermore, there was no significant variation in 
gene expression in the case of cells arrested at G1 using Aphidicolin.   
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In experiment 2, there was no significant variation in PRNP expression in the TMZ or 
BCNU when assessed after 24h of treatment alone, without resting (Figure 3-10 B). 
According to Experiment 3, the expression of PRNP in the cells was significantly 
increased when compared with untreated cells. It is clear that a longer treatment and 
incubation period promotes the expression of PRNP gene in the cells arrested at G2/M 
by TMZ and BCNU. The significance value was higher with TMZ than with BCNU, 
however (Figure 3-10 C).  
In general, these results confirmed that the PRNP gene in U87 cells increased in 
G2/M cells, resulting from G2/M-induced treatments, Nocodazole, TMZ and BCNU, 
with some variations depending on the duration of the treatment and the rest after the 
treatment. The gene profile of G2/M U87 cells resulting from TMZ treatment in the 
previous study showed that 83 genes were changed relative to the G1/S cells and the 
PRNP gene was the most significantly altered gene among these genes
6
.  In our 
results, TMZ increased levels of the PRNP gene in U87 cells more than BCNU. In the 
previous section (3.4.4), the induction of p53 in TMZ treated cells was also higher 
than with BCNU. p53 is induced in response to DNA damage resulting from various 
stimuli, including chemotherapies
62
. It has been reported that PrP
c
 may protect the 
tumour cells from pro apoptotic stimuli such as chemotherapy and DNA damage
184
. 
Thus, increasing the PRNP gene, as a cytoprotective factor, in cells treated with TMZ 
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Figure (3-10): PRNP expression in treated U87 cells. mRNA expression of PRNP in cells were treated 
with synchronising agents and alkylating agents (Experiment 1) (A). mRNA expression of PRNP in 
cells were cultured with TMZ or BCNU, Experiment 2 (B) and Experiment 3 (C). The expression was 
measured in comparison to untreated cells as a control using the 2
-ΔΔCt
 method and normalised to the 
human housekeeping gene GAPDH. The results were performed in triplicate for three independent 
experiments. The data represents mean ± SD and were analysed using one-way ANOVA, and Tukey’s 
test (n=9, *=p<0.05, **=p<0.01, ****= p<0.0001). 
3.4.6 PrP
c
 expression level by Western blotting (Experiment 1, 2 and 3) 
Western blot assay was performed to evaluate the PrP
c
 level in treated cells and to 
find out the correlation between the gene and protein level in all the experiments 
mentioned above (section 3.3.5). PrP
c
 expression was quantified in the U87 cells 
treated with synchronising agents (Aphidicolin and Nocodazole) or alkylating agents 
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(TMZ and BCNU) compared to the protein level in untreated cells. A band of ~42 
kDa (β-actin) as a loading control was produced by all the treated cells and the control. 
A clear band of ~35 kDa represents the PrP
c
 level in treated and untreated cells.  
Experiment 1: The band for PrP
c
 (~35 kDa) in cells treated with alkylating or 
synchronised agents had the same intensity as with the untreated cells. Thus, there 
was no significant change in the PrP
c
 level observed in any of the treated cells (Figure 
3-11). The protein expression results in cells treated with TMZ or Nocodazole were 
therefore inconsistent with the gene expression results for cells treated with these 
compounds, as indicated in section (3.4.5 Experiment 1). In the case of the gene 
expression, there was a small bit statistically significant increase in the level of the 
PRNP gene, but it may be that this was not enough to produce a noticeable change in 
the protein level.  
 
Figure (3-11): Western blotting for PrP
c
 in U87 cells (Experiment 1). Image of the membrane that 
was exposed to anti-prion antibody 3F4 and reprobed with β-actin as a loading control (A). The bar 
chart represents the mean ± SD of the control and treated groups (B). The data were normalised to the 
intensity of β-actin and the control group. The results were analysed using one-way ANOVA with 
Tukey’s test for at least three separated experiments (n=3). 
In addition, the cells were treated for 24h with TMZ or BCNU (Experiment 2) to 
evaluate the expression of protein. Figure (3-12) shows that the expression of PrP
c
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was not affected in the cells treated with TMZ or BCNU. These results were 
consistent with those for the gene expression.  
 
Figure (3-12): Western blotting analysis of PrP
c
 in U87 cells (Experiment 2). The cells were exposed 
to alkylating agents for 24h. The membrane was probed with 3F4 (PrP) antibody and β-actin as a 
positive control (A). The chart shows the analysis of the protein level in the treated cells (B). The data 
was normalised to the intensity of β-actin and control group and represents mean ± SD. The results 
were performed in at least three independent experiments and analysed using one-way ANOVA, with 
Tukey’s test (n=3).   
The PrP
c
 level in cells treated with TMZ or BCNU for 24h followed by 48h of 
incubation post treatment (Experiment 3) was also evaluated to determine the effect 
of a longer dosing period and longer incubation after treatment. The results in Figure 
(3-13) revealed a significant decrease in the PrP
c
 level in treated cells compared to the 
control group. These results were in contrast with the results of the PRNP gene level 
mentioned above (Section 3.4.5 Experiment 3), which showed a significant increase 
in PRNP level. One explanation could be that the transcription of the PRNP gene may 
be affected due to the G2/M accumulation of U87 cells for a long period. Another 
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Figure (3-13): Western blotting analysis for PrP
c
 in U87 cells treated 24+48h with TMZ and BCNU 
(Experiment 3). The PVDF membrane was exposed to 3F4 antibody and reprobed with β-actin as a 
positive control (A). The bar chart shows the comparisons among all tested groups (B). The data were 
normalised to intensity of β-actin and control group. The results represent mean ± SD for at least three 
independent experiments (n=3). The statistical analysis was carried out using one-way ANOVA with 
Tukey’s test (****=p<0.0001). 
3.4.7 Characterisation of PrP
c
 expression by flow cytometry 
Evaluation of PrP
c
 by flow cytometry was carried out to assess the total PrP
c
 (cell 
surface and intracellular) by fixed and permeabilised U87 cells, and cell surface PrP
c
, 
using the live cells in each experiment. This experiment was also carried out to 
confirm the results of the western blotting. 
3.3.7.1. PrP
c
 expression in treated cells (Experiment 1) 
In flow cytometry, the cells were gated as a forward scatter (FSC) and side scatter 
(SSC) to exclude clumped cells and any cellular debris. In other words, the gates were 
used to select single cells. The histograms were made from the population of single 
cells in these gates. The histograms represent the account of single cells/events to 
standard filter (blue 530-30) i.e. florescent intensity (Figure 3-14, A and B). Our 
results showed that there was no significant effect on PrP
c
 in treated cells (fixed and 
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live) relative to the control group (Figure 3-14, C and D). These findings were in 
agreement with the western blot results.   
 
Figure (3-14): The expression of PrP
c
 in treated U87 cells by flow cytometry (Experiment 1). A and 
B, PrP
c
 expression in the gated population is demonstrated in the histograms (live cells and fixed 
respectively). C and D represent mean ± SD for the expression of PrPc for all samples (live cells and 
fixed respectively) that were performed in duplicate for at least three experiments and normalised to 
isotype (n=6). The results were analysed by one-way ANOVA, with Tukey’s test. 
3.4.7.2 PrP
c
 level in U87 cells treated with TMZ and BCNU (Experiment 2) 
To investigate the level of PrP
c
 in U87 cells treated with alkylating agents over 24h, 
the cells were treated with 100 µM of TMZ or BCNU and a flow cytometry assay was 
carried out. Figure (3-15, A and B) revealed the histograms of fluorescent intensity for 
single cells at a standard filter (blue 530-30). As can be seen, the level of PrP
c
 in TMZ 
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or BCNU treated cells was not affected relative to the control group in either 
experiment for either live or fixed cells (Figure 3-15, C and D respectively). These 




 expression in treated U87 cells by flow cytometry (Experiment 2). PrP
c
 
expression in the gated population is represented in the histograms (A and B). The C and D represent 
mean ± SD of the normalised expression of PrPc in all groups (live cells and fixed respectively). These 
experiments were performed three times, each in duplicate (n=6). The results were analysed by one-
way ANOVA, with Tukey’s test. The data showed no significant change in protein level.  
3.4.7.3 PrP
c
 level in treated cells with alkylating agents (Experiment 3) 
To assess the level of PrP
c
, the cells were treated with TMZ or BCNU for 24 h and 
then left to rest for 48h in fresh medium (Experiment 3). PrP
c
 level was determined 
using flow cytometry in live and fixed cells (Figure 3-16, A and B, respectively). This 
figure showed the histograms of all groups according to the value of fluorescent 
intensity. The results of live cells matched those in fixed cells. It is obvious that there 
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was a significant reduction in PrP
c
 level in the cells treated with TMZ or BCNU 
compared to the control group (Figure 3-16, C and D). These observations completely 




 expression in treated U87 cells by flow cytometry ((Experiment 2). A and B, PrP
c
 
expression in the gated population is represented in the histograms (live and fixed cells respectively). C 
and D represent the expression of PrP
c
 in treated cells (live and fixed cells respectively). The results 
reveal mean ± SD of three independent experiment, each performed in duplicate (n=6). All data were 
statistically analysed by one-way ANOVA, Tukey’s test (**=p<0.01, ***=p<0.001). The results 
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3.5 Summary of key experimental results  
 Aphidicolin and Nocodazole served to accumulate the U87 cells in G1 and 
G2/M phases, respectively. TMZ and BCNU both arrested the U87 cells in 
G2/M, but BCNU was more potent in the accumulation of these cells. Resting 
subsequent to the treatment with TMZ and BCNU increased the number of 
G2/M cells. 
 TMZ and BCNU increased the level of regulatory cell cycle proteins p21 and 
p53.  
 TMZ and Nocodazole arrested the cells in the G2/M phase and increased 
PRNP gene expression in U87 cells in Experiment 1 (6h+48h) whereas 
Aphidicolin (G1 arrest) did not induce PRNP gene expression in these cells. 
 In Experiment 3 (24h+48h) TMZ and BCNU increased the level of the PRNP 
gene and the downregulated PrP
c
 level. 
 Overall, both alkylating agents (TMZ and BCNU) arrested the U87 cells in 
G2/M and altered the level of PRNP and PrP
c
, while TMZ upregulated the 
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3.6 Discussion  
The aim in this chapter was to assess and compare the effect of the common 
glioblastoma treatments, TMZ and BCNU, on the level of PrP
c
 using U87 cells as a 
model for human glioblastoma under the assumption that PrP
c
 may be upregulated in 
response to the accumulation at G2/M resulting from these treatments. To achieve this 
goal, various experiments were carried out, including cell cycle analysis by flow 
cytometry, the expression of genes by qPCR and protein expression by Western blot 
and flow cytometry. 
The growth profile of U87 glioblastoma cells was investigated to determine the 
population of cells over time. The doubling time of these cells was approximately 30h, 
which is close to ATCC protocol reported value (34h). This growth curve also showed 
that the U87 cells used in this study were in the growth phase, and the data was used 
to estimate the seeding density in subsequent experiments (Figure 3-2). The cell 
viability assay was performed to determine the proportion of viable cells upon 
exposure to different agents or treatments. For all treatments used, MTT assay data 
showed that all the reagents or treatments did not reduce the cell viability at tested 
concentrations, except for Nocodazole at a higher concentration of 1 µM (Figures 3-3, 







) chosen in this study were guided by previous studies.   
To develop the assay, optimise experimental conditions and make data comparable 
with known cell cycle arresting agents, the cells were treated with Aphidicolin or 
Nocodazole. The reason for synchronising cells using Aphidicolin and Nocodazole 
was to validate the data that resulted from TMZ and BCNU by flow cytometry 
measurement and to produce a model of the G1 and G2/M cells which was then used 
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to compare the expression of PrP
c
 in those cells and the TMZ- or BCNU-arrested 
cells. Several studies have revealed that Aphidicolin arrests mammalian cells in the 
G1 phase
222
 and it is known that it can inhibit B-family DNA polymerases and then 
suppress DNA replication in eukaryotic cells
220
. The current study showed that 14.8 
µM of Aphidicolin over 24h can arrest U87 cells in G1 by approximately 84% (Figure 
3-6 B). Nocodazole, as an antineoplastic agent, also has an effective role in cell cycle 
synchronisation. It can arrest most cells in G2/M by binding to tubulins and 
microtubules. Nocodazole disrupts the formation of the microtubule in the cell, 
thereby suppressing cell cycle progression
223
. Our work revealed that 1 µM of 
Nocodazole arrested 80% of U87 cells in G2/M after 24h (Figure 3-6 C).  
In untreated U87 cells, the population of cells distributed in G1, S and G2/M was 
69%, 8%, and 22% respectively. This distribution was changed when the cells were 
treated with TMZ or BCNU. Our results showed that TMZ and BCNU arrested the 
cells in G2/M in a time-dependent manner. U87 cells were starting to lose 2N content 
(G1 cells) after 12h treatment with TMZ or BCNU (Figures 3-8, A and B).  Indeed, 
the cell cycle population was slightly affected in cells that were exposed to TMZ for 
12h and 24h, and gradually increased in a similar trend over the same treatment 
regime as BCNU in comparison to untreated cells. In addition, BCNU had more 
profound effects in arresting cells in G2/M than TMZ at 12h, 24h, 6h+24h and 
12h+24h (Figure 3-8, C).  
These results regarding TMZ are in agreement with what Hirose et al. reported when 
they found that TMZ arrested U87 cells in G2/M. They treated these cells for 3h and 
then left them in fresh media without treatment for 1 to 10 days, and found that the 
cells began to accumulate in G2/M after day 1
224
. 
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The BCNU treated cells in our study started to lose some 2N contents (G1 phase) 
when treated for 12h. The G2/M population was significantly increased in a time-
dependent manner, particularly after the incubation of BCNU treated cells with fresh 
medium for 24h and 48h. Wei Xu et al. stated that U87 cells started to accumulate in 
S and G2/M after treating for 12h and rest 24h but the accumulation in G2/M was 
increased after 48h as a result of the upregulating of p53 and p21 proteins
202
. Our 
results showed that the cells arrested in G2/M recorded a greater increase when 
treated for 6h, 12h and 24h with 24h and 48h incubation without TMZ or BCNU. This 
could be attributed to the accumulation of p53 and p21, which regulate the cell cycle, 
resulting from DNA damage by TMZ or BCNU.  Our western blot results showed that 
the level of p53 and p21 was significantly increased in cells treated with TMZ or 
BCNU (24h+48h, Experiment 3). TMZ also upregulated the p21 level approximately 
three-fold, whereas BCNU increased the level of p21 approximately four-fold. 
Regarding p53, TMZ and BCNU induced the level of this protein by around 2 and 1.5 
folds respectively (Figure 3-9). In respect to p21 and p53 in BCNU treated U87 cells, 
our results are in agreement with previous findings, albeit with some variations. Xu et 
al. found that BCNU at 12h+48h increased the level of p21 and p53 about ten and 
five-fold respectively
202
.  On the other hand, p21 and p53 in TMZ-treated cells 
increased about 3.6- and 2-fold at 3h+48h,
224
 and these results generally agreed with 
our results, with some variations. These variations could be ascribed to the differences 
in the period of treatments or to experimental techniques.  
Since PrP
c
 has been shown to be involved in many apoptotic pathways due to its 
interaction with some proapoptotic molecules
184
,it has generally been found that 
PRNP levels increase in different types of glioblastoma cell lines
5
. Resistance to anti-
cancer therapy arises for various reasons
225
 but the arrest of glioblastoma cells in 
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G2/M by TMZ has been shown to be involved in the resistance to the treatments. We 
aimed to determine whether PRNP or PrP
c
 expressions were affected by TMZ or 
BCNU as common treatments for glioblastoma, examining this across different time 
points and cell cycle phases. In this work, PRNP expression was evaluated in U87 
cells treated with synchronising agents (Aphidicolin or Nocodazole) and alkylating 
agents (TMZ or BCNU). The results showed that the mRNA expression of PrP
c
 was 
not affected in Experiment 1 and 2, except that it significantly increased following 
treatment with TMZ, and likewise with Nocodazole (Experiment 1). Cells 
synchronised in the G1 phase by Aphidicolin revealed no significant changes in gene 
expression compared to the control group, however (Experiment 1). Furthermore, the 
PRNP gene was significantly upregulated in Experiment 3 (24h+48h) compared to 
the control group. TMZ was found to increase PRNP expression more than BCNU. 
This could be related to the high impact of TMZ on p53 induction, possibly as a result 
of TMZ-induced DNA damage, as shown in section (3.4.4). PrP
c
 may protect the 
tumour cells from pro-apoptotic stimuli such as chemotherapy and DNA damage
184
. It 
is possible, therefore, that high induction of PRNP in TMZ treated cells may be 
stimulated to protect the cells from the damage caused by these treatments. In general, 
the sharp increase of PRNP in TMZ or BCNU treated cells may be attributed to the 
arrest of the cells in the G2/M phase. Zhuang et al. found via array hybridisation 
assay that alterations in the distribution of the cell population from G1/S to G2/M 
changed the expression of many genes and PRNP most of all. In addition, they also 
demonstrated that PRNP was downregulated in the arrested cells in the G1 phase,
6
 a 
finding that was in contrast with our result concerning Aphidicolin treated cells (G1 
cells). There are no previous studies that have used qPCR to document PRNP 
expression in cells treated with alkylating and synchronising agents, however.  
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Unexpectedly, our results showed that the PrP
c 
expression level was incompatible 
with the PRNP gene level in the treated U87 cells. In both western blot and flow 
cytometry assay results TMZ and BCNU significantly downregulated PrP
c
 
expression; the opposite to their effect on the PRNP level. Few studies have 
investigated the level of PrP
c
 and its gene in alkylating agents, however. According to 
Zhuang et al., PrP
c
 was highly expressed in U87 cell lines which were arrested in the 
G2/M phase by TMZ or Nocodazole. They evaluated this protein-based upon 
Nocodazole (as a synchronising agent in the G2/M phase), Aphidicolin (arresting cells 
in the G1/S phase) and TMZ (alkylating agent 6h and 48h post-treatment). They 
suggested that PrP
c
 is upregulated when the cells accumulate in G2/M, particularly 
with TMZ (6h and 48h post-treatment), whereas PrP
c
 is downregulated in U87 cells 
synchronised at G1 phase
6
. Under the same conditions, however, our results showed a 
different trend. Regarding alkylating agents (TMZ and BCNU) (6h+48h) and 
synchronising agents 24h (Experiment 1), the western blot and FACS assay revealed 
that the protein level remained unchanged. In addition, the results for PrP
c
 level with 
TMZ and Nocodazole (Experiment 1) were inconsistent with the results for PRNP 
gene expression in TMZ or Nocodazole treated cells, as seen in Section (3.4.5 
Experiment 1). This may be attributed to the fact that the increase in the PRNP gene 
level was only slight and may have been insufficient to induce any remarkable 
increase in the PrP
c
 protein level. To our knowledge, this is the first study which has 
evaluated the effects of BCNU and TMZ treatment on the expression of PrP
c
 at 
different time points. Furthermore, 24h with TMZ or BCNU treatment, followed by 
48h resting (Experiment 3), resulted in one of the highest populations of cells 
accumulated in the G2/M phase. The level of PrP
c
 at this time point, however, was 
less than with the untreated control group, according to the western blot and FACS 
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results. This was despite the fact that qPCR showed an increase in PRNP gene levels 
compared to the control group. There may be several reasons for the observed result, 
none of which are obvious or strongly supported by the literature. One possible 
explanation could be that the lengthy treatment accumulation of the U87 cells at the 
G2/M phase may have affected the transcription of the PRNP gene. Another potential 
explanation could be that the high expression of PRNP may have accelerated 
degradation of PrP
c
. A more farfetched explanation could be that treatment led to 
increased levels of other genes which were competing with the PRNP gene in 
translation.  
To conclude, TMZ and BCNU accumulate the U87 cells in G2/M, particularly after 
incubation in fresh medium subsequent to the treatment. BCNU was more potent in 
the accumulation of U87 cells at G2/M. The accumulation of cells in G2/M by TMZ 
or BCNU led to an increase in the level of p53 and p21. The PRNP gene level was 
upregulated in TMZ and Nocodazole treated cells (6h+24h and 24h respectively) 
whereas Aphidicolin, which arrests the cells in G1, did not affect this gene. The 
PRNP gene level was also upregulated in TMZ and BCNU treated cells (24h+48h), 
but the induction of the PRNP gene in TMZ treated cells was higher than with BCNU 
treated cells. This may be due to the cytoprotective effect of PrPc, suggested by 
previous studies. Interestingly, the protein level at this time point was downregulated. 
It would be interesting, therefore, to address the effect of alkylating agents TMZ and 
BCNU on the cellular behaviour of U87 cells, and their response by knocking down 
PRNP gene expression.   
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Chapter 4: Silencing of PRNP inhibits the proliferation of U87 cells 
4.1 Introduction  
Although several lines of research have demonstrated that PrP
c
 is involved in many 
cellular processes such as apoptosis and cell proliferation, its exact physiological 
function remains unclear
3
, and even in respect to proliferation and apoptosis, the exact 
function of PrP
c
 in the cell is controversial and appears to depend on the cell type. For 
example, overexpression of PrP
c





 and stem cells of 
glioblastoma
140
 whilst knockout of PrP
c





. Furthermore, the silencing of PrP
c
 in gastric 
carcinoma cells (AGS) reduced cell proliferation and induced apoptosis through 
induction of Bax and p53
227
, whereas cell growth and apoptosis mediated by Bax and 
p53 were not observed in PRNP knockdown cells, HT29 colorectal cancer cells
228
. 
p53 as tumour suppressor protein contributes to DNA repair or induces apoptosis by 
its downstream effect on Bax
37,229
.   
The impact on treated and untreated glioblastoma cells of knocking down PrP
c
 is still 
unclear. In untreated cells, silencing of PrP
c
 by PRNP antisense in T98G glioblastoma 
cells has been shown to have a remarkable effect on apoptosis by increasing the 
apoptotic factors such as caspase3/7 and p53
185
. It was also found that silencing PrP
c
 
reduced the growth of glioblastoma tumours in mice
184
. In a separate study, knocking 
down PRNP in J889 human glioblastoma cells reduced cell proliferation and induced 
apoptosis via induction of caspase 3 activity
185
. Various other studies have shown that 
silencing of PrP
c
 reduces the resistance to chemotherapy in gastric, colon and breast 
cancer cells
168,228,153
. To the best of our knowledge, the effect of knockdown PrP
c 
on 
cell proliferation, apoptosis and cell resistance to TMZ and BCNU chemotherapies in 
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glioblastoma cells has not yet been studied. We hypothesise that the silencing of PrP
c
 
may inhibit the proliferation of U87 cells and reduce their resistance to alkylating 
agents. The effect of PRNP knockdown on proliferation, apoptosis and the cell cycle 
will therefore be evaluated in this chapter in respect to both treated and untreated U87 
cells. 
4.1 The aim 
This chapter aims to study the effect of PRNP knockdown on the proliferation and 
apoptosis of U87 cells treated with alkylating agents, based on the assumption that it 
might inhibit cell resistance to these treatments. To achieve this aim, the following 
objectives will be carried out.   
 Knockdown of the PRNP gene in U87 cells using PRNP siRNA which has 
been produced by DarmaFect. RT-qPCR (gene level), FACS, western blot 
and immunocytochemistry (protein level) techniques will be used to confirm 
the knockdown in these cells.  
 Evaluation of cell proliferation of the PrPc silenced U87 cells using MTT and 
Alamar blue assay, and proliferation marker ki67 using immunocytochemistry 
(ICC).  
 Investigation of the effect of PRNP knockdown on cell apoptosis using 
Annexin V with PI assay. 
 Assessing the response of knockdown cells to TMZ and BCNU using MTT 
assay. 
 Evaluation of the cell cycle for treated knockdown U87 cells with and without 
alkylating agents. 
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 Quantification of cell cycle regulatory proteins p53 and p21 in knockdown 
cells treated with TMZ or BCNU, as well as in untreated cells.  
4.2. Methods 
4.2.1. Cell proliferation and viability MTT assay 
To determine cell proliferation and/or viability, U87 cells were cultured in 96-well 
plates. The plates were left overnight in the incubator to allow the cells to attach. The 
next day, transfection reagents, which were prepared as described in chapter 2 
(section 2.2.9), were added to each well. The actual transfection reagents used 
(DarmaFect and siRNA) were different depending on the incubation time and cell 
density according to the manufacturer’s instructions, as shown in the table below 
(Table 4-1).  
At the end of the incubation time, the MTT assay protocol (section 2.2.2) was 
followed to quantify the viability of cells.  
Table (4-1): Cell density and the volume of transfection reagents in the proliferation 
and viability assay 




5µM (µl) Scramble 
siRNA (µl) 
24 h 5000 0.08 1  
24 h 5000 0.08  1 
48 h 4000 0.064 1  
48 h 4000 0.064  1 
3 days 3000 0.048 1  
3 days 3000 0.048  1 
4 days  2000 0.032 1  
4 days  2000 0.032  1 
5 days  1000 0.016 1  
5 days  1000 0.016  1 
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4.2.2. RT-qPCR 
In order to quantify the expression of the PRNP gene in transfected U87 cells, the 
cells were cultured in 6-well plates overnight and then the medium was removed. 
Transfection reagents were prepared following the instructions in section (2.2.9) and 
these were added as described below (Table 4-2). Fresh medium was added to obtain 
a total volume of 1500 µl. 
Table (4-2): Cell density and the volume of transfection reagents used at each time 
point to determine the PRNP level. 
 
After 24 h or 48 h of incubation with transfection reagents, the total RNA was 
extracted from the cells using the PureLink RNA Mini kit (Ambion Life 
Technologies) (section 2.2.4.1). RNA extractions were normalised using RNase-free 
water, and then 1-6 µl of RNA extract was used to synthesise cDNA according to the 





 Green Master Mix system (Applied Biosystem) and the 
primers that were described in section (2.2.4.3).  
4.2.3. PrP
c
 expression by flow cytometry  
PrP
c 
expression in knockdown cells was determined using flow cytometry after 48 h 
and five days as recommended by DharmaFECT™ Transfection Reagents-siRNA 
transfection protocol. The cells were cultured in a T25 flask at a cell density of 5×10
5
 






24 h 200000 3.2 40  
24 h 200000 3.2  40 
48 h 100000 1.6 40  
48 h 100000 1.6  40 
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 for 48 h and five days respectively. The next day, the medium was 
aspirated, and the transfection reagents were prepared following the instructions in 
section (2.2.9) where three millilitres of the total volume of PRNP and scrambled 
siRNA were prepared and added to their corresponding flasks. Fresh medium was 
added to another flask as a control. After the desired incubation time, all flasks 
(control, PRNP siRNA and scrambled siRNA) were washed with PBS, and then the 





, p53 and p21 expressions by western blot 
Western blotting assay was used to evaluate the PrP
c
 expression level in transfected 
U87 cells and to confirm the results of flow cytometry. The cells were seeded in a T25 






 for 48h, three days and five days 
respectively. This step was followed by treating the cells with transfection reagents as 
described in section (2.2.9) where the volume of scrambled and PRNP siRNA 
reagents were added, and a total volume of 3 ml was obtained. At the end of the 
incubation period, the western blotting procedure in section (2.2.5) was performed to 
quantify the level of PrP
c
. 
Western blotting assay was also used to evaluate the level of p53 and p21in 
transfected cells. The cells were first treated for three days with transfection reagents 
and then treated for 48 h with 100 µM of TMZ or BCNU. The control group was 
treated with 0.5% of DMSO alone for five days (three days + 48 h). The western 
blotting assay, as described in section (2.2.5) was carried out to quantify the level of 
p53 and p21. The dilution factor for primary antibodies of p53 and p21 was 1:500 in 
blocking solution (5% milk in TBS-T), as recommended in the protocol published by 
Santa Cruz Biotechnology. The horseradish antibody (secondary antibody) was 
probed at 1:4000 in TBS-T.  
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4.2.5. Proliferation assay using Alamar Blue 
Alamar blue assay was used to quantify the proliferation of transfected cells at 
different time points (between one and five days) in order to validate the results of the 
MTT assay. The cells were cultured in a 24-well plate as shown in figure (4-1). In the 
figure, the columns 1, 2, 3 and 4 represent the blank (without cells), control 
(untransfected cells), scrambled and PRNP siRNA, respectively. One 24-well plate 
was used for each time point. The table below (4-3) shows the cell densities and 
transfection reagents used for all time points. After 24 h, the transfection reagents 
were prepared in 500 µl medium as described in section (2.2.9) and then added to the 
cells. The blank and control wells were left without treatment, and 500 µl of fresh 
medium was added to each well. Alamar blue protocol in section (2.2.11) was 
followed to quantify cell viability after the desired incubation time.   
 
Figure (4-1): The design of Alamar blue experiment. 
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Table (4-3): A summary of the cell densities and transfection reagents for all 






in each well 
DarmaFect 
(µl) 
5 µM Scramble or 
PRNP siRNA (µl) 
1 24 h 30000 0.48 5 
2 48 h 20000 0.32 5 
3 3 days 10000 0.16 5 
4 4 days 7500 0.12 5 
5 5 days 5000 0.08 5 
 
4.2.6. Cytotoxicity LDH assay 
LDH assay was performed to evaluate the toxicity of transfection reagents on U87 
cells over the course of five days. This experiment was conducted to ensure that any 
reduction in proliferation did in fact result from the knockdown of the PRNP gene and 
not from toxicity due to the transfection reagents. The cells were cultured in five 96-
well plates at 1500 cells per well. The figure below (Figure 4-2) shows the design of 
this experiment. The transfection reagents were prepared according to the protocol 
mentioned in section (2.2.9). The LDH assay protocol was applied (see section 
2.2.10) to collect the data each day.  
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Figure (4-2): The experimental design for LDH assay. The cultured cells were divided into four groups 
Maximum LDH activity, Control, Scramble and PRNP siRNA. 
4.2.7. Immunocytochemistry (ICC) by confocal microscopy   
ICC assay was used to investigate the PrP
c
 and ki67 proteins in transfected U87 cells. 
The cells were cultured onto sterile coverslips which were previously mounted in a 
24-well plate as mentioned in section (2.2.7). ICC for PrP
c
 expression in transfected 
cells was evaluated here to validate the results of FACS and western blotting. The 
cells were seeded and transfected as in table (4-3) above for two days (48 h) and five 
days, respectively. Ki67 was assessed in knockdown cells, both treated and untreated 
with TMZ, in order to investigate the proliferation of these cells. To evaluate if the 
cells were positive for ki67, the cells treated with transfection reagent for five days as 
described in table (4-3) above. During the incubation, 100 µM of TMZ (25 µl of 20 
mM stock solution to each well) were added at day 3, and the plate was then left for 
48 h. Later, the protocol for ICC using confocal microscopy was followed to image 
the coverslips, as described in section (2.2.7).  
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4.2.8. Apoptosis assay by Annexin V with PI  
The apoptosis assay was carried out in order to evaluate the apoptotic cells in the 
transfection reagents. The cells were seeded in a 6-well plate at a seeding density of 
25×10
3
 cells per well. The next day, the cells were treated with transfection reagents 
as described in section (2.2.9) and incubated for five days. The Annexin V protocol 
(see section 2.2.3) was applied in order to quantify the rate of apoptosis.  
4.2.9. Cell cycle assay by flow cytometry 
The population of TMZ treated and untreated knockdown cells in each cell cycle 
phase was assessed by flow cytometry. The cells were cultured in a 6-well plate at a 
seeding density of 25×10
3
 cells per well. The following day, the cells were treated 
with transfection reagents as described in section (2.2.9) and then incubated for five 
days. In this experiment, the samples were grouped as a control, PRNP siRNA, 
scrambled siRNA, control/TMZ, PRNP siRNA/TMZ and scrambled/TMZ. The 
control/TMZ, PRNP siRNA/TMZ and scrambled/TMZ samples were treated with 100 
µM of TMZ (25 µl of 20 mM stock solution to each well) on day 3, then left for 48 h. 
Later, all samples were washed, and the protocol for cell cycle analysis (see section 
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4.3 Results 
4.3.1 Assessment of U87 cell viability in PRNP siRNA and Darmafect reagents 
According to the recommendations in the DarmaFect protocol, at least 80% of the 
cells in the transfection reagents should be viable if transfection is to be successful.  
To validate the effect of siRNA and DarmaFect reagents on U87 cells, the cells were 
treated with the recommended concentrations: 0.1 µl/5000 cells of DarmaFect reagent 
and 25 nM siRNA Figure (4-3 A). The results showed that 0.1 µl of the DarmaFect 
reagent with 25 nM siRNA reduced cell viability to around 62% after 48 h. It was 
therefore necessary to optimise the viability of the U87 cells by testing different 
concentrations of DarmaFect reagent and siRNA over a period of 48 h so as to obtain 
the best concentration of these reagents. Figure (4-3 B) revealed that 0.05, 0.06 or 
0.08 µl with 25 or 50 nM siRNA recorded cell viability of more than 80%. There was 
also no significant change in cell viability (around 80%) between 50 nM scrambled 
siRNA (NON-TARGET) and 50 nM PRNP siRNA (ON-TARGET) over the 48 hours 
(Figure 4-3 C). To achieve the maximum knockdown effect, 0.08 µl DarmaFect 
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Figure (4-3): Quantification of cell viability in transfected U87 cells using MTT assay. A, the bar chart 
shows the viability in transfected cells with 25 nM siRNA and 0.1 µl/5000 cells DarmaFect reagent for 
48 h. B, the chart reveals the viability of cells in the serial concentrations of siRNA/DarmaFect (25 
nM/0.05, 50 nM/0.05, 25 nM/0.06, 50 nM/0.06, 25 nM/0.08 and 25 nM/0.08). C, the chart shows that 
50 nM scrambled and PRNP siRNA with 0.08 µl/5000 cells DarmaFect exhibits cell viability around 
80%. These data represent mean ± SD of three independent experiments and each experiment was 
performed in six wells (n=18).  
4.3.2 The effectiveness of PRNP gene knockdown in transfected cells 
To assess the efficiency of PRNP gene knockdown in transfected U87 cells, the cells 
were treated with the transfection reagent for 24 h and 48 h, as recommended by the 
DarmaFect protocol, followed by qPCR analysis. The bar charts below (Figure 4-4) 
illustrate the level of the PRNP gene in the transfected and control groups. Gene 
expression decreased by approximately 90% and 86% in knockdown cells compared 
to the control group at 24 h and 48 h, respectively (Figure 4-4). 
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Figure (4-4): Relative PRNP gene expression in transfected and non-transfected U87 cells. 
Amplification plot for the cDNA of three samples was quantified using qPCR (A). Expression of the 
PRNP gene in transfected cells with siRNA reagents for 24 h and 48 h (B). The expression was 
measured in comparison to the control group using the 2
-ΔΔCt
 method and normalised to human 
housekeeping gene GAPDH. The results represent mean ± SD of three separate experiments, each 
performed in triplicate (n=9) (****=p˂0.001).  
4.3.3 PrP
c
 expression in knockdown cells 
To ensure that subsequent experiments obtained the largest reduction of PrP
c
 protein 
expression in the transfected cells, the level of PrP
c
 in knockdown cells was examined 
at different time points (two, three and five days) by flow cytometry, western blot and 
ICC by confocal microscopy.  
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 expression in transfected cells by Flow cytometry   
To quantify the level of PrP
c
 in the knockdown U87 cells, the cells were transfected 
for two and five days and then flow cytometry assay was performed. The level of the 
protein was found to have declined by around 80% in cells treated with PRNP siRNA 
in comparison with scrambled and untreated cells, while the percentage of positive 
cells in PRNP siRNA (i.e. cells with PrP
c
 expression) decreased to 23% after 48 h 
(Figure 4-5 Day 2).  In addition, the protein level was assessed after five days using 
flow cytometry. The protein level of each sample was normalised to the comparable 
isotype and the percentage of positive cells in each sample was calculated as a 
percentage to the control. Figure (4-5 Day 5) illustrates that the protein level 
remaining decrease by about 83% and the positive cells were around 20% compared 
to control, the level of protein in scramble cells was decreased in day 5 when 





Chapter 4: Results section 2 
- 109 - 
 
 
Figure (4-5) Expressions of PrP
c
 in transfected U87 cell according to flow cytometry. The level of PrP
c
 
and percentage of positive parent cells both decreased in PRNP siRNA cells (after two and five days) 
(A) and (B) respectively. The histograms showed the cell number and fluorescent intensity of all 
samples (C). The data represents mean ± SD of three different experiments, each performed in 
duplicate (n=6). The data was statistically analysed using t-test (****=p˂0.001).  
4.3.3.2 PrP
c
 expression in transfected cells by Western blot and ICC  
To further confirm the results of PrP
c
 expression in knockdown cells, western blot and 
confocal microscopy were carried out for untreated, scrambled and PRNP siRNA 
cells. As can be seen in Figure (4-6 A), the PrP
c
 level was significantly decreased in 
PRNP siRNA cells compared to the control and scrambled cells on days 2, 3 and 5. 
The PrP
c
 level in knockdown cells was significantly decreased on days 2 and 3 
relatives to the scrambled and untreated cells, by 79% ± 7% and 81% ± 3%, 
respectively. On day 5, the protein level was also significantly reduced relative to 
untreated cells, while the protein level in the scrambled cells was slightly decreased 
compared to the control (untreated cells). In addition, ICC images showed that the 
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 level in PRNP siRNA cells declined on days 2 and 5 in comparison to the control 
and scrambled cells. It can be seen that the intensity of PrP
c
 (green colour) was 
reduced in knockdown cells relative to the scrambled and control groups (Figure 4-6, 
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Figure: (4-6) Expressions of PrP
c
 in transfected U87 cells.  According to western blot analysis, the 
level of PrP
c
 decreased in PRNP siRNA cells (2, 3 and 5 days), the data were normalised to the 
intensity of β-actin and the control group (A). Confocal microscopy images show the expression of 
PrP
c
 in control, scrambled and PRNP siRNA cells after two days (B) and five days (C). The western 
blot results represent mean ± SD of three independent experiments (n=3) (**=p˂0.01, 
****=p˂0.0001).    
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4.3.4 PRNP knockdown reduces the proliferation of U87 cells  
The MTT cell proliferation assay was carried out to study the effect of PrP
c
 silencing 
on the proliferation of U87 cells. The proliferation rate of PRNP knockdown cells was 
decreased in comparison with the scrambled cells in a time dependent manner (Figure 
4-7 A and B). The line graph (Figure 4-7, A) shows that the proliferation of PRNP 
siRNA cells decreased dramatically over five days, with the lowest value of 
approximately 45% recorded on the fifth day. This graph represents five experiments 
(i.e. each experiment represents a single time point) using different cell seeding 
densities and incubation times (1 to 5 day/s). In these experiments, the cell density on 
days 1, 2, 3, 4 and 5 was 5000, 4000, 3000, 2000 and 1000 cells, respectively, in order 
to avoid the over confluence of cell culture in the well plate at the end of the 
experiment. The quantity of transfection reagent (DarmaFect) was added in proportion 
to the cell seeding density, as described in section (2.2.9). The trends in Figure (4-7, 
A) were confirmed using the same cell density (1000 cells) and quantity of DarmaFect 
over 5 days to avoid potential cytotoxicity resulting from variability in DarmaFect 
concentrations (Figure 4-7, B). These results were also confirmed using Alamar blue 
assay as shown in Figure (4-7, C). These observations indicate that silencing of PrP
c
 
reduces the proliferation of U87 cells.  A possible explanation for the downregulation 
of PrP
c
 is that the proliferation of cancer cells is indirectly inhibited due to 
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Figure (4-7): Cell proliferation of transfected U87 cells. Knockdown of PRNP gene in U87 cells 
reduces cell viability using the proliferation assays MTT (A and B) and Alamar blue (C). All data were 
calculated as a percentage to the control group. These results represent mean ± SD for three different 
experiments, each performed six times (n=18).  The results were statistically analysed using t-test (**= 
p˂ 0.01, ***=p˂0.001 ****= p˂0.0001).   
4.3.5 Knockdown of PrP
c
 in U87 cells does not induce cytotoxicity according to 
LDH assay 
According to MTT and Alamar blue assays, the number of cells was reduced due to 
the knockdown of the PRNP gene. Both of these techniques depend on the metabolic 
activity of viable cells
230
. LDH assay, on the other hand, measures the activity of 
lactate dehydrogenase (LDH) as a result of damaged cells
231
. The LDH assay was 
performed in order to prove that the reduction of cells did not result from the toxicity 
of the transfection reagent. The line graph in Figure (4-8) shows that there was no 
significant change in cytotoxicity between PRNP siRNA and scrambled lines. The 
toxicity was approximately 20% or less at all time points, which is acceptable 
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according to the DarmaFect protocol. These results indicated that the transfection 
reagents were not significantly cytotoxic during the incubation periods.  
 
Figure (4-8): Cytotoxicity of transfection reagents in U87 cells by LDH assay. The line graph shows 
no significant change across all time points. The results were calculated as a percentage of the control. 
The data represent mean ± SD of three separate experiments, each performed at least five times (n=15). 
These data were analysed using one-way ANOVA with Tukey’s test.  
4.3.6 PrP
c
 knockdown inhibits proliferating marker ki67 
Proliferation marker ki67 was evaluated to confirm the reduction of cell proliferation 
in PRNP knockdown cells. Many studies have used ki67 as an independent index for 
predicting cancer progression
232
. ICC by confocal microscopy was used to estimate 
the number of ki67 positive cells. The images in Figure (4-9, A) show the total 
positive cells in the scrambled and PRNP siRNA samples after five days. The bar 
chart below (Figure 4-9, B) shows that the percentage of ki67 positive cells among the 
knockdown cells decreased significantly after five days to about 55% of the total, 
compared to scrambled cells where approximately 70% of the total number of cells 
were positive for ki67. Thus, knockdown of PRNP reduced the proliferation rate of 
U87 cells.  
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Figure (4-9): ICC for ki67 in PRNP knockdown cells. (A) In the ICC images, cell nuclei were stained 
with DAPI (blue) and ki67 was stained with anti ki67 antibody (green), the analysis of these images 
was performed using Image J. (B) The bar chart reveals the percentage of cells to the total number of 
cells in each sample as mean ± SD of three experiments, each performed in duplicate, and the data were 
calculated for 30 images for each sample (10 images per experiment) n=6. These data were statistically 
analysed by t-test (**=p<0.01).  
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4.3.7 Knockdown of PRNP gene does not induce apoptosis in U87 cells either 
when treated with TMZ or untreated  
To find out whether knockdown of PrP
c
 in U87 cells induced or inhibited the 
apoptosis, Annexin V assay with PI staining was carried out with and without TMZ. 
The flow cytometry blots (Figure 4-10) show the population of apoptotic, live and 
dead cells. As reviewed in sections 1.7.2.3, PrP
c
 may improve the viability of cancer 
cells by inhibiting pro-apoptotic stimuli. We, therefore, expected that the knockdown 
of PrP
c
 would induce the apoptosis of U87 cells. Unexpectedly, however, statistical 
analysis of the current results indicated that the apoptosis in both untreated and treated 
knockdown cells was not significantly different to that of the scrambled cells (Figure 
4-10, A and B). 
Figure (4-10): The apoptosis of PrP
c
 knockdown cells using Annexin V with PI. The dot blots and bar 
chart reveal the apoptosis ratio of scrambled and PRNP siRNA cells, A (untreated) and B (treated with 
TMZ). The results represent mean ± SD of three different experiments and each experiment was 
performed in duplicate (n=6). The data were statistically analysed by t-test.   
Scramble 
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 silencing does not influence chemotherapeutic resistance in U87 cells 
by MTT assay 
To examine whether the PRNP knockdown affects the response of U87 cells towards 
alkylating agents TMZ and BCNU, MTT assay was carried out using a range of TMZ 
and BCNU treatment doses which have previously shown dose-dependent effects on 
U87 cells. The scrambled and PRNP siRNA cells were treated for 48 h with TMZ and 
BCNU at low (20-100 µM) and high doses (100-300 µM and 50-200 µM, 
respectively). The line graphs reveal that there were no significant differences in the 
cell viability of treated PRNP siRNA cells compared to treated scrambled cells over 
48 h (Figure 4-11). Thus, the knockdown of PrP
c
 in U87 cells did not increase or 
decrease the response to these treatments according to MTT assay. To our knowledge, 
this is the first study to have evaluated the effect of TMZ and BCNU on PRNP 
knockdown U87 cells. One other study, however, has explored the knockdown of PrP
c
 
in the breast cancer cell line, MDA-MB-435, showing that this knockdown induced 
resistance to doxorubicin but was not affected by other treatments (paclitaxel and 
staurosporine) after 48 h
8
.   
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Figure (4-11): Knockdown of PrP
c 
in U87 cells does not affect the response to TMZ or BCNU.  A, the 
line graphs show the cell viability in low dose treatments for 48 h. B, the line graphs revealed the 
viability of cells treated with a high dose of TMZ and BCNU for 48 h. The data represent mean ± SD 
of three independent experiments, each performed in six wells for (n=18). These results were analysed 
by t-test. 
4.3.9 PRNP knockdown cells affect the cell cycle of TMZ treated U87 cells 
Cell cycle analysis was performed in order to assess the population of transfected U87 
cells in each phase with and without TMZ treatment. Our previous results in section 
3.3.3.2 showed that TMZ arrested U87 cells at different time points. Transfected cells 
were therefore treated with TMZ for 48 h. The histograms show the percentage of 
cells in each phase, and the bar chart reveals the analysis of this experiment (Figure 4-
12, A and B). The cell cycle phases in untreated PRNP siRNA and scrambled cells 
were identical to those in the control group, whereas the G1 and G2/M populations 
were significantly changed in treated PRNP siRNA cells in comparison with treated 
control and scrambled cells Figure (4-12). The mechanism of how the knockdown of 
PrP
c
 alters the population of cell cycle phases in glioblastoma cells treated with 
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alkylating agents has not as yet been described in the literature, however. Our results, 
though, suggest that the decrease in treated knockdown cells at G2/M may be ascribed 
to the alteration of the regulatory cell cycle proteins p53 and p21. This based on the 
evidence that the accumulation of TMZ-treated U87 cells in G2/M required both p53 
and p21
233
. The levels of these proteins will be assessed in the next section (4.3.10).  
 
Figure (4-12): Determination of cell cycle phases in knockdown cells using PI. A, the histograms show 
the population of cell cycle phases in the control, scrambled and PRNP siRNA cells with and without 
TMZ. B, the bar chart shows that there is no change among the groups without TMZ but that the cells 
were accumulated in G2/M in groups treated with TMZ. The treated PRNP siRNA cells showed less 
accumulation in G2/M compared to treated control and scramble cells. The bars represent mean ± SD 
of three separate experiments, and each experiment was performed in duplicate (n=6). The data were 
analysed using one-way ANOVA, Tukey’s test (****= p˂0.0001).  
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4.3.10 p53 and p21 in PRNP knockdown cells treated with TMZ and BCNU  
As shown in the previous section (4.3.9), knockdown of the PRNP gene in U87 cells 
altered the population of cell cycle phases when the cells were treated with TMZ. This 
led us to investigate the effect of TMZ and BCNU on p53 and p21, as regulators of 
the cell cycle, in knockdown cells. In each case, U87 cells were treated with 
transfection reagents for three days to obtain PRNP or scrambled knockdown lines. 
The transfection reagents were then withdrawn, and the cells were immediately 
treated with either TMZ or BCNU for 48 h before the analysis was carried out by 
western blot assay. Our results showed that the p53 level increased in both treated 
scrambled and PRNP siRNA cells compared to the control (cell treated with 0.5% 
DMSO). In addition, there was no significant change in the p53 level between treated 
PRNP siRNA and scrambled cells (Figure 4-13, A). The western blot assay showed 
that the level of p21 increased significantly in PRNP siRNA cells treated with TMZ or 
BCNU when compared with comparable treated scrambled cells (Figure 4-13, B), 
however. It appears, therefore, that, regardless of the type of alkylating agent, p21 
significantly increased in treated knockdown cells, and a higher value of p53 level 
was recorded in these cells, but without significant differences between PRNP siRNA 
and scrambled cells when treated with either TMZ or BCNU. In general, p53 is 
upregulated in response to the DNA damage induced by alkylating agents and p21, as 
a p53 transcription target, also induced in response to these agents
202
. Although the 
effect of knockdown of PrP
c
 on TMZ or BCNU treated glioblastoma cells has not 
been studied yet, we may speculate that the consequent upregulation of p21 may serve 
to rescue the PRNP knockdown cells from the cytotoxic effects of alkylating agents in 
that it acts like a tumour suppressor protein. In addition, upregulation of p21 has been 
previously shown to induce resistance of glioblastoma cells to BCNU and cisplatin
234
. 
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Although previously, the accumulation of treated U87 cells with alkylating agents in 
G2/M was thought to require both p53 and p21
233
, in our results it seems that the 
upregulation just of p21 in treated knockdown cells may induced G1 arrest, perhaps 
due to its effect on cyclin dependant kinases (CDKs)
235
.      
 
Figure (4-13): Western blot for p53 and p21 in treated and untreated transfected U87 cells. (A) p53 
increased in treated transfected cells with TMZ or BCNU and there is no significant changes in p53 
level between treated scrambled and PRNP siRNA cells in both treatments. (B) TMZ and BCNU 
upregulated p21 in treated knockdown and scrambled cells and the level of p21 significantly increased 
in treated PRNP siRNA cells in comparison with treated scrambled cells. The data was normalised to 
β-actin and calculated as a percentage of the control group. These results represent mean ± SD of three 
experiments (n=3). The data were analysed using one-way ANOVA, Tukey’s test (**= p˂0.01, ***= 
p˂0.001). 
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4.4. Summary of key experimental results  
 PRNP gene expression was reduced in knockdown cells in comparison to 
scrambled and untreated cells to approximately 10% and 14% of the control 
values after 24 h and 48 h treatment with transfection reagents, respectively.  
 The level of PrPc protein was decreased in knockdown cells approximately by 
80% after 2, 3 and 5 days compared to the scrambled and control groups 
according to flow cytometry, western blot and confocal microscopy assays. 
 Knockdown of the PRNP gene inhibited the proliferation of U87 cells 
according to MTT and Alamar blue assays and reduced the proliferation 
marker ki67 in knockdown cells compared to scrambled cells after five days.  
 PRNP knockdown did not induce the apoptosis of U87 cells according to 
Annexin V with PI assay.  
 There was no significant change in cell viability between TMZ or BCNU 
treated knockdown cells and scrambled cells. 
 The proportion of cells in the G1 and G2/M cell cycle phases changed in TMZ 
treated knockdown cells in comparison with treated scrambled and control 
cells. 
 The level of p21 increased in TMZ or BCNU treated knockdown cells 
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4.5. Discussion    
The expression of PrP
c
 may rescue different type of cells, such as neurons, from the 
environmental and internal stress
184
. In addition, however, the overexpression of PrP
c
 
may protect tumour cells from the pro-apoptotic initiators such as DNA damage and 
chemotherapy
236
. The level of PrP
c
 expression in U87 cells treated with TMZ and 
BCNU has not yet been examined in depth, however. Our speculation was that 
knockdown of PrP
c
 in U87 glioblastoma cells may affect cellular behaviour and 
sensitivity to alkylating agents. This chapter aimed to address this speculation by 
knocking down PRPN gene in U87 cells using PRNP siRNA and investigating the 
impact of this on cell proliferation and apoptosis when those cells were treated with 
TMZ and BCNU alkylating agents.  
In this work, the optimum condition for knocking down PrP
c
 in U87 cells was 
identified initially using PRNP siRNA. We found that PRNP siRNA suppressed PrP
c
 
expression in U87 cells by approximately 80% after 48 h, as quantified by qPCR, 
western blot, flow cytometry, and confocal microscopy (Figures 4-4, 4-5 and 4-6). 
Although a higher level of protein reduction was not obtained, 80% reduction in 
protein level is a good measure for the effectiveness of knockdown in cell lines as 
recommended by the DarmaFect protocol. The knockdown of PrP
c
 continued until 
day 5 day, but thereafter the level of PrP
c
 in scrambled cells decreased by around 20-
30% compared to the control group. In respect of positive cells (PrP
+
 cells), there was 
no significant change in scrambled cells at day 5 relative to the control. This change 
may be attributed to the long period of exposure to the transfection reagent. It is 
difficult to explain why the protein level decreased in scrambled cells because the 
sequence of the non-target siRNA was not provided in the manufacturer’s instruction. 
One possible explanation, however, is that the decrease in protein level could be 
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subjected to two different pathways including deficiency in protein synthesis or 
inducing protein degradation. Our result regarding the knockdown of PrP
c
 level in 
U87 cells is an agreement with that of Silber et al. who reported that PRNP siRNA 
inhibited the level of PrP
c




To determine whether the knockdown of PrP
c
 induces or reduces the proliferation of 
U87 cells, the cells were transfected for different durations from day 1 to day 5. A 
reduction in the number of cells was observed after day 2 in a time-dependent manner 
according to MTT and Alamar blue assays (Figure 4-7). In addition, to exclude the 
effect of the potential toxicity of DarmaFect (the transfection reagent) on U87 cells 
over this period, LDH assay was performed with the results showing that the toxicity 
was not significant over the transfection periods (1-5 days) (Figure 4-8). These 
findings indicate that knockdown of PrP
c
 in U87 inhibits the proliferation. This may 
be ascribed to the PI3K/Akt pathway and Cyclin D1 protein which are probably 
regulated and activated by PrP
c169
. Our results are in agreement with those of Li et al., 
who found a reduction in the proliferation of J889 glioblastoma cells in response to 
PRNP siRNA
185
. In addition, inhibition of PrP
c
 in many glioblastoma cells using 
DNA-antisense oligonucleotide decreased the viability of these cells
184
. Indeed, the 
role of PrP
c
 in the proliferation may depend on the type of cells as reviewed in section 
(1.2.5.2.5). For example, suppression of PRNP in gastric cancer cells SW620 and 
HT29 and breast cancer cells MDA-MB-435 did not reduce the proliferation of 
cells
228,8
. Furthermore, we also quantified the proliferation marker ki67 in knockdown 
and scrambled cells using confocal microscopy to confirm the reduction in 
proliferation. Although the function of ki67 is still unclear, it is a commonly accepted 
marker for assessing cell proliferation. It is observed in all cell cycle phases apart 
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from the G0 and G1 phases at which point it is undergoing proteasome-mediated 
degradation
237
. In our results, the positive ki67 cells in PRNP knockdown cells were 
significantly less than in scrambled cells by around 55% and 70% of total cells 
respectively after five days incubation with the transfection reagent (Figure 4-9). This 
may be related to the decrease in the proliferation of knockdown cells. Regarding the 
proliferation marker ki67 there is no literature to support this result. Nonetheless, we 
suggest that the reduction of ki67 positive cells is a marker for the reduction of 
proliferation in U87 knockdown cells.   
Furthermore, in our results, the knockdown of PrP
c
 in U87 cells did not lead to more 
extensive apoptosis in TMZ or BCNU treated and untreated knockdown cells, 
according to Annexin V assay with PI staining (Figure 4-10). On the one hand, we 
expected that knockdown of PrP
c
 in untreated cells would induce apoptosis due to 
PrP
c
’s known anti-apoptotic effect in many types of cells (reviewed in 1.2.5.2.3). Our 
result is in line with previous findings that have shown that the knockdown of PrP
c
 
using DNA-antisense oligonucleotides did not induce the apoptosis of cells from 
another glioblastoma cell line (T98G)
184
. In contrast, Li et al. found that knockdown 
of PrP
c
 in untreated J889 glioblastoma cells using PRNP siRNA induced the apoptosis 
of these cells by upregulating caspase 3
185
. Another study showed that knockdown of 
PrP
c
 in AGS gastric carcinoma cells promoted cell apoptosis through activation of 
Bax and p53
227
. On the other hand, the effect of PrP
c
 knockdown in glioblastoma cells 
treated with alkylating agents has not been studied in detail. Our result contradicts 
Zhuang et al.’s finding that knockdown of PrP
c
 in U87 cells induced apoptosis when 
treated with TMZ by activation caspase 3
6
. Other results showed that knockdown PrP
c
 
in breast cancer cells MDA-MB-435 reduced the apoptosis mediated by doxorubicin 
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and chemotherapy-induced cytotoxicity, by increasing some of Bcl-2 family proteins 
such as Bcl-xL and Bcl-2
8
. 
Resistance to chemotherapy has been considered a big issue in cancer treatment. The 
overexpression of PrP
c
 may be implicated in the sensitivity of many kinds of cancer 
cells to the chemotherapy and indeed knockdown of PrP
c
 has been shown to improve 
the sensitivity of several cancer cells to chemotherapy
168,152
. The work concerning 
PrP
c
 in glioblastoma cells treated with TMZ and BCNU is very limited, however. We 
speculated that knockdown of PrP
c
 in U87 cells may decrease cell viability when 
treated with TMZ or BCNU. Unexpectedly, our work demonstrated that the 
knockdown of PrP
c
 in U87 cells did not affect cell viability in treated cells with TMZ 
or BCNU compared to treated scrambled cells, even with high doses (Figure 4-11). 
This indicated that knockdown of PrP
c
 by PRNP siRNA in U87 cells does not 
improve the sensitivity of these cells to chemotherapeutic agents TMZ or BCNU. Our 
result is in agreement with Yu et al. who found that knockdown of PrP
c
 in breast 
cancer cells MDA-MB-435 did not induce resistance to other chemotherapies, 
paclitaxel and staurosporine (treatments that induce apoptosis)
8
. In contrast, the 
overexpression of PrP
c
 in gastric cancer cells has been shown to induce resistance to 
Adriamycin whereas the silencing of this protein promotes sensitivity towards 
Adriamycin
168
. Meslin and co-workers also found that the depletion of PrP
c
 promotes 
the sensitivity of breast cancer cells to Adriamycin through TRAIL-mediated 
apoptosis and upregulation of pro-apoptotic protein Bax
152
. In addition, it has been 
reported that the overexpression of PrP
c
 protected the astrocytes from staurosporine-
induced apoptosis by activation of caspase 3
238
, whereas the knockdown of PRNP in 
astrocyte cells promoted sensitivity towards staurosporine
239
. 
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As mentioned in chapter three, TMZ treated U87 cells accumulated in the G2/M 
phase after 24 h. To investigate the effect of PrP
c
 knockdown on the cell cycle, 
therefore, the cells were exposed to TMZ for 48 h. Our results indicated that the 
population of treated knockdown cells was less arrested in G2/M compared to treated 
control or scrambled cells (Figure 4-12). We speculated that this change may be 
attributed to the variation of the regulated cell cycle proteins p53 and p21. p53 has 
been shown to be upregulated in response to the DNA damage mediated by alkylating 
agents, while p21, the transcriptional target of p53, is also induced in response to 
these treatments
202
. The influence of knockdown PrP
c
 on TMZ or BCNU treated 
glioblastoma cells has not been reported yet. To validate our speculation, the level of 
these proteins was evaluated using western blot analysis. We found that the level of 
p53 in knockdown cells treated with TMZ or BCNU increased when compared with 
the control (untreated cells) but there was no significant variation between PRNP 
knockdown and scrambled cells treated with either TMZ or BCNU. Surprisingly, p21 
significantly increased in knockdown cells treated with TMZ or BCNU in comparison 
with treated scramble cells (Figure 4-13). To our knowledge, this observation has not 
been reported by other researchers. We found that the increase of p21 induces the 
treated knockdown cells to accumulate in G1 rather than G2/M. A possible 
explanation is that the upregulation of p21 may be promoted in response to TMZ or 
BCNU and this induction may protect the knockdown cells from the cytotoxicity of 
these treatments. Many studies have indeed shown that p21 protects various types of 
cells from apoptosis and that the silencing of this protein induces tumourigenesis
235
.  
Furthermore, the high level of p21 may induce G1 arrest due to its effect on cyclin-
dependent kinases (CDKs). Also, the accumulation of cells in G2/M after the DNA 
damage by TMZ or BCNU requires both p53 and p21 in U87 cells
233
. 
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It has also been reported that p53 might contribute to sensitising tumour cells to 
chemotherapy
240
 or inducing the resistance due to its function in DNA repair
229
. Kay 
et al., for example, reported that p53 has an active role in the induction of p21 during 
DNA damage in response to intrinsic or extrinsic stimuli. Furthermore, p21 can be 
induced independently to p53 in many conditions such as the development of normal 
tissue, wild type p53 cells, mutant p53 cells and through cell differentiation
241
. Other 
studies have reported that upregulation of p21 in glioblastoma cells induces resistance 
to cisplatin and BCNU
234
. p21 is upregulated in a downstream effect of p53 and is a 
key for regulating the cell cycle arrest in response to DNA damage. In addition, p21 
may also have an oncogenetic function due to its roles as a pro-cancer and 
antiapoptosis
242,235
. Accordingly, the knockdown of PrP
c
 in U87 cells increased the 
level of p21 in response to DNA damage-mediated by TMZ or BCNU. The resistance 
of knockdown cells to alkylating agents might not be detectable by MTT assay, where 
there was no significant change in treated knockdown cells compared to treated 
scramble cells.      
To summarise, this is the first study to have evaluated the effect of knockdown of 
PRNP gene on U87 cells treated with alkylating agents. A high level of PRNP 
knockdown was obtained using PRNP siRNA. Knockdown of PrP
c
 significantly 
reduced the proliferation of U87. Furthermore, the knockdown of PrP
c
 did not induce 
apoptosis in U87 cells regardless of whether or not they were treated with TMZ. It 
was also seen that cell cycle populations in TMZ treated knockdown cells changed in 
comparison to treated scrambled and control cells. The knockdown of the PRNP gene 
may induce the resistance to alkylating agents TMZ and BCNU. This may be 
attributed to increasing the level of p21 in TMZ or BCNU treated knockdown cells. 
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Chapter 5: Evaluation of the effect of proteasomal inhibitor, MG132, on PrPc in 
U87 cells and on the apoptosis when combined with TMZ  
5.1 Introduction 
In eukaryotes, proteasomes are located in the nucleus and the cytoplasm. Abnormal, 
misfolded or damaged proteins are degraded by the the proteasome. These proteins 
are usually tagged by ubiquitin (a protein consisting of 76 amino acids)
243
. Cancer 
cells produce a large amount of damaged proteins when compared to normal cells, 
and this can overwhelm and deactivate proteasome
244
. The term of proteasome refers 
to 26S (S means Svedberg, which is the unit for sedimentation coefficient) 
proteasome, a large multi-catalytic ATP-dependent protease complex, containing 20S 
protein and 19S regulatory subunits. At least four ubiquitins are linked and guide the 
unneeded protein to the 19S subunits and 20S core to produce 3-22 amino acid 




Figure (5-1): The proteasome structure and its function. Protein is conjugated with ubiquitins then 
served into the proteasome. The protein is degraded to a peptide which fragments the protease in the 




Proteasome inhibitors have in general been used to investigate the function of the 
proteasome in malignant cells
244
. It has been reported that proteasome inhibitors 
induce apoptosis in vitro for many types of cancer such as breast cancer
246
, multiple 
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. There are different classes of 
proteasome inhibitors such as peptide aldehydes, streptomyces metabolite, dipeptidyl 
boronic acids, vinyl sulfone tripeptides and natural products which can inhibit the 
degradation of protein by various mechanisms
244
. MG132 or (carbobenzoxyl-L-
leucyl-L-leucyl-L-leucinal) is a peptide (Figure 5-2) which suppresses the proteasome 
by inhibiting serine protease
245
. It precisely inhibits the activity of the 20S subunit by 




Figure (5-2): The structure of MG132  
It has been reported that MG132 induces apoptosis through different pathways. One 
such pathway is the formation of reactive oxygen species (ROS) and loss of 
glutathione production. This process may affect the function of mitochondria and 
cause the release of cytochrome c, which inhibits cell viability (Figure 5-3 A)
11
. The 
coordination of MG132 with TRAIL upregulates the death receptor 5 in cancer cells 
and this combination induces the intrinsic apoptosis by activation of caspases 3 and 8 
(Figure 5-3 B)
249
. Another process for MG132-mediated apoptosis is the inhibition of 
the transcriptional regulator protein NF-κB, which can promote the survival of tumour 
cells
10
. Various factors such as TNF, IL-1, IL-6, viruses and bacteria can activate the 
IκB kinase enzyme complex, which is upstream of NF-κB
250
. MG132, meanwhile, 
can suppress the degradation of IκB kinase complex
251
. As a consequence, 
downregulated NF-κB inhibits the anti-apoptotic protein Bcl-2, and this then induces 
cell death  (Figure 5-3 C)
252
. In addition, MG132 can induce p53-independent 
apoptosis in cancer cells
10
 since p53 is mutated in most cancer cells
253
. Noxa is one of 
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the pro-apoptotic proteins that are activated in response to proteasome inhibitor 
MG132. The anti-apoptotic proteins in the Bcl-2 family interact with Noxa and then 
release cytochrome c, which activates caspase-induced apoptosis (Figure 5-3  D)
254
.   
 
Figure (5-3): Diagram showing MG132-induced apoptosis. A. MG132 mediated apoptosis by ROS 
formation and glutathione reduction. B. MG132-induce cell death through upregulating TRAIL-death 
receptor 5. C. MG132-induced cell apoptosis by inhibition of NF-κB. D. p53-independent apoptosis by 
MG132. Adapted from Guo, N. and Peng, Z. under the Creative Commons Attributed Licence
10
 
Bettina et al. showed that p53 was increased in glioblastoma cells treated with 
MG132, and apoptosis was induced in a p53-dependant manner. In wild type p53 
glioblastoma cells LN-229, MG132 mediated p53-dependant apoptosis, whilst in 
mutant p53 cells LN-18, the apoptosis was in a p53-independent. In both cell types, 
p21 was accumulated due to the toxic effect and inhibition of protein degradation 
resulting from MG132
255
. Another study confirmed these results using other types of 
glioblastoma cells. Generally, MG132 induced G2/M arrest in both types of 
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glioblastoma cells (wild type and mutant p53 cells)
256
. In MG132 treated glioblastoma 
cells, the G2/M arrest in wild type p53 cells is associated with the induction of p53 as 
a regulator of the cell cycle
255,256
. In contrast, Xue-Feng et al. found that MG132 
arrested glioblastoma cells U87 and U251 in G2/M due to the increase in p53 and 
decrease in the p21 level
13
. MG132 in combination with chemotherapy was shown to 
increase the apoptosis of cancer cells in few studies. For example, the combination of 
MG132 with cisplatin was found to induce apoptosis in human oesophageal squamous 
cell carcinoma cells
257
. The combination of MG132 with TMZ has not been tested 
before, however, and needs to be elucidated.  
Since the ubiquitin/proteasome system is a part of the endoplasmic reticulum (ER)-
associated machinery for protein degradation (ERAD), proteasome inhibitors may 
accumulate some unfolded and misfolded proteins in the cytoplasm that subjected to 
retrograde transport from the ER
258
. This accumulation may then cause ER stress. The 
ER stress resulting from proteasome inhibitors may reduce the translocation of PrP 
and accumulate the cytosolic PrP
259
. It has been found that the accumulation of PrP by 
proteasome inhibitor MG132 may occur as a result of two different cellular processes:  
ERAD which contributes to about 10% of nascent PrP and the post-Golgi turnover of 
PrP (33-35 kDa species) which is interfered by MG132
14
.   
In light of this, we hypothesised that U87 cells treated with MG132 may increase the 
level of PrP
c
 expression due to the induction of ER stress and inhibition of proteasome 
function. Furthermore, the apoptotic effect of MG132 may promote the death of U87 
cells when combined with TMZ.  These actions will be addressed in this chapter.     
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5.2 The aim 
In this chapter, we aimed to evaluate the effect of MG132 upon the level of PrP
c
 and 
GBM treatment, TMZ. 
To achieve this aim, the following objectives will be addressed: 
 Evaluate cell viability in U87 cells treated with MG132 and calculate the IC50 
using MTT assay.  
 Quantify the level of PrPc in MG132 treated cells using western blot, flow 
cytometry and ICC assays. 
 Assess the apoptosis rate of U87 cells treated with MG132 and/or TMZ by 
annexin V with PI staining.  
 Evaluate the proliferation of U87 cells treated with MG132 or MG132/TMZ 
by MTT assay 
 Quantify the effect of MG132 or MG132/TMZ combination on the cell cycle 
using flow cytometry assay. 
 Estimate the level of p53 and p21 in cells treated with MG132 or 
MG132/TMZ.      
5.3 Methods 
5.3.1 Preparation of treatments 
MG132 and TMZ were dissolved in DMSO at 1 mM and 5 mM respectively as stock 
solution. The stock solution was aliquoted and kept at -80 ºC. The desired 
concentration was prepared by diluting the stock solution in DMSO depending on the 
final concentration and then diluting ten times using PBS.  
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5.3.2 Cell viability assay 
MTT assay was used to determine the viability of U87 cells treated with the 
proteasome inhibitor MG132. The cells were seeded in a 96-well plate at 10000 cells 
in each well. The plate was incubated overnight and then treated with MG132 at 
different concentrations (1, 2, 3, 4 and 5 μM) for 12 h. The purpose of this experiment 
was to check the efficacy of MG132 on U87 cell viability during this period, which 
will be used to assess the level of PrP
c
 in treated cells, as previously reported with 
neuron cells
14
. The second 96-well plate with the same cell seeding density was 
treated with different concentrations of MG132 (0.1, 0.5, 1, 2, 3, 4, and 5 μM) for 24 
h in order to determine the IC50 of MG132, and these concentrations were within the 
same range as previously reported
256
. The third 96-well plate was seeded with 5000 
cells to evaluate the proliferation of U87 cells treated with 25 μM TMZ and/or 
MG132 (0.1, 0.5, 1, 2) for 48 h. The concentrations for MG132 over 48 h were within 
the range of concentrations previously reported
256
, whereas the combination with 
TMZ  has not been reported yet. After the cells had been incubated with the 
treatments for the desired time, the MTT assay protocol (see section 2.2.2) was 
followed to evaluate the viability of the U87 cells in all 96-well plates.  
5.3.3 Western blot assay 
PrP
c
, p21 and p53 levels in cells treated with MG132 were evaluated using western 
blot. Regarding PrP
c
 level, the cells were seeded in a 6-well plate at 200000 cells in 
each well. On the next day, they were treated with 2 and 4 µM of MG132 for 12 h or 
0.5 and 1 µM of MG132 for 24 h. To evaluate p21 and p53, another 6-well plate was 
seeded at 80000 cells and treated with MG132 (0.1, 0.5 and 1 μM) or a combination 
with 25 μM TMZ for 48 h. In all experiments, the control group was treated with 0.5% 
DMSO for the same time incubation. After the desired incubation time, cell lysate 
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was prepared, and the protein levels were assessed using the western blot method 
described in section (2.2.5).  
5.3.4 Flow cytometry assay for protein level 
To validate the results of the PrP
c
 level in MG132 treated cells obtained by western 
blot, flow cytometry assay was carried out. The cells were seeded and treated in a 6-
well plate as described in the western blot method above (section 5.2.3). The cells 
were then harvested and the protocols for live and fixed cells (see section 2.2.6) were 
performed in order to assess the level of PrP
c
 in treated cells.  
5.3.5 Microscopical assay  
ICC by confocal microscopy was used to confirm the PrP
c
 level in MG132 treated 
U87 cells that had been obtained from western blot and flow cytometry. The cells 
were seeded onto sterile coverslips which were mounted in a 24-well plate, as shown 
in the figure below (Figure 5-4). Next, 30000 cells were seeded in each well, and then 
next day treated with 2 µM or 4 µM of MG132 for 12 h. The control group was 
treated with 0.5% DMSO for the same incubation time.  Later, the confocal 
microscopic images were obtained as described in section (2.2.7). 
 
Figure (5-4): The experimental design for using confocal microscopy to evaluate PrP
c
 in treated cells 
with MG132. 
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5.3.6 Annexin V with PI assay 
Annexin V with PI assay was used to determine the apoptosis rate in MG132 and/or 
TMZ treated U87 cells. The cells were cultured in 6-well plates at a density of 80000 
cells per well and then, the following day, the cells were treated with MG132 and/or 
TMZ, as shown in figure 5-5 below. The plates were incubated for 48 h, and then the 
protocol of Annexin V with PI assay (see section 2.2.13) was applied to quantify the 
number of apoptotic cells. 
 
Figure (5-5): The experimental design for U87 cells treated with MG132 and/or TMZ for apoptosis 
assay.  
5.3.7 Cell cycle assay by flow cytometry 
Cell cycle assay using flow cytometry was carried out to quantify the number of cells 
treated with MG132 and/or TMZ in each phase of the cell cycle. The cells were 
seeded and treated in 6-well plates as described for the apoptosis assay above (section 
5.3.7). After 48 h of incubation with the treatments, the cells were washed and 
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detached. The cell cycle protocol was then applied (see section 2.2.3) to quantify the 
population of cells in each phase.  
5.4 Results 
5.4.1 Cell viability for U87 treated with MG132 
Since different concentrations of MG132 were to be tested in this work it was 
important to check the viability of cells treated with different concentrations of this 
treatment. MTT assay was therefore carried out to assess the viability of U87 cells 
treated with MG132. The bar chart below (Figure 5-6, A) revealed the viability of 
U87 cells in serial concentrations of MG132 (1, 2, 3, 4 and 5 µM) for 12 h. The 
concentrations 3, 4 and 5 µM of MG132 led to a significant decrease in the viability 
of cells after 12 h. The lowest value of cell viability was 57%±5.8 at 5 µM (Figure 5-6, 
A). In the next experiment, we therefore decided to use 2 or 4 μM to determine the 
level of PrP
c
 after 12 h (section 5.3.2).  
A cell viability assay was carried out after 24 h to estimate the IC50 for MG132. The 
line graph shows the viability of U87 cells using different concentrations of MG132 
(0.1, 0.5, 1, 2, 3, 4 and 5 µM). Our results indicate that there was a dramatic decrease 
in the cell viability of U87 cells treated with MG132 in a dose-dependent manner with 
IC50 = 2.26 μM (Figure 5-6, B). This could be related to the apoptotic effect of 
MG132 cells
255
 as will be described in section (5.4.6). In a previous study, it was 
demonstrated that MG132 decreased the viability of many glioblastoma and this 
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Figure (5-6): Viability of U87 cells in different concentrations of MG132. (A) The bar chart represents 
the percentage of viable cells relative to the control after 12 h. (B) The line graph shows the IC50 of 
MG132 in treated cells after 24 h. Quantification of mean ± SD of three repeats, each performed in 
octuplicates (n=24). The data were analysed using one-way ANOVA with Tukey’s test (***=p˂0.001, 
****= p˂0.0001). 
5.4.2. MG132 increases the PrP
c
 level according to the western blot assay   
Western blot assay using PrP(3F4) was carried out to determine the level of PrP
c
 in 
MG132 treated U87 cells. The result of this experiment showed that the PrP
c
 level 
increased after 12 h treatment with 2 and 4 µM of MG132. The protein level was not 
affected when the cells were treated for 24 h at 0.5 and 1 µM (Figure 5-7 A). 
According to this experiment, the level was increased by about 1.5- to 1-fold in cells 
Chapter 5: Results section 3 
- 139 - 
 
treated with 2 and 4 µM for 12 h respectively (Figure 5-7 B). The induction of PrP
c
 
could be attributed to the ER stress resulting from MG132 and/or to the inhibition of 
the ERAD-proteasome degradation pathway, which may inhibit the degradation of 
nascent PrP
c






 level in U87 treated with MG132 by western blotting. The western blot image of 
PrP
c
 and β-actin in the control and treated groups for 24 h with 0.5 and 1 µM of MG132 (A) and for 
12 h with 2 and 4 µM of MG132 (B). The bar chart shows the analysis of images (C). The data were 
normalised to the control and represents mean ± SD for at least three independent experiments (n=3). 
The results were analysed using t-test (*=p˂0.05, **= p˂0.01). 
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 level in treated cells with MG132 by flow cytometry 
A flow cytometry assay was carried out to confirm the results of the western blotting. 
This experiment was applied on live cells to evaluate the protein level on the cell 
surface, as well as to fixed and permeabilised cells to assess the total protein level. 
The figure below reveals that the protein level increases significantly in live and fixed 
cells that had been treated by MG132 for 12 h in comparison to the control group. 
There was no significant change in protein levels between cells treated with 2 and 4 
µM. The protein level increased about 1.4-fold in treated cells compared to untreated 
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Figure (5-8): The expression of PrP
c
 in MG132 treated U87 cells after 12 h according to flow 
cytometry assay. PrP
c
 expression in the live cells (A) and fixed cells (B). The bar charts in A and B 
show that protein level increases in treated cells with 2 and 4 µM MG132 compared to control group. 
The results were normalised to isotype and represent mean ± SD of three different experiments, each 
performed in duplicate (n=6). All data were statistically analysed using t-test (*=p˂0.05).   
5.4.4 PrPc level in MG132 treated U87 cells using confocal microscopy 
To confirm the results of western blot and flow cytometry, the cells were treated with 
MG132 at 2 and 4 µM, and then the PrP
c
 level was assessed using ICC confocal 
microscopy to show the expression of PrP
c
 in treated and untreated cells (Figure 5-9 
A). The fluorescent intensity of PrP
c
 in treated cells (2 and 4 µM) was higher than that 
in the control group (Figure 5-9 B). This reflects the increase of PrP
c
 level in U87 
cells treated with MG132.  These results are consistent with the findings of western 
blot and flow cytometry assays (section 5.4.2 and 5.4.3).   
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 expression in MG132 treated and untreated cells by confocal microscopy. (A) The 
cells were exposed to anti-prion protein antibody 8H4 and then labelled with Alexa Fluor 488 (green). 
The nuclei were labelled with DAPI (blue). (B). The fluorescent intensity was calculated using Image J. 
The fluorescent intensity was normalised to the control and the bars represent mean ± SD of three 
repeats, each performed in duplicate and three images were taken for each sample (n=18). Statistical 
analysis was carried out using t-test (**=p˂0.01). 
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5.4.5 MG132/TMZ combination does not promote the apoptosis of U87 according 
to Annexin V with PI staining assay 
Annexin V assay with PI staining was carried out to determine the effect of MG132 
alone and in combination with TMZ on the apoptosis of U87 cells. The cells were 
treated with MG132 (0.1, 0.5 and 1 μM) and/or 25 μM TMZ. The apoptosis rate 
increases in cells treated with MG132 in a dose-dependent manner for 48 h (Figure 5-
10). MG132 induced the apoptosis due to its effect on many signalling survival 
pathways, as reviewed in section (5.1). To date, however, there has been no published 
experimental work on the MG132/TMZ combination. We expected that the 
combination of MG132 with TMZ may sensitise U87 cells to TMZ. In our results, 
however, the combination of MG132 with TMZ did not promote any significant 
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Figure (5-10): Apoptosis assay by flow cytometry for MG132 treated cells. U87 cell lines treated with 
TMZ, MG132 and MG132/TMZ for 48 h. The right-hand quadrate in the dot plot represents the 
apoptosis cells that were exposed to the treatments (A).  The bar chart shows that the apoptosis 
increases in MG132-treated cells in a dose-dependent manner (B). These bars represent mean ± SD of 
three different experiments, and each experiment was performed in duplicate (n=6). The data were 
analysed using one-way ANOVA, Tukey’s test (*=p˂0.05, **=p˂0.01, ****=p˂0.0001).   
Chapter 5: Results section 3 
- 145 - 
 
5.4.6 The effect of MG132/TMZ combination upon the proliferation of U87 cells   
An MTT proliferation assay was carried out to evaluate the effect of MG132 on cell 
viability when combined with TMZ. The cells were treated with MG132 (0.1, 0.5, 1, 
and 2 μM) alone and in combination with 25 μM TMZ for 48 h. The viability of the 
cells decreased dramatically with or without TMZ combination and there were no 
significant changes in cell viability in cells treated with MG132/TMZ in combination 
compared to MG132 alone (Figure 5-11). The results of MG132 alone (black line in 
Figure 5-11) over 48 h confirmed the results in section (5.3.1), namely a decrease in 
MG132 treated cells in a dose dependent manner. This reduction of cell proliferation 
could be attributed to the effect of MG132 on the PI3/Akt pathway which correlated 
with cell proliferation
256
. In addition, the high impact of MG132 on cell viability can 
be ascribed to the apoptotic effect of this treatment, as shown in section (5.4.5). It has 
been reported that MG132 reduces the viability of different types of cells due to its 
effect on many survival pathways (see section 5.1). For example, Alfeu et al. found 
that MG132 decreased the proliferation of glioblastoma cell through inhibition of the 
PI3/Akt pathway which is upregulated in glioblastoma cells
256
.  
Concerning the effect of the MG132/TMZ combination on U87 cell proliferation, we 
expected that this combination may enhance the efficacy of TMZ on U87 cells. Our 
results, however, showed that the combination of MG132 with TMZ did not reduce 
the proliferation of U87 cells after 48 h compared to MG132 alone (Figure 5-11). This 
finding supported the results in respect to apoptosis in section (5.4.5). Further 
investigations will be performed in the next sections to elaborate the effect of the 
MG132/TMZ combination on the proliferation and apoptosis of U87 cells by 
evaluating the cell cycle and p53/p21, respectively.   
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Figure (5-11): Cell viability for U87 cells treated with MG132 and/or TMZ over 48 h by MTT assay. 
The line graph shows the viability of treated cells with the different concentrations of MG132 in (0.1, 
0.5, 1 and 2 μM) with and without combination with TMZ. There was no significant change in cell 
viability of the MG132/TMZ combination compared to cells treated with MG132 alone. The values 
represent mean ± SD of three separated experiments, each performed eight times (n=24) and analysed 
using t-test.  
5.4.7 MG132 induces cell cycle arrest 
A flow cytometry assay was now carried out to evaluate the effect of MG132 and/or 
TMZ on the cell cycle of U87 cells. A low 0.1 μM concentration of MG132 did not 
affect the cell cycle, but 0.5 and 1 μM did induce cell cycle arrest in G2/M after 48 h 
by around 32% and 29%, respectively (Figure 5-12). The accumulation of MG132 
treated cells in G2/M may be attributed to the induction of p53 and p21, which serve 
to regulate the cell cycle, as shown in the next section (5.4.8). Additionally, the G2/M 
arrest by MG132 supported the results of section (5.4.6) concerning the decrease of 
the cell proliferation with MG132 alone. 
It is obvious that TMZ arrests the cells in G2/M after 48 h by approximately 72%. 
The combination of 0.1 μM MG132 and 25 μM TMZ reduced G2/M cells to about 
68%, but this was non-significant relative to TMZ alone. Interestingly, the 
combination of TMZ with 0.5 or 1 μM MG132 reduces the number of G2/M cells 
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approximately from 72% to 32% and 25% respectively (Figure 5-12). Furthermore, 
the population of the cell cycle in cells treated with 0.5 and 1 μM MG132 alone was 
insignificant compared to the comparable combination groups (0.5 and 1 μM 
MG132/TMZ). These results indicated that the combination did not affect the cell 
proliferation when compared with MG132 and this supported the results of section 
5.4.6 concerning the combination effect. Since it seems as if the target of both 
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Figure (5-12): Cell cycle analysis for MG132 treated U87 cells. A, the histograms reveal the cells in 
the population of each phase after treatment with MG132 and/or TMZ. B, the bar chart illustrates the 
percentage of cells in each cell cycle phase. Quantification of mean ± SD for three repeats, each carried 
out in duplicate (n=6). The data were statistically analysed using one-way ANOVA, Tukey’s test 
(*=p˂0.05, **=p˂0.01, ***=p˂0.001, ****=p˂0.0001).   
 
5.4.8 MG132 increases the level of p53 and p21 
MG132 altered the population of cell cycle phases and induced apoptosis in U87 cells 
as shown in previous sections. p53 and p21 are regulators of the cell cycle and may 
play a role in the apoptosis of MG132 treated cells. Western blot analysis was 
therefore carried out to estimate the effect of MG132 and/or TMZ on p53 and p21 in 
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the U87 cell line. It has been mentioned in chapter 3 that TMZ accumulated the cells 
in the G2/M phase due to the increase of regulatory cell cycle proteins, p21 and p53. 
Figure (5-13) shows that the level of these proteins increases significantly in cells 
with 0.5 and 1 μM MG132 for 48 h, by approximately 3-folds for p21 and 1.5-fold for 
p53. The induction of p53 and p21 may be attributed to the genotoxic stress of 
MG132. p53, as a tumour suppressor protein, plays an important role in the regulation 
of the cell cycle, in apoptosis and chemoresistance
256
. In our results, the accumulation 
of p53 in treated cells may induce p53-dependent apoptosis.  
The combination of 25 µM TMZ with 0.1 μM of MG132 for 48 h did not affect these 
proteins compared with TMZ-treated cells. The combination of 0.5 or 1 μM MG132 
with 25 μM TMZ increased p21 and p53 levels by around 2.5-3.5 and 1.8-1.5 fold 
respectively. Furthermore, the level of these proteins in 0.5 and 1 μM MG132/TMZ 
treated cells was insignificant compared to MG132 treated cells (single treatment). 
These results therefore showed that the combination did not affect p53 and p21 and 
this confirmed the results of cell cycle section (5.4.7) and proliferation section (5.4.6).       
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Figure (5-13): The expression of p53 and p21 and in MG132 treated U87 cells with and without TMZ. 
A, shows the western blot images for p53 and p21 in treated cells with MG132 and/or TMZ. B, reveals 
the analysis of data. Both of these proteins are upregulated in treated cells with 0.5 and 1 μM MG132 
and/or TMZ. The results represent mean ± SD of three independent experiments (n=3) and statistically 
analysed using one-way ANOVA, Tukey’s test (*=p˂0.05, **=p˂0.01, ****=p˂0.0001).    
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5.5 Summary of key experimental results 
 The viability of U87 cells decreased in MG132 treated cells in a dose-
dependent manner by IC50 = 2.26 μM 
 MG132 upregulates the level of PrPc in U87 cells after a short incubation time 
at high concentrations of 2 and 4 μM. 
 The morphology of U87 cells was changed when treated with MG132. 
 The apoptosis rate of U87 cells increased when treated with MG132, whereas 
there was no significant change in apoptosis between MG132 and 
MG132/TMZ treated cells. 
 MG132 arrested the cells in the G2/M phase of the cell cycle and induced p21 
and p53 levels in a dose-dependent manner, but there was no significant 
change in the G2/M population when comparing MG132, and MG132/TMZ 
treated cells.   
5.6 Discussion 
The ubiquitin proteasomal pathway has been shown to play a vital role in the 
proteolysis of most intracellular proteins and regulates many cellular processes such 
as differentiation, apoptosis and cell cycle. The proteasome, therefore, is considered 
an effective target for cancer treatment
10
. Proteasome inhibitors such as MG132, 
lactacystin and bortezomib (PS341) have been introduced in the literature and have 
been found to inhibit cell proliferation and induce apoptosis through different survival 
pathways
260
. MG132, as a proteasome inhibitor, has been specifically shown to reduce 
cell viability and promote the apoptosis of different glioma cells
255,256
. The 
combination of MG132 with cisplatin has also been shown to enhance the apoptosis 
of various cancer cells such as human oesophageal cancer cells
257
. The combination of 
MG132 with TMZ has not been investigated yet, however. Although the targets of 
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MG132 and TMZ are different, we speculated that the combination of these molecules 
may sensitise U87 cells to TMZ.  
In our work, we found that MG132 can remarkably reduce the growth of U87 cells in 
a dose-dependent manner, with an IC50 = 2.26 μM over a 24 h treatment period 
(Figure 5-6). This may be attributed to the apoptotic and cytotoxic effect of MG132. 
Generally, this finding is in agreement with another study by Alfeu et al.; they found 
that MG132 reduced cell viability of different glioma cells such as C6, U138 MG, 
U87 and U373 in a dose-dependent manner with IC50 = 2.8, 2.5, 5.1 and 2.6 μM 
respectively after 48 h, but did not affect astrocytes
256
. Xue-Feng et al. stated that 
MG132 suppressed the proliferation of U87 and U251 glioma cells in both a time- and 
dose-dependent manner according to MTT assay
13
.  
The proliferation of U87 cells was also decreased when treated with MG132 for 48 h 
both in combination with TMZ and without combination. These results therefore 
indicate that the combination of MG132 with TMZ does not affect the proliferation of 
U87 relative to treatment with MG132 alone (Figure 5-13). The reduction in the 
proliferation of cells when they are treated with MG132 may be related to the effect of 
this treatment on many survival pathways. For instance, MG132 decreased the 
proliferation of glioblastoma cells by inhibition of the PI3/Akt pathway, which is 
upregulated in glioblastoma cells
256
. Furthermore, in our results, the apoptosis of U87 
cells was increased in cells treated with MG132, and this could be attributed to the 
accumulation of p53 and p21. p53 plays an important role in cell cycle regulation, 
apoptosis and chemoresistance
256
. Other studies have found that MG132 can promote 
the activation of caspase 3 and the release of cytochrome c in glioblastoma cell lines, 
LN-308 and LN-18. These studies showed that apoptosis is p53/p21 dependent due to 
the increase of p53 and p21 in wild type p53 cells treated with any apoptotic stimuli 
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such as MG132. In addition, MG132 induced the apoptosis in U87 cells through 
upregulation of p53 and p21. In contrast, apoptosis in glioma cells with the p53 
mutation undergo a p53 independent mechanism
261,12,256
. Furthermore, MG132 
promotes the apoptosis of U87 by increasing p53 and downregulating p21
13
.  
In our results, MG132 accumulated the cells in G2/M by increasing the level of p53 
and p21 since these regulate the cell cycle. The induction of G2/M arrest could also 
elucidate a decrease in the proliferation of MG132 treated cells. These results are in 
agreement with the previous results that showed that MG132 induces G2/M arrest in 
glioblastoma cells which results from the increase of p53 and p21
255,256
. Furthermore, 
proteasome inhibitors can reduce p21 and p27 degradation thus initiating growth 
arrest and apoptosis
262,256
. In contrast, our results partially disagree with Xue-Feng et 
al. who ascribed the accumulation of cells in G2/M to the increase in the level p53 
level and a decrease in p21 expression in U87 cells treated with MG132
13
.  
Similar observations concerning proliferation, apoptosis and cell cycle arrest were 
found in this work when combined MG132 with TMZ. It has been reported that TMZ 
accumulates glioma cells in G2/M
224
.  TMZ arrests U87 cells in G2/M by 71% of total 
cells after 48 h whereas the combination with MG132 reduces the G2/M to around 31% 
which is the same percentage of G2/M cells in U87 cells treated with MG132 alone 
(Figure 5-11). Furthermore, the apoptosis rate and the level of p21 and p53 in 
MG132/TMZ-treated cells were consistent with those in cells treated with MG132 
alone. This is a somewhat unexpected result. To our knowledge, the effect of the 
combination of TMZ and MG132 on U87 cells have not been studied prior to this 
work but our results show that there is no cumulative effect when TMZ is combined 
with MG123. It is unclear as to why this is, but a potential explanation could be that 
MG132 competes with or counteracts TMZ.  
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Regarding the effect of MG132 on PrP
c
, in our results, high concentrations of MG132 
(2 and 4 μM for 12 h) increased the level of PrP
c
 in U87 cells whereas 0.5 and 1 μM 
for 24 h did not affect the PrP
c
 level in these cells. The upregulation of this protein 
was about 1.5-2-fold possibly due to MG132’s ability to reduce the protein 
degradation resulting from the function of the ERAD proteasome pathway (Figure 5-7, 
5-8, 5-9). Yifat et al. showed that MG132 increases the level of PrP
c
 in CHO-MHM2 
and N2a cells due to resistance of PrP
c
 to proteolysis by endoplasmic-reticulum-
associated protein degradation (ERAD) in the metabolism of PrP
c14
. Other studies 
reported that MG132 upregulates the cytosolic 27-34 kDa of PrP
c
 in Hela-PrP, N2a-
PrP and N2a cell lines. This has been linked to the blockage of the proteasome which 
results in the unfolded protein response (UPR) as a consequence of endoplasmic 
reticulum stress
259
. Furthermore, Jiyan Ma et al.
122
 suggested that the metabolism of 
PrP
c
 was partially regulated by the ERAD-proteasome degradation pathway when the 
proteasome was inhibited, suggesting that a similar pathway may regulate cytosolic 
PrP
c
 and potentially membrane PrP
c
 levels in U87 cells. There is no literature to our 
knowledge to support the contention that inhibition of the ERAD-proteasome 
degradation pathway increases membrane associated PrP
c
 levels, and thus further 
analysis is needed. 
Furthermore, the toxicity of high doses of MG132 (2 and 4 μM) changes the 
morphology and promotes the detachment of U87 cell as is clearly seen in the actin 
filaments staining (phalloidin 488) reported in this chapter. Alfeu et al. mentioned that 
in the case of U138MG cells more than 1 μM of MG132 causes the cell membrane to 
lose its integrity, weakens the attachment of cells and changes the cell morphology
256
.  
To conclude, MG132 induces the apoptosis of U87 cells in a p53-dependent manner. 
Unexpectedly, however, the combination of MG132 with TMZ does not improve the 
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apoptosis rate compared to cells treated with MG132 alone. The efficacy of TMZ on 
U87 was null when combined with MG132. Our results have also showed for the first 
time that a short period of treatment of U87 cells with high concentration of MG132 
reduces the degradation of PrP
c
 and, therefore, increase its level.   
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Chapter 6: Investigation of the effect of small molecules (Fanconi anaemia 
pathway inhibitors, FAPi) on the level of PrP
c
 in U87 cells 
6.1 Introduction  
The Fanconi Anaemia (FA) pathway is operated by a network of proteins responsible 
for DNA repair, with 22 genes/proteins so far discovered in this family.
263
 Any defect 
in these genes will result in a disease called Fanconi Anaemia which is a recessive 
genetic disorder (Table 6-1)
264
. In addition to its connection with FA disease, however, 
FA pathway plays an important role in DNA repair in mammalian cells. It was 
revealed that 12 of these proteins is a minimum requirement in the normal function of 
the FA pathway (Figure 6-1)
16
. The 22 proteins in FA pathway can be divided into 
three groups according to their role in the complex: 
1- Upstream proteins or FA core complex involve 10 proteins, FANCA, FANCB, 








2- Nexus ID2 complex includes FANCI and FANCD2 which are substrates for 




3- Downstream of FANCD2/FANCI complex consists of FANCD1, FANCJ, 
FANCN, FANCO, FANCP, FANCQ
263
, FANCR, FANCS265, FANCU and 
FANCV
264
 which play effective roles in DNA repair.  
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Table (6-1): The FA genes and their function. 
 
FANCD2 monoubiquitination occurs after DNA damage, with a complex of upstream 
proteins being required to activate this process. Monoubiquitination is directed to 
nuclear foci, and this interaction repairs the DNA damage
266
. Specifically, the 
interaction of FANCD2 protein with BRCA1 and BRCA2 proteins promotes the 
Protein’s 
group 
Gene’s name Function  
A FANCA FA core complex member 
B FANCB FA core complex member 
C FANCC FA core complex member 
D1 FANCD1/BRCA2 Downstream of FANCD/FANCI complex 
D2 FANCD2 Formation FANCD/FANCI complex 
E FANCE FA core complex member 
F FANCF FA core complex member 
G FANCG/XRCC9 FA core complex member 
I FANCI/KIAA1794 Monoubiquitinated. Forms heterodimer with 
FANCD2 
J FANCJ/BRIP1/BACH1 Downstream of FANCD/FANCI complex 
L FANCL/PHF9  FA core complex member 
M FANCM FA core complex member 
N FANCN/PALB2 Downstream of FANCD/FANCI complex 
O FANCO/RAD51C Downstream of FANCD/FANCI complex 
P FANCP/SLX4 Downstream of FANCD/FANCI complex 
Q FANCQ/ERCC4/XPF Downstream of FANCD/FANCI complex 
R FANCR  Downstream of FANCD/FANCI complex 
S FANCS Downstream of FANCD/FANCI complex 
T FANCT FA core complex member 
U FANCU Downstream of FANCD/FANCI complex 
V FANCV Downstream of FANCD/FANCI complex 
W FANCW FA core complex member 
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repair of DNA lesions. Furthermore, FANCD2 monoubiquitination and the formation 
of nuclear foci occur in the S phase of the cell cycle
16
.  
Sims et al. stated that FANCI has the second most important role in the FA pathway 
after FANCD2. They confirmed this role by determination of FANCI 
monoubiquitination in cell lines in which the core complex protein was knocked down. 
Inhibition of FANCA and FANCG entirely rescinded the ubiquitination of FANCI in 





Figure (6-1): The mechanism of DNA repair via the FA pathway. Adapted from Chen et al. with kind 
permission of Springer Nature Group
16
. 
Chemotherapeutic agents such as cisplatin, TMZ and BCNU kill cancer cells by 
producing DNA interstrand crosslink (ICL) which prevents DNA disentangling and 
blocks its replication and transcription. Eukaryotic cells, however, use the FA 
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pathway to repair such damage rendering anti-cancer drug inactive and causing 
resistance. The FA pathway also has an important role in assisting other types of 
DNA repair processes such as nucleotide excision repair, translesion synthesis, 
homologous recombination
268
.   
According to previous studies, resistance to chemotherapies arises from the complex 
pathways which are associated with many processes of DNA repair. TMZ and BCNU 
increase monoubiquitinated FANCD2 and nuclear foci formation in glioblastoma 
cells that have proficient FA pathway and the sensitivity to these treatments was 
increased in deficient FA pathway’s cells
16
. Patil and co-workers confirmed these 
findings when they found that FANCD2 has a significant level of expression in high-
grade gliomas when compared with lower grades in GBM tissue samples. They also 
reported that silencing of the FA pathway or inhibiting of FANCD2 improved the 
efficacy of TMZ and BCNU
17
. In addition, Nimustine (ACNU) and TMZ were used 
in vitro to evaluate the FA pathway, which causes DNA damage as a result of these 
treatments. FANCD1 and FANCG particularly contribute to DNA repair after the 
damage by ACNU or TMZ. Silencing of FANCD1 improved the efficacy of these 
agents in A172 glioblastoma cells
269
. These results attracted the researcher to develop 
novel molecules that may inhibit the FA pathway and thence increase the sensitivity 
of glioblastoma cells to chemotherapy.  
In previous work within our group by Drs. Matthew Sellwood and Peng Hua it was 
demonstrated that novel small molecules FA pathway inhibitors (FAPi compounds) 
could downregulate FANCD2, which is activated in response to TMZ or BCNU 
treatment and this action may improve the effectiveness of these alkylating agents on 
U87 cells (unpublished results). In addition to the effect of FAPi compounds on the 
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level of FANCD2, some of these molecules may also suppress the level of PrP
c
 in 
glioblastoma cells. Although there is no specific structure of compounds targeting 
PrP
c
, many different scaffolds may have a potential active hit to PrP
c18
. It has been 
found that different analogues of amide compounds and other scaffolds have a 
possible potential effect to suppress the level of PrP
c
 in glioblastoma cells T98G 
according to SPC (single point confirmation) and ELISA. It is not known why some 
compounds selectively reduced PrP
c
 levels in glioblastoma cells, T98G
18
. We 
hypothesise that these compounds may have a dual function by inhibiting the FA 
pathway and reducing the level of PrP
c
 in U87 cells. In this chapter, ICC by 
ImageXpress Micro imaging system as a high throughput screening system (HTS) 
will be used for the first time to evaluate the PrP
c
 expression level in treated U87 cells 
with the combination of TMZ or BCNU with FAPi compounds or with FAPi 
compounds alone. 
6.2 The aim 
The aim of this chapter is to assess the level of PrP
c
 in U87 cells when treated with 
small molecules (benzimidazole amide derivatives, Figure 6-2) and possible effects 
upon treatment by TMZ and BCNU. The aim of this work will be addressed via 
following objectives:  
 Investigate the effect of these molecules on cell viability in treated cells with 
FAPi compounds in combination with TMZ or BCNU.  
 Evaluation of FANCD2 level in cells treated cells with TMZ or BCNU using 
western blotting.  
 The ICC method using the ImageXpress Micro as a high-throughput or high 
content screening assay (HTS), will be employed to evaluate the level of PrP
c
 
in treated cells with FAPi compounds in combination with TMZ or BCNU. 
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Prior to this, since this method was not used in the context of PrPc level in 
U87 cells, the optimization and validation of this method will be performed 
using the following experiment. 
 Optimising the concentration of anti-prion antibodies (3F4 and 8H4)  
 Evaluation of PrPc expression level in transfected cells with PRNP 
siRNA and compare that with previous results in chapter 4. 
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6.3 Methods 
In this chapter the incubation times and the concentrations of FAPi compounds and 
alkylating agents were used according to the previous work by Drs.  Matthew 
Sellwood and Peng Hua.   
6.3.1 Preparation of treatments 
The small molecules and alkylating agents (TMZ and BCNU) were dissolved in 
DMSO at 10 mM and 20 mM respectively as a stock solution. The stock solutions 
were then aliquoted into smaller portions in small vials and kept at -80 ºC. The 
working solution was prepared by diluting the stock solution with DMSO (1:5) and 
then with PBS (1:20). The final concentration of small molecules (FAPi compounds) 
and alkylating agents was 5 µM and 50 µM, respectively; as used in previous work by 
Drs.  Matthew Sellwood and Peng Hua (unpublished data).  
6.3.2. Cell viability assay 
MTT assay was carried out to evaluate the cell viability of U87 treated with the small 
molecules in combination with TMZ or BCNU. The cells were cultured in 96-well 
plate at 5000 cells in each well and left overnight for attachments. The cells were 
treated with small molecules by adding 2.5 µl of working solution (i.e 5 µM final 
concentration) using a multichannel pipette. The control group was treated with 2.5 µl 
of 10% DMSO. The plate was then incubated for 8 h in the incubator at 37 ᵒC. This 
step was followed by adding 2.5 µl of working solution of TMZ or BCNU (i.e 50 µM 
final concentration) to each well of the treated groups and 2.5 µl of 10% DMSO to 
each well of the control group. The plate was then left for 40 h under standard 
incubation conditions before the MTT protocol (section 2.2.2) was performed to 
evaluate the viability of the treated U87 cells. The Figure (6-3) below shows the 
design of this experiment.  
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Figure (6-3): The experimental design of MTT assay used to evaluate cell viability of U87 cells treated 
with FAPi compounds/TMZ or BCNU. 
6.3.3 Western blot assay 
To assess the level of FANCD2 in treated U87, the cells were cultured in a 6-well 
plate at 200000 cells and allowed to attach overnight, the cells were then treated with 
50 µM TMZ or BCNU. The plate was then incubated for 24 h and the protocol for 
western blotting was applied (section 2.2.5) to quantify the FANCD2 level. In this 
experiment, the PVDF membrane was exposed to anti FANCD2 antibody and 
secondary antibody (goat anti-mouse IgG) at 1:500 and 1:4000, respectively, as 
described in the manufacturer’s instructions for these antibodies. The membrane was 
re-probed with β-actin as a loading control.  
6.3.3 High throughput and high content small molecule screening method 
High-throughput screening (HTS) technology is an automated microscope-based assay 
which provides information on individual and multiple cells using several fluorescent 
stains to evaluate accurately many targets that are trigger by drugs and small 
molecules
270
.  The large number of cell images is rapidly quantified by image analysis 
using specific algorithms to provide initial evidence of the predictive validity for the 
cytotoxicity and efficacy of drug candidates
271
. This technique has therefore become 
an effective tool in drug discovery and in the pharmaceutical industry and has also 
attracted the interest of cell researchers
272
. To date, however, this method has not been 
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used to quantify the binding of PrP
c
 to anti-prion antibodies hence the following 
experiments will elucidate this binding further.  
6.3.3.1 Optimisation of ImageXpress Micro as a high content screening assay 
This method was used to evaluate the level of PrP
c
 in cells treated with FAPi 
compounds in combination with TMZ or BCNU. Prior to this experiment, the 
concentration of anti-prion antibodies (3F4 and 8H4) had to be optimised. These anti-
prion antibodies were selected because they are commonly used for immunostaining 
in various studies
273,184
. The 3F4 antibody binds strongly to PrP human and hamster 
with a specific requirement of two Met residues at positions 109 and 112 of the 
human PrP
274
, while the 8H4 antibody reacts with PrP monkey, bovine, rat, human, 
sheep and mouse, and its epitope residues found in amino acids 145-180 of the human 
prion protein
275
. The 96-well plate (Greiner Bio-One Ltd, cat no. 655098) was treated 
with polyornithine bromide, as described in section (2.2.8) and the cells were then 
cultured with 10000 cells in each well. Next day, the cells were fixed and the ICC 
protocol was followed (see section 2.2.8) to evaluate the fluorescent intensity of the 
PrP
c
 level. In this protocol, the cells were exposed to different concentrations of 
primary and secondary antibodies. Two kinds of anti-prion antibodies (3F4 and 8H4) 
in serial dilution and two dilution factors for secondary antibody (Donkey anti-mouse 
Alexa flour 488) were used to evaluate PrP
c
 expression level (Figure 6-4).   
 
Figure (6-4): The experimental design to optimise the PrP
c
 antibodies.  
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6.2.3.2 Validating the screening method 
Since the ICC method using ImageXpress Micro have not been used to evaluate the 
PrP
C
 level. The cells were seeded in a 96-well plate (Greiner Bio-One Ltd, cat no. 
655098) at a density of 5000 cells per well. After overnight attachment, the cells were 
transfected with scrambled and PRNP siRNA for 48 h as described in section (2.2.9). 
The ICC protocol (section 2.2.8) was followed to assess the level of PrP
c
 in the 
transfected U87 cells.   
6.3.3.3 The screening of FAPi compounds to evaluate PrP
c
 level 
The Greiner 96-well plate was prepared and coated with polyornithine bromide as 
described in section (2.2.8). The cells were seeded with 5000 cells in each well and 
then next day treated with FAPi compounds and alkylating agents TMZ or BCNU as 
described in section (6.3.2). After the incubation hours, the protocol for ICC was 
followed (section 2.2.8) to quantify the  PrP
c
 level. In this experiment, the wells were 
exposed to primary antibody 8H4 at 1:250 and secondary antibody (Donkey anti-
mouse Alexa flour 488) as shown in the Figure (6-5) below.  
 
Figure (6-5): The design of screening compounds by ImageXpress Micro. All wells were exposed to 
primary and secondary antibody except six wells (Control-primary, Control-Secondary), which were 
exposed to primary or secondary antibody only to determine the non-specific binding.  
6.3.4 The analysis of the images 
The procedure of the imaging was followed from the main menu of the MetaXpress 
software. A 20x objective was used to image all the selected wells. The acquired 
images were then analysed by designing a protocol using MetaXpress software 
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version 6.1. Briefly, the nuclear area was identified by DAPI staining (Blue channel, 
excitation 374/50, emission 447/60), then the PrP
c
 signal (Green channel, excitation 
438/24, emission 483/32) was localised by aligning the cell shape on the segment of 
DAPI staining. Using a special algorithm, the total number of cells was calculated 
based on the fluorescent intensity of the blue channel. The intensity of the green areas 
represents PrP
c
 level in each cell. The total intensity of all cells was then calculated 
and then divided by the total number of cells to obtain the mean of individual 
intensity. 
The collected data were normalised as a percentage to the control group. The results 
were statistically analysed using student’s t-test as mean ± SD.   
6.4 Results 
6.4.1 Cell viability for U87 cells treated with FAPi compounds in combination 
with TMZ or BCNU  
To investigate whether FAPi compounds induce toxicity to U87 cells in combination 
with TMZ or BCNU, an MTT assay was carried out. The cells were treated for 8 h 
with 5 µM FAPi compounds and then treated with TMZ or BCNU for 40 h. Figure (6-
6) reveals that none of these compounds affects the viability of U87 cells. The cell 
viability was between 84% ± 11 to 103% ± 12 and between 88% ± 11 to 110% ± 7 for 
treated cells with FAPi compounds in combination with TMZ or BCNU respectively 
in comparison with the control group. Due to the non-toxic effect of these compounds 
when combined with TMZ or BCNU, they were used in the ImageXpress Micro 
screening method (section 6.4.4). Our findings confirm the results of previous work 
by Drs.  Matthew Sellwood and Peng Hua using the same combinations (unpublished 
data).   
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Figure (6-6): Cell viability assay for U87 cells treated with FAPi compounds in combination with 
TMZ or BCNU. The A and B bar charts reveal cell viability of U87 cells treated with FAPi compounds 
in combination with TMZ or BCNU respectively. The cell viability was normalised to the control 
group. The bars represent mean ± SD of three independent experiments, each performed in triplicate 
(n=9). The data were statistically analysed using one-way ANOVA, Tukey’s test (each compound was 
compared to the control and TMZ or BCNU treated cells).  
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6.4.2 FANCD2 expression in treated U87 cells with TMZ or BCNU 
To find out whether TMZ or BCNU induced the FA pathway in U87 cells through 
upregulation of the FANCD2 level, the cells were treated with these agents for 24 h 
and western blot assay was then used to evaluate FANCD2 expression. Figure (6-7) 
shows that the level of FANCD2 was significantly increased in treated cells compared 
to the control group. This induction was in response to the DNA damage caused by 
alkylating agents which activated many pathways such as the FA pathway to repair 
this damage. This pathway is required to protect the cells from the DNA interstrand 




Figure (6-7): Western blot for FANCD2 in U87 cells treated with TMZ and BCNU for 24h. (A), 
represents the image of western blot. (B), the bar chart represent mean ± SD and shows the significant 
increase of FANCD2 in treated cells in comparison to the control group. This experiment was repeated 
three times and normalised to the control group (n=3). The results were analysed using t-test 
(*=p<0.05).  
6.4.3 FAPi compounds suppress FA pathway   
In previous work by this research group, ICC and western blot assays were used to 
investigate the level of FANCD2 in U87 cells treated with FAPi/TMZ or FAPi/BCNU 
combinations. Seven compounds were chosen to present in this chapter.  
Chapter 6: Results section 4 
- 169 - 
 
These small-molecule compounds have reliable inhibition against FA re-activated by 
chemotherapeutic agents, TMZ and BCNU (Figure 6-8 A and B). In western blot 
assay, although there was no significant difference between the TMZ or BCNU band 
on the one hand and the compounds’ pre-dosing bands on the other when using 1 μM 
(data not shown). When the pre-dosing concentration was increased to 5 μM, the band 
of FANCD2 FAPi conditions was observed to be significantly fainter than those TMZ 
or BCNU, even reaching the DMSO control level (Figure 6-8 B and C). Altogether, 
therefore, this family of small-molecules has great potential to be developed for 
specifically inhibiting FA pathway in U87 cells. 
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Figure (6-8): The level of FANCD2 in FAPi treated U87 cells. A, Immunofluorescence detection and 
quantification of U87 cells exhibiting nuclear FANCD2 foci (a marker of an active FA pathway). The 
cells were treated with 5 μM compounds prior to 50 μM TMZ or BCNU for 40 h. Images were 
captured and analysed using Volocity software. Error bars represent the standard deviation of the 
means. All duplicated data suggest that these compounds offer a reliable inhibition of FANCD2 
signalling. B and C, Representative western blots showing FANCD2 and actin (loading control) 
expression in U87 cells treated with TMZ or BCNU activate the FA pathway. Pre-treatment with FAPi 
and then the combination with TMZ or BCNU inhibit FA pathway activation as evidenced by 
significantly reduced FANCD2 after TMZ or BCNU treatment. These experiments were performed by 
Drs. Matthew Sellwood and Peng Hua.  
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6.4.4 Development of high throughput and high content small molecule screening 
method 
High-content imaging by ImageXpress Micro has numerous applications in the drug 
discovery field including target identification and screening of chemical compounds. 





, the next set of experiments were aimed to evaluate whether ICC by 
ImageXpress Micro is suitable to evaluate PrP
c
 level in U87 cells or not. 
6.4.4.1 Optimisation and validation of ImageXpress Micro as a high throughput 
and high content screening assay  
To optimise this method and to obtain an accurate indication of the binding of PrP
c
 
with the anti-prion antibody, ICC was carried out using different concentrations of 
3F4 and 8H4 anti-prion antibodies. Figure (6-9, A) reveals the profile of the 96-well 
plate which was exposed to the serial dilution of both primary antibodies and two 
dilutions of secondary Alexa Fluor 488 (1:1000 and 1:500). The profile image of the 
96-well plate shows a gradient of brightness indicating the binding of both antibodies 
to the fluorescent secondary antibody. The fluorescent intensities of both primary 
antibodies decreased gradually with 1:1000 of the secondary antibody, whereas with 
1:500 of secondary antibody the fluorescent intensities fluctuated (Figure 6-9, B). 
These results would suggest that both 3F4 and 8H4 are suitable for use in this 
experiment since they displayed proper binding with PrP
c
 when these antibodies were 
exposed to 1:1000 of the secondary antibody. The two yellow squares in the image A 
(Figure 6-9, A) show that no obvious background was seen when the cells were 
exposed to only secondary Alexa Fluor 488, leading to a low level of non-specific 
binding as shown in the value of fluorescence compared to the primary antibody in 
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both dilutions of secondary antibody, 1:1000 and 1:500 (Figure 6-9, B). It was 
therefore decided to use 1:250 of 8H4 with 1:1000 of secondary antibody in the ICC 
experiment in this chapter. To our knowledge, this method concerning PrP
c
 has not 
been reported previously.   
To validate the ICC technique using ImageXpress Micro, the cells were transfected 
with PRNP siRNA for 48h and the level of PrP
c
 was evaluated in both the transfected 
and untreated cells. Nine images were taken for each well and all images were 
analysed using MetaXpress Software. Figure 6-9, B shows that the transfected cells 
displayed a decreasing fluorescent intensity for PrP
c
 in knockdown cells. The level of 
PrP
c
 decreased relative to scrambled and untreated cells (control) to around 30% 
(Figure 6-9, C). These results confirmed our western blot and flow cytometry assay 
findings in the previous chapter of this thesis where we found that the level of PrP
c
 in 
knockdown cells decreased to approximately 23% and 21%, respectively compared to 
scrambles and control groups after 48 h incubation with transfection reagents (see 
chapter 4, section 4.3.3.1 and 4.3.3.2).  The slight variation in the values of PrP
c
 level 
therefore, could be related to the experimental or system variations.  
As shown in these experiments, this method might be appropriate to screen the effect 
of small molecules on PrP
c
 level in U87 glioblastoma cells. 
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Figure (6-9): The level of PrP
c
 by ICC using ImageXpress Micro. A, shows the profile of a 96-well 
plate for determining PrP
c
 level in U87 cells exposed to 3F4 and 8H4 antibodies. B, the bar chart 
reveals the fluorescent intensity of PrP
c
 in U87 as mean ± SD using 3F4 and 8H4 antibodies. The 
experiment was repeated three times, each performed in triplicate (n=9). C, the image represents the 
profile of 96-well plate which reflects the fluorescent of PrP
c
 in transfected cells for 48h. D, the chart 
shows mean ± SD of three different experiments and each experiment was performed in six wells 
(n=18). The data were normalised to the control group.  
6.4.4.2. PrP
c
 expression in treated U87 cells with FAPi compounds/TMZ or 
BCNU combination using ImageXpress Micro 
ICC using ImageXpress Micro imaging was applied to assess PrP
c
 expression level in 
cells treated with FAPi compounds/TMZ or BCNU combination as described in 
section 6.3.4. In previous studies by Drs. Matthew Sellwood and Peng Hua, FAPi 
compounds were found to suppress the activity of that FA pathway which is otherwise 
activated in response to alkylating agents. In brief, the combination of these 
compounds with TMZ or BCNU inhibited the FA pathway when compared with 
treated cells with TMZ or BCNU alone (section 6.4.3). We speculated that these 
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compounds might also reduce the level of PrP
c
 in glioblastoma cells. Figure (6-10) 
shows that the combination of FAPi compounds with TMZ or BCNU did not exhibit 
any remarkable change in PrP
c
 protein level compared to the control group after 48 h 
(8 h with FAPi compounds+40 h in combination with TMZ or BCNU). The structure 
of these compounds has an amide group. Michael et al. showed that some of amide 
analogues and other molecules may be hit PrP
c
 in T98 glioblastoma cells and then 
decrease its level
18
. This combination may distract or disturb the hit. The next 
experiment was therefore performed to evaluate the PrP
c
 level in cells treated with 
FAPi compounds alone.  
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Figure (6-10): FAPi compounds do not affect PrP
c
 expression in combination with TMZ or BCNU. 
The A and B bar charts show the expression of PrP
c
 in treated cells. The data were normalised to the 
control as a percentage and represents mean ± SD of four independent experiments, each performed in 
triplicate (n=12). The data were statistically analysed using t-test (each compound compared to the 
control group).  
6.4.4.3 The expression of PrP
c
 in treated U87 cells with FAPi compounds 
To evaluate the effect of FAPi compounds on the PrP
c
 level in U87 cells, the cells 
were treated with FAPi compounds for 48 h at 5 μM and ICC using ImageXpress 
Micro. We expected that the single treatment with FAPi compounds may affect PrP
c
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level in U87 cells. Figure (6-11, A) shows the profile image for the 96-well plate 
which was treated with FAPi compounds. The bar chart reveals that FAPi compounds 
did not affect PrP
c
 expression in U87 cells compared to the control group after 48 h 
(Figure 6-11, B).  
 
Figure (6-11): FAPi compounds do not affect PrP
c
 level in U87 cells after 48 h of treatment with 5 µM 
FAPi compounds. A, represents the profile of the 96-well plate of treated cells. B, reveals no significant 
effect on PrP
c
 level compared to the control group.  The results were normalised to the control group 
and represent mean ± SD of three different experiments, each performed in triplicate (n=9).  The data 
were statistically analysed using t-test (each compound compared to the control group).   
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6.5 Summary of key experimental results 
 The FAPi compounds did not induce cytotoxicity to U87 cells in combination 
with TMZ or BCNU at 5 μM.  
 FANCD2 was upregulated in TMZ or BCNU treated cells after 24 h 
 FAPi compounds inhibited the FA pathway, which was activated by TMZ or 
BCNU through suppressing FANCD2. 
 ICC using ImageXpress Micro as a high content screening assay provided 
suitable results in the optimisation and validation of this method using; 
different concentration of primary antibodies and in the evaluation of PrP
c
 in 
knockdown cells.  
 The expression of PrPc in FAPi compounds in U87 cells treated in 
combination or without combination with TMZ or BCNU did not affect using 
ImageXpress Micro imaging assay.      
6.6 Discussion  
The FA pathway is considered to be one of the main DNA repair pathways in 
mammalian cells. It has been found to be induced in glioblastoma cells treated with 
alkylating agents such as TMZ and BCNU by the formation of monoubiquitinated 
FANCD2, the key part of the FA pathway
16
. This pathway is very sensitive to a 
variety of DNA damage or crosslinking stimuli, thus, many attempts have been 
carried out to identify novel small molecules as inhibitors to this pathway
277
. In our 
western blot assay results, TMZ and BCNU increase the level of FANCD2 when U87 
cells were treated for 24 h (Figure 6-7). This result is in line with previous work 
reporting that TMZ or BCNU induced the level of FANCD2 in U87 cells
16,17
. It has 
been demonstrated that glioma cells with an inhibited FA pathway are more sensitive 
to alkylating agents when pre-dosed with FA inhibitors such as Curcumin
17
. FAPi 
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compounds were synthesised and used in previous work by our group (Drs. Matthew 
Sellwood and Peng Hua) revealing that these compounds have a reliable inhibitory 
effect on the highly-stimulated FA pathway induced by chemotherapeutic drugs, by 
significantly reducing the level of FANCD2 (Figure 6-8). The exact mechanism of 
these molecules has not been elucidated yet, even for the commercially available FA 
pathway inhibitors such as curcumin
278,277
. 
Since these novel compounds inhibit the FA pathway, we speculated that they may 
also have a possible potential to hit PrP
c
 level in glioblastoma cells and inhibit the 
expression level of this protein. This possibility could be related to the structure of 
these compounds, which have an amide group with different substitution groups. In 
another study, the amide analogues (have an amide with different substitutions) may 
have an active hit on PrP
c
 in glioblastoma cells
18
. 
The ICC method using ImageXpress Micro was employed to evaluate the level of 
PrP
c
 in U87 cells treated with FAPi compounds with or without TMZ or BCNU. Prior 
to the screening of FAPi compounds in the ImageXpress Micro imaging assay we had 
to evaluate the viability of U87 cells in the combination of these compounds with 
TMZ or BCNU and validate this imaging method. The results of the MTT assay 
showed that the combination of these compounds with TMZ or BCNU did not induce 
any obvious cell death at the intended dose (Figure 6-6).  
To our knowledge, this is the first time that ICC by ImageXpress Micro has been used 
to evaluate the PrP
c
 level in glioblastoma cells. Thus, it is necessary to validate this 
method for PrP
c
 evaluation. Different concentrations of two types PrP
c
 primary 
antibodies (3F4 and 8H4) which are commonly used in immunofluorescent 
staining
273,184
 showed graduated brightness in the images and gave a linear 
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proportional fluorescent intensity with the increase of the antibodies’ concentrations 
(1:100, 1:250 and 1:500 of primary antibodies with 1:1000 of fluorescent secondary 
antibody) (Figure 6-9 A and B). Both of these antibodies were suitable to be used in 
this experiment, however, 8H4 was used in the next experiments at 1:250 with 1:1000 
of Alexa flour secondary antibody. Furthermore, to confirm the validity of this 
method, the cells were transfected with PRNP siRNA in order to suppress the level of 
PrP
c
 in these cells. As has been mentioned in chapter 5, the transfection of U87 cells 
by PRNP siRNA silenced about 78% of PrP
c
 after 48h. The result of PrP
c
 knockdown 
using ImageXpress Micro shows that the level of PrP
c
 in PRNP siRNA cells 
decreased by approximately 70% relative to scramble and untreated cells (Figure 6-9, 
B and C) and this result coincides with the previous result in chapter 5. Therefore, 
ICC using ImageXpress Micro could be an appropriate method to screen many 
compounds.  
Consequently, in this chapter, we investigated whether or not FAPi compounds inhibit 
the level of PrP
c
 in U87 using ImageXpress Micro. These compounds may have a 
potential to suppress the level of PrP
c
 due to the amide group in their structure. For 
this reason, we speculated that FAPi compounds might have a dual function inhibition 
of the FA pathway and reduce the level of PrP
c
. The combination of these compounds 
with TMZ or BCNU, however, did not cause any reduction in the PrP
c
 level in treated 
U87 cells after 48 h (8 h with FAPi and 40 h in combination with TMZ or BCNU 
(Figure 6-10). We expected that the combination of FAPi compounds with TMZ or 
BCNU might disrupt the ability of these compounds to decrease PrP
c
 protein in U87 
cells. The ICC experiment was therefore carried out for treated cells with FAPi 
compounds alone. The results revealed that there is no significant change in the level 
of PrP
c
 in relative to the control group (Figure 6-11).  Our results did not agree with 
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the findings of Michael et al. who found that many scaffolds such as the amide 
analogues reduced the level of PrP
c
 in T98G glioblastoma cells. Using ELISA assay 
they identified and confirmed that these compounds have a potential effect to hit the 
PrP
c
 in T98G cells
18
. Further investigations could be carried out to determine the 
effect of FAPi compounds on PrP
c
 level in glioblastoma cells. For example, 
increasing the incubation time with FAPi compounds may exhibit a remarkable 
decrease in the level of PrP
c
 in these cells. In addition, other measurements may 
confirm our results such as flow cytometry, western blot and ICC by confocal 
microscopy which may be more accurate than ICC by ImageXpress Micro.  
To conclude, these preliminary results demonstrated that the FAPi compounds 
examined are FA pathway-specific compounds, and do not have much effect on the 
PrP pathway, especially on PrP
c
 expression itself. This is the first time ICC has been 
used alongside by ImageXpress Micro for high content image for screening several 
compounds to evaluate the effect of these compounds on PrP
c
 level in glioblastoma 
cells U87. Further investigation could be carried out, such as increasing the duration 
of treatment or using other quantification methods to confirm and validate the effect 
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Chapter 7: Screening of small molecule chemical libraries as anticancer agents 
using U87 glioblastoma cells. 
7.1 Introduction  
Substituted heteroaromatic compounds have been known to have a wide range of 
biological activity including anti-cancer activities
279
.  Most anti-cancer therapies act 
via promoting programmed cell death, such as apoptosis
280
. A previous member of the 
Chen group (Dr Peng Hua) has tested a library of heteroaromatic compounds from 
which dicynopyridine (A), pyridine (B), indole (C), acridine (D), benzimidazole (E), 
thiazol (F) and oxazole (G) (Figure 7-1) displayed obvious cytotoxicities to 
teratocarcinoma stem cell line Ntera2 (NT2) while he was searching for compounds 
that enhance the proliferation of NT2 cells. The potential applications of these 
compounds as anticancer drugs have not yet explored. In addition, some of these 
compounds may have an activity to lower PrP
c
 level. For example, the previous work 
for the group found that some analogues of 9-aminoacridines may bind PrP
c
 according 
to surface plasmon resonance (SPR) binding assay
281
. These compounds have been 
also tested previously by a member of group (Dr Jennifer Louth) on SMB cells (prion-
infected brain cell of mouse
282
) and zebrafish, where it was found that these molecules 
did not induce cytotoxicity with IC50 ≤ 20 μM (unpublished data)   
These novel small molecules were synthesised previously by the members of group 
(Tummalu Reddy, Paul Taylor, Steven Farrara, Vinciane Borsenberger, Aziz 
Mekhalfia, Claire Pascoe, Hannah Hope, Mark Thompson and Katie Judd). Their 
anticancer activities in NT2 cells inspired us to hypothesis that these molecules might 
also inhibit the growth of U87 cells and act via PrP
c
 route.  
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Figure (7-1): List of the small molecules subdivided into seven families. 
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7.2 The aim 
This chapter aims to evaluate the effect of small molecule chemical libraries, that 
previously displayed anticancer activities on NT2 cells, on U87 glioblastoma cells. 
The influence of the effective small molecules on PrPc expression and other 
biomarkers will also be evaluated. To achieve this aim, the following objectives will 
be carried out: 
 Evaluate the cell viability for U87 cells treated with these small molecules 
using MTT assay. 
 Assess the apoptotic effect of small molecules on U87 cells using Annexin 
V with PI. 
 Evaluate the population of treated cells in each cell cycle phase using flow 
cytometry. 
 Assess the level of p53 and p21 in treated cells. 
 Evaluate the effect of the compound that induced apoptosis on the level of 
PrP
c
 to determine whether it induces or reduces the level of this protein.      
7.3 Methods 
7.3.1 Compounds preparation  
The novel small molecules were synthesised and purified using HPLC by the previous 
members in the group, as listed in section 7.1. These compounds were dissolved in 
DMSO at 10 mM and then aliquoted into small portion and placed in small vials, 
which were kept at -20 °C before use. The desired working concentration was 
prepared by diluting the stock solution with an appropriate volume of DMSO and 
PBS prior to each experiment.  
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7.3.2 Cell viability by MTT assay 
MTT assay was used to determine the viability of U87 cells treated with the small 
molecules. The cells were seeded in 96-well plates at a density of 10000 cells in each 
well, and the following day were treated with the compounds as illustrated in Figure 
(7-2). The cells were incubated at 37 ºC for 24 h. The protocol for MTT assay (section 
2.2.2) was applied in order to determine the viability of cells in these compounds. The 
data were analysed as a percentage to the untreated cells (control group).  
Furthermore, MTT assay was used to calculate the IC50 for compound 175. The cells 
were seeded in 96-well plate at 1000 cells and then treated with serial concentrations 
(1, 2.5, 5, 10, 20 μM) of this compound for five days.   
Figure (7-2): The experimental design of MTT assay for the small molecules.  
7.3.3 Apoptosis assay 
Annexin V with PI staining was carried out as described in section 2.2.13  to evaluate 
the apoptotic effect of small molecules on U87 cells. The cells were seeded in a 6-
well plate at 50000 cells in each well and then treated with 5 μM of the small 
molecules for 48 h, as reported by other groups using glioblastoma cells for anticancer 
drug screening
262,13
.  The apoptosis for all samples was quantified using flow 
cytometry. The apoptotic cells were calculated as a percentage of total cells. 
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7.3.4 Cell cycle assay  
To quantify the population of cells in each cell cycle phase, the cells were cultured in 
6-well plates, and then left overnight for attachments. This step was followed by 
treating the cells with compound 175 at 1, 2.5 and 5 μM. After five days, the cells 
were washed and harvested using non-enzymatic dissociation solution. The protocol 
for cell cycle using PI with RNase (section 2.2.3) was followed to assess the number 
of cells in each cell cycle phase. In this chapter, we focused on compound 175 due to 
its significant apoptotic impact on U87 cells (section 7.4.2). Although 48 h incubation 
with the treatment led to only a slight change in cell cycle over the used 
concentrations (data not shown), the incubation time was extended to five days to 
ensure the effectiveness of this compound on cell cycle phases clearly seen.    
7.3.5 Western blot assay 
PrP
c
, p21 and p53 levels in treated cells with compound 175 were evaluated using 
western blot. To evaluate these proteins, the 6-well plate was seeded at 25000 cells 
and then the on the following day the cells treated with compound 175 (1, 2.5 and 5 
μM) for five days. The control group was treated with 0.5% DMSO. This step was 
followed by the preparation of cell lysate, and the protein levels were then assessed 
using the western blot method described in section (2.2.5).  
7.4 Results 
7.4.1 Cell viability of U87 treated with the small molecules 
To determine the effect of 30 compounds on the viability of U87 glioblastoma cells, 
MTT assay was carried out for all these compounds after 24 h treatment with different 
concentration of these compounds (1, 5, 10 and 20 µM). Most of these compounds did 
not induce any reduction in cell number of the cultured cells (data not shown) except 
for eight compounds. For these eight, MTT assay exhibited different responses. The 
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bar chart below shows the viability of U87 cells in treated cells compared to the 
control group (Figure 7-3). Our results indicate that these compounds are generally 
non-toxic for U87 cells at 5 µM except compound 765. As can be seen, that 
compound 752 in group G and 759, 762, 765 and 866 in F group reduce the viability 
of U87 cells at a high concentration of 20 µM to just 25%-45% compared to the 
control group. Compound 816 and 175 slightly decrease the cell viability to 
approximately 72% and 83% at 20 μM respectively. It was therefore decided to use 5 
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Figure (7-3): Cell viability of U87 cells treated with eight compounds. The viability was calculated as 
a percentage to the control group. The bars represent mean ± SD of three different experiments and 
each experiment was performed in triplicate (n=9) and analysed using t-test (each concentration of 
compound compared to the control group), *=p˂0.05, **=p˂0.01, ***=p˂0.001, ****=p˂0.0001.   
7.4.2 Apoptosis assay for the treated U87 cells with small molecules 
Eight of the small molecules displayed a reduction in cell viability at variable 
concentration due to the cytotoxic effect of these molecules, as shown in the previous 
experiment (section 7.4.1). To quantify this effect, an apoptosis assay was performed 
in U87 cells treated with these compounds for 48 h at 5 µM for each compound. The 
scatter charts show the population of live, dead and apoptotic cells in flow cytometry 
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analysis. The upper right square in each scatter chart (Figure 7-4, A) reveals the total 
apoptotic cells in each sample. It can be seen that compound 175 increased the 
apoptosis rate in U87 cells, whereas other compounds did not induce any apoptotic 
effect (Figure 7-4, A). The bar chart shows the statistical analysis for this experiment 
(Figure 7-4, B). These results indicate that compound 175 can increase the apoptosis 
rate by about 12% after 48 h (Figure 7-4, B). This could be attributed to the general 
cytotoxic effect of this compound, which is one of the 9-aminoacridine family. Some 
of the acridine compounds bind to the DNA and then induce cytotoxicity
283,284
. 
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Figure (7-4): The effect of eight small molecules on the apoptosis of U87 cells using Annexin V with 
PI. A, represents scatter charts of U87 cells treated for 48 h. B, the bars show mean ± SD of three 
different experiments, each performed in duplicate (n=6). The data were analysed using t-test (each 
compound was compared to the control) (**=p˂0.01). 
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7.4.3 Dose-dependent studies of U87 cells treated with compound 175 over 5 days 
According to apoptosis assay, compound 175 induces the most apoptosis of U87 cells 
after 48 h. A cell viability assay was therefore carried out as described in section 7.3.2 
to calculate IC50 for this compound over five days treatment period. The time was 
extended to five days because 24 h and 48 h did not show any remarkable decrease in 
cell viability. In addition, this compound did not dissolve properly when its 
concentration increased where we observed that this compound aggregated at 40 and 
50 µM. The line graph shows that the viability of U87 cells was decreased 
dramatically in a dose-dependent manner with IC50=10.9 µM (Figure 7-5).  
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Figure (7-5): Viability of U87 cells in the different concentrations of compound 175. The line graph 
represents mean ± SD of the percentage of viable cells compared to the control. Cell viability was 
calculated in treated cells after five days to evaluate the IC50 of compound 175. This experiment was 
performed in triplicate and repeated three times (n=9).  
7.4.4 Cell cycle studies by compound 175  
To evaluate the effect of compound 175 on the cell cycle of U87 cells, a flow 
cytometry assay for cell cycle was carried out after five days as described in section 
7.3.4. Figure (7-6, A) shows the histograms which represent the population of cells in 
each phase of the cell cycle. These results reveal that compound 175 arrested the cells 
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in G2/M in a dose-dependent manner (1, 2.5 and 5µM) after 5 days by around 18%, 
27% and 46%, respectively whereas the G1 cells were dramatically decreased 
depending on the concentration of compound 175 (Figure 7-6, B). These results 
support the cell viability result with the decrease in cell proliferation possibly 
attributable to the arrest of cells in G2/M. Furthermore, the G2/M arrest may result 
from the DNA damage induced by this compound, or possibly from p53 induction 
resulting from the effect of acridine compound (see section 7.4.5).  The induction of 
p53 as a tumour suppressor protein in response to DNA damage induces the cell cycle 
arrest or apoptosis
285
. p53 and p21 as regulators for cell cycle will therefore be 
evaluated in the next section (7.4.5).  
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Figure (7-6): The cell cycle analysis of U87 cells treated with compound 175. A, the histograms reveal 
the population of treated cells with compound 175 in each cell cycle phase. B, the bar chart represents 
mean ± SD and shows the percentage of cells in each cell cycle phase. The treated cells were 
accumulated in G2/M in a dose-dependent manner. The experiment was performed in triplicate and 
repeated three times (n=6). All data were analysed using one-way ANOVA, Tukey’s test (**= p˂0.01, 
***= p˂0.001, ***= p˂0.001****= p˂0.0001).   
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7.4.5 The level of p21 and p53 by compound 175 
Since compound 175 accumulates U87 cells in the G2/M phase, as shown in section 
(7.4.4), western blot analysis was carried out in U87 cells to estimate the effect of this 
compound on the regulators of the cell cycle p53 and p21as described in section 7.3.5. 
Figure (7-7) shows that these proteins dramatically increased when treated with 1, 2.5 
and 5 μM of compound 175 for five days. p53 and p21 were significantly increased in 
treated U87 cells with compound 175 in a dose-dependent manner. This induction 
may be ascribed to the arrest of U87 cells in G2/M (section 7.4.4) allowing repair of 
the DNA damage caused by compound 175. The G2/M accumulation required both 
p53 and p21 in glioblastoma cells. As a further explanation, the p53 may be increased 
as a result of the apoptotic effect of compound 175, as shown in section (7.4.2) where 
p53 was induced in response to DNA damage or apoptotic stimuli
285
. Another study 
has revealed that acridine derivatives promoted the apoptosis of tumour cells by 
induction of p53 and Bax
286
.  
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Figure (7-7): Compound 175 upregulates p21 and p53 in U87 cells. A, shows the western blot images 
for p53 and p21 in treated cells with compound 175. B, the bar charts reveal the analysis of data as 
mean ± SD of three independent experiments (n=3). The data were normalised to the control group. 
Both of these proteins are upregulated in treated cells with 1, 2.5 and 5 μM of compound 175. The 
results were statistically analysed using one-way ANOVA, Tukey’s test (*= p˂0.05, **= p˂0.01, ***= 
p˂0.001). 
7.4.6 The effect of compound 175 on PrP
c
 level in U87 cells  
Besides the apoptotic impact of compound 175 on U87 cells, we expected that the 
compound may change the level of PrP
c
 in U87 cells on the basis that previous work 





 in U87 cells treated with compound 175 was evaluated using western 
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blot assay as described in section 7.3.5. Figure (7-8) below indicates that there was no 
significant change in the level of PrP
c 
in cells treated with compounds 175 over five 
days at tested concentrations of 1, 2.5 and 5 µM when compared to the control. The 
level of PrP
c
 was normalised to the loading control (β-actin) for each sample and then 




 level in treated U87 cells with compound 175. A, the western blot image shows the 
expression of PrP
c
 in 175-treated cells. B, the bars represent mean ± SD of PrP
c
 level in treated cells in 
relative to the control. There was no significant change in proteins level in 175-treated cells compared 
to the control. This experiment was repeated for at least three times (n=3) and the data were analysed 
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7.5 Summary of key experimental results  
 Thirty compounds were tested as an anti-cancer treatment on glioblastoma 
cells U87 cells, with just eight compounds reducing the viability of U87 cells.  
 One of the eight compounds, compound 175, increased the apoptosis rate of 
U87 cells after 48 h.  
 Compound 175 decreased the viability of U87 cells in a dose-dependent 
manner and the IC50 was 10.9 μM. 
 Compound 175 arrested the cells in G2/M phase after five days in a dose-
dependent manner. 
 p21 and p53 levels increased in a dose-dependent manner in compound 175 
treated cells as a result to G2/M arrest. 
 Compound 175 did not induce the level of PrPc in U87 cells. 
 
7.6 Discussion 
Many of heteroaromatic compounds have promising bioactivities against cancers as 
well as other physiochemical properties
279
. In this work, 30 novel compounds were 
tested on U87 cells. these compounds were selected based on these compounds have 
been tested previously by a member of group (Dr Jennifer Louth) on SMB cells 
(Scrapie mouse brain cells infected with Chandler scrapie strain
282
) and zebrafish, 
where it was found that these molecules did not induce cytotoxicity with IC50 ≤ 20 
μM (unpublished data); further cytotoxicity work has also been carried out by the 
group (Dr Peng Hus) on the teratocarcinoma stem cell line Ntera2 (NT2), and they 
found that these compounds displayed cytotoxicity on this cell (unpublished data). We 
therefore speculated that these compounds may have a potent toxic effect on U87 cells.  
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Our results showed that most of these compounds did not induce any cytotoxicity, 
even at high concentrations (20 µM). Eight of these compounds reduced the viability 
of U87 cells, and this reduction was fluctuated from compound to another compound 
but 5 µM did not induce any cytotoxic effect on U87 cells, except for compound 765 
(Figure 7-3). The results of the apoptosis assay by Annexine V with PI staining for the 
eight compounds showed that only compound 175 promoted apoptosis for U87 cells 
after 48 h compared to the control group (Figure 7-4), possibly related to the cytotoxic 
effect of this compound. Furthermore, compound 175 inhibited the growth of U87 
cells after five days with an IC50 of 10.9 µM according to MTT assay (Figure 7-5). To 
our knowledge, this is the first time that compound 175 has been shown to be active 
against glioblastoma cells, we, therefore, focused on this compound as a treatment for 
glioblastoma cancer. This compound belongs to the 9-aminoacridine family which has 
previously been reported as inducing cytotoxicity for some cancer cells. Com and co-
workers synthesised various 9-aminoacridine derivatives and they tested them on 
leukaemia L1210 cells. They stated that some of these compounds suppressed the 
growth of these cells, although the IC50 results varied depending on the variation of 
the structure of these compounds
283
. Also, another study revealed that 9-
phenoxyacridines and 9-(phenylthio) acridines have moderate toxicity to mouse and 
human leukaemia cell lines L1210 and HL60, respectively
284
. Furthermore, 
Christopher et al. stated that di and tri substituted 9-aminoacridine reduced the 
viability of human ovarian carcinoma A2780
287. Goodell et al. stated that the growth 
of pancreas cancer cells BxPC-3, MIA PaCa-2 and SU.86.86 was inhibited when 
treated with some 9-aminoacridine derivatives
288,289
.  
To investigate the effect of compound 175 on U87 cells, a cell cycle assay was carried 
out. The results of this test showed that compound 175 has a crucial impact on the cell 
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cycle phases of U87 cells. This compound accumulates the cells in the G2/M phase in 
a dose-dependent manner. It arrests the cells in G2/M by around 48% when the cells 
were treated for five days at 5 µM (Figure 7-6). These results may support the results 
regarding cell viability in that the accumulation of cells in G2/M would have reduced 
the proliferation of cells. The G2/M arrest may be attributed to the effect of this 
compound on DNA through intercalating. It has been reported that some acridine 
compounds intercalate to DNA due to its planar structure and then bind covalently via 
the amine group to DNA. This binding thereby may also exert cytotoxicity
283,284
. In 
addition, other studies have shown that some of the 9-aminoacridine derivatives 
compounds inhibit topoisomerase II (topo II) which regulates the over-winding or 
under-winding of DNA
283,290,291
. The disruption of Topo II by some of 9-
aminoacridine derivatives compounds leads to a change in cell cycle phases and 
accumulates the cells in the G2 phase
292,293
.  
Furthermore, the induction of G2/M arrest in cells treated with compound 175 may 
increase the level of p53 and p21 which arises in response to DNA damage (Figure 7-
7). These results are in agreement with previous findings which have illustrated that 
p53 induced G2 arrest in response to the inhibitors of topo II
293
. On the other hand, as 
we mentioned before, according to Annexine V assay, compound 175 increased the 
apoptosis in U87 cells (Figure 7-4) and this induction may be as a result of increasing 
the level of p53 since this induces apoptosis in some cancer cells through the p53-
dependent apoptotic pathway, particularly in wild-type p53 cells. Wenge et al. found 
that 9-aminoacridine derivatives promoted the apoptosis in various cancer cells 
through upregulating p53 and Bax
286
. The increase in the level of p53 in response to 
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Beside the cytotoxic effect of compound 175 and the consequent increase in apoptosis, 
which may correlate with the induction of p53, we expected that the level of PrP
c
 in 
U87 treated with compound 175 would also change due to the potential binding of 
this compound to PrP
c
. The expectation was that compound 175 may target PrP
c
 then 
subsequently reduce the level of this protein in U87 cells. In this work, however, we 
found that the level of PrP
c
 was not affected in treated cells (Figure 7-8). It has been 
reported that 9-aminoacridine, phenothiazine and other tricyclic derivatives exhibited 
an excellent binding to PrP
c
 through specific amino acid residues
294,281
. Furthermore, 
the previous work for the group revealed that some analogues of 9-aminoacridines 
could bind PrP
c
 according to surface plasmon resonance (SPR) binding assay
281
.  
To our knowledge, this is the first study concerning the effect of the acridine 
compound on glioblastoma cells. Due to the effect of compound 175 on U87 cells, 
however, further investigation should be carried out to investigate the impact of 9-
aminoacridine derivatives on glioblastoma cells. Furthermore, the other eight 
compounds which induced cytotoxicity to U87 cells need further study to determine 
the cause of their cytotoxic effect. 
To conclude, 30 compounds were tested as anti-glioblastoma. Eight of these 
compounds reduced the viability of U87 cells. Compound 175 decreased the 
proliferation of cells by IC50 = 10.9 μM after five days. It also increased the apoptosis 
rate of U87 after 48 h. In addition, compound 175 arrested the cells in G2/M and 
accumulated p53 and p21 in a dose-dependent manner. This compound belongs to the 
acridine derivatives, and this work is the first to examine an acridine compound in the 
context of glioblastoma cells. More in-depth work is needed, however, to investigate 
the effect of acridine compounds as anti-glioblastoma treatment.  
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Chapter 8: General discussion, Conclusions and Future perspectives  
Glioblastoma is an aggressive and fatal disease that affects brain cells. It is more 
resistant to chemotherapy than other astrocytomas. Currently, TMZ and BCNU with 





has been reported to be implicated in GBM and PRNP gene is highly expressed in 
GBM than other brain cancers
5
. Despite this, the precise physiological role of PrP
c
 is 
still unclear. It is involved in many cellular functions such as apoptosis and 
proliferation. PrP
c
 is linked to resistance towards treatments for many cancers cells
3
 
and notably, it has been implicated in causing resistance to TMZ in glioblastoma 
cells
6
.  However, an in-depth investigation of PrP
c
 and its gene expressions affected 
by GBM treatments; TMZ and BCNU, were yet under covered. In this thesis, 
experiments were carefully designed to evaluate the level of PrP
c
 in glioblastoma cell 
line U87 treated with alkylating agents, TMZ and BCNU. The effects of alkylating 
agents on cells with PrP
c
 knockdown were also investigated. The impact of 
proteasome inhibitor MG132 on PrP
c
 apoptosis, proliferation and sensitisation in 
U87cells treated with TMZ were also evaluated. Further investigations were carried 
out to evaluate the polypharmacological effects of combinations of TMZ or BCNU 
with novel small molecules that suppress the FA pathway on PrP
c
 level.  Cytotoxic 
studies of novel small molecules (30 compounds) that are active against embryonic 
carcinoma (EC) cells NTera 2 and U87 cells were also performed to evaluate their 
potentials as anti-GBM agents and their effects on PrP
c
. In the following sections, the 
main findings of this thesis are discussed. 
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8.1 The level of PrP
c
, its gene expressions and cell cycle phases change in U87 
cells treated with TMZ or BCNU 
The effects of alkylating agents TMZ and BCNU on the level of PrP
c
 in U87 cells 
were evaluated based on our hypothesis that PrP
c
 level may be increased during G2/M 
phase induced by the alkylating agents.  
Our results confirmed that Aphidicolin and Nocodazole arrest U87 cells in G1 and 
G2/M respectively. These treatments are commonly used to synchronise the 
eukaryotic cells in G1 (Aphidicolin)
222
 and G2/M (Nocodazole)
223
 phases. These 
experiments were performed to produce a model of G1 and G2/M cells which were 
used to evaluate the PrP
c
 level in these cells and to validate the data resulting from the 
treatment of the cells with TMZ and BCNU. Our results revealed that TMZ and 
BCNU arrested U87 cells in G2/M in a time-dependent manner. The accumulation of 
cells in G2/M phase increased when treated cells were incubated without the 
treatment. BCNU has more potency to arrest the cells in G2/M at 12h, 24h, 6h+24h 
and 12h+24h and the trend was similar for TMZ in the rest time points.  Generally, it 
has been found that TMZ and BCNU arrested U87 cells in G2/M
224,202
. The G2/M 
arrest of U87 could be ascribed to the upregulation of p53 and p21, regulators of the 
cell cycle, resulting from DNA damage by TMZ or BCNU. We found that p53 and 
p21 levels were significantly upregulated in treated cells with TMZ or BCNU. It was 
also found that p53 and p21 were accumulated in U87 cells in response to TMZ and 
BCNU
224,202
. Our results are in agreement with those reported.  
The levels of PRNP and PrP
c
 were evaluated in U87 cells synchronized at G1 and 
G2/M by Aphidicolin and Nocodazole respectively, as well as in U87 cells treated by 
TMZ or BCNU at different time points (6h+24h, 24h, and 24h+48h).  Our results 
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showed that PRNP gene expression was significantly increased in synchronized cells 
by Nocodazole (i.e. G2/M cells) and in treating cells with TMZ (6h+48h), while the 
protein level was not affected. Furthermore, cells treated with TMZ and BCNU 
(24h+48h) were significantly upregulated, whereas the protein levels were 
significantly downregulated. PrP
c
 may protect the cells from pro-apoptotic or DNA 
damage stimuli such as chemotherapy
184
.  
Overall, TMZ and BCNU arrested the U87 cells in G2/M and altered the level of 
PRNP and PrP
c
 but TMZ upregulated the PRNP gene to a higher level than BCNU. 
The induction of the PRNP gene in treated cells may be ascribed to G2/M 
accumulation induced by TMZ or BCNU. It has been found that PrP
c
 and its gene 
were upregulated in G2/M cells mediated by TMZ. According to array hybridization 
assay, PRNP was one of the group of genes that were upregulated in G2/M 
synchronized cells
6
. However, these findings were inconsistent with our results in 
respect to the protein level. The study of PrP
c
 in glioblastoma cells treated with both 
TMZ and BCNU treatments has not been previously reported.  Thus, the 
downregulation of PrP
c
 in treated cells could be attributed to different reasons. A 
possible reason may be that the protein could be degraded due to the higher 
expression of the PRNP gene. In addition, cells remaining for a long period at G2/M 
phase may affect the translation of this gene.  
We concluded that BCNU is more potent in accumulating U87 cells in G2/M than 
TMZ. The accumulation of cells in G2/M phase may be attributed to the increase of 
the level of p21 and p53 which are regulators of the cell cycle. PRNP gene was 
elevated in treating cells with Nocodazole, which synchronizes cells in G2/M phase, 
whereas there is no significant change in the gene level in treated cells with 
Aphidicolin that arrested the cells in G1 phase. In addition, PRNP gene expression 
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was upregulated in treating cells with alkylating agents, 24h and 48h post-treatment. 
This may be an indication of may perhaps be due to the cytoprotective function of 
PrP
c
, suggested by other previous studies. PrP
c
 expression under this condition was 
downregulated and these results were not in agreement with the gene expression 
results. This reduction of PrP
c
 may be attributed to the degradation of this protein or 
the competition of other genes in translation. 
Further studies could be carried out to evaluate PRNP, and PrP
c
 using different types 
of glioblastoma cells such as U251 and T98G treated with TMZ or BCNU in a dose 
and time-dependent manner, with and without post-treatment. The accumulation of 
cells in G2/M phase may induce the resistance to chemotherapy, and the level of 
PRNP may increase in this cell phase. Therefore, apoptosis and proliferation assays 
may help to investigate whether upregulation of PrP
c
 promotes or inhibits the 
apoptosis rate. It is also possible that the combination of TMZ or BCNU with 
Aphidicolin may decrease the level of G2/M cells, which may improve the sensitivity 
of cells toward these treatments.  Furthermore, more investigation is needed to detect 
PrP
c
 after prolonged cell arrest at G2/M by these treatments.  
8.2 Knockdown of PRNP inhibits the proliferation of U87 cells 
As mentioned in the previous section (8.1) the levels of PrP
c
 and its gene were altered 
in response to alkylating agents. The effect of PrP
c
 levels in treated glioblastoma cells 
with these agents has not been studied yet. We speculated that knockdown of PrP
c
 
may reduce cell proliferation and induce apoptosis rate in untreated and treated cells 
with alkylating agents due to its anti-apoptotic effect in many cell types. Hence, 
knockdown experiments were performed in U87 cells to investigate the effect of this 
gene in untreated and treated cells with alkylating agents. These experiments showed 
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80% knocking down after 48h using siRNA, and the silencing continued after 5 days.  
It has been found that PRNP siRNA reduced the level of PrP
c
 in T98G glioma cells 
after 48h by approximately 80%
18
. Silencing of the PRNP gene in U87 cells inhibited 
the proliferation of untreated cells and did not improve the proliferation in treated 
cells. In addition, our results also showed that knockdown of PrP
c
 in U87 did not 
affect apoptosis in both untreated and treated cells. The effect of PrP
c
 knockdown on 
the proliferation of untreated U87 cells may be attributed to the PI3K/Akt pathway 
and Cyclin D1 protein which may be regulated and activated by PrP
c169
. Li et al. 
found that silencing of PrP
c
 in J889 glioblastoma cells reduced the proliferation and 
induced the apoptosis of these cells
185
. Another study showed that suppressing PrP
c
 in 
many glioblastoma cells using DNA-antisense oligonucleotide decreased cell 
proliferation
184
. The effect of PrP
c
 on cell proliferation depends on the cell type as 
reviewed in section (1.7.2.5). For instance, silencing of PRNP in gastric cancer cells 







 in gastric carcinoma cells AGS induced 
apoptosis by activation Bax and p53
227
. Zhuang et al. revealed that knockdown of 
PrP
c
 in U87 cells increase the apoptosis rate when treated with TMZ through 
activation of caspase 3
6
. The knockdown of PrP
c
 in breast cancer cells MDA-MB-435 
did not induce resistance to chemotherapies (paclitaxel and staurosporine) that 
induced apoptosis
8





cancer cells. In addition, the knockdown of 
PRNP in astrocyte cells promoted sensitivity to staurosporine
239
. 
Further investigations were performed to elucidate the effect of PRNP knockdown on 
U87 cells. The knockdown cells were treated with TMZ for 48h to evaluate the cell 
cycle phases and the level of p53 and p21, the regulators of the cell cycle. Results 
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here showed that the population of treated knockdown cells was less arrested in G2/M 
than treated control or scramble cells. This may be ascribed to the level of p53 and 
p21 where the G2/M arrest in glioblastoma cells required both of these proteins
233
. 
The results showed that these proteins were upregulated, but it is interesting to note 
that p21 was more upregulated in treated knockdown cells than cells treated with the 
scrambled control. These findings have not been reported in the literature before. The 
high level of p21 may induce G1 arrest due to its effect on cyclin-dependent kinases 
(CDKs). It has been reported that p21 may protect many types of cells from 
apoptosis
235
. Other studies reported that the induction of p21 in glioblastoma cells 
induces resistance to cisplatin and BCNU
234
. In addition, p21 may be considered as an 
oncogene due to its effect as a pro-cancer and antiapoptosis
242,235
. Therefore, it is 
possible that p21 induces the resistance to alkylating agents and this resistance may be 
undetectable by MTT assay. 
In conclusion, this is the first study to evaluate the effect of PRNP knockdown on U87 
cells treated with TMZ or BCNU. The level of knockdown was approximately 80% 
after 48h. Knockdown of PrP
c
 significantly reduced the proliferation of U87 but did 
not induce cell proliferation in treated cells with TMZ or BCNU. Furthermore, the 
knockdown of PrP
c
 did not induce apoptosis in untreated and treated U87 cells with 
TMZ. In TMZ treated knockdown cells, the distribution of cell populations in cell 
cycle phases was changed in relative to treated scramble and control cells. 
Surprisingly, the expression of p21 was significantly upregulated in the treated 
silencing cells with alkylating agents and this upregulation may induce the resistance 
to TMZ and BCNU.  
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For future perspective, the effect of PrP
c
 knockdown on the resistance to alkylating 
agents needs further study. PrP
c
 in two types of glioblastoma cells (one of which has a 
wild type p53, and the other group has a mutant p53) can be silenced and then treated 
with TMZ or BCNU at different time points. Cell cycle assay can be used to quantify 
the cells in each phase. The results of cell cycle assay correlate with the level of p21 
and p53 which regulate the cell cycle and have an active role in the apoptosis. 
Furthermore, apoptosis markers such as Bax and caspase 3 could be evaluated to 
explain whether the knockdown of the PRNP gene induces resistance or promotes 
sensitivity of cells toward alkylating agents.      
8.3 Proteasomal inhibitor, MG132, does not improve the apoptosis when 
combined with TMZ but it affects PrP
c
 level in U87 cells   
Several proteasome inhibitors such as MG132, lactacystin and bortezomib (PS341) 
have been reported to decrease cell proliferation and induce apoptosis through their 
effects on many survival pathways
260
. MG132 reduced cell proliferation and promoted 
the apoptosis of many glioblastoma cell lines
255,256
. The combination of MG132 with 
cisplatin improved apoptosis in several cancer cells such as human oesophagal cancer 
cells
257
. The combination of MG132 with TMZ has not been investigated yet. It was 
hypothesised that this combination may sensitise U87 cells to TMZ. Furthermore, 
ERAD is a ubiquitin/proteasome system that blocks unfolded and misfolded proteins 
in the ER. MG132 may induce ER stress, reducing the translocation of PrP
c
 and 
causing an accumulation of nascent PrP
14
 or cytosolic PrPc
259
. We also speculated 
that MG132 may upregulate PrP
c
 in U87 cells.    
Our results showed that MG132 significantly decreases the growth of U87 cells with 
IC50 values of 2.26 μM after 48h. The combination of MG132 with TMZ did not 
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reduce the proliferation of cells compared to MG132 alone. The reduction of cell 
growth could be related to the apoptotic effect of MG132. It has been found that 
MG132 reduces the viability of many glioblastoma cells with a different IC50 
depending on cell type through differing survival pathways, but did not affect 
astrocytes
256,13
. The results for the combination with TMZ have not been previously 
reported.  
Further investigations have been performed to evaluate the effect of MG132 on U87 
cells. MG132 induced apoptosis in U87 cells whereas there is no significant change in 
the apoptosis rate when compared with the combination of MG132 with TMZ. 
MG132 arrested the cells in the G2/M phase and induced the level of p53 and p21. 
The combination treatment did not exhibit any significant change in cell cycle or the 
level of these proteins compared to single treatment with MG132. The accumulation 
of p53 and p21 could be explained by the apoptotic effect of MG132 where these 
proteins are upregulated in response to cytotoxic stimuli and may promote the 
apoptosis. p53 plays an important role in cell cycle regulation and apoptosis. It has 
been shown that MG132 induced p53-dependent apoptosis in glioblastoma cells and 
upregulated caspase 3, particularly in p53 wild type cells
261,12,256
. The effects of the 
combination of TMZ and MG132 on U87 cells have not been previously studied. 
Although the targets for MG132 and TMZ are different, the mechanisms of the 
actions could possibly be that MG132 competes or counteracts TMZ. It has been 
found that the combination of cisplatin with MG132 sensitised different cancer cells 




Further studies were carried out to study the effect of MG132 on PrP
c
 in U87 cells. 
MG132 increases the level of PrP
c
 in U87 cells, and this action may be attributed to 
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the ability of this treatment to reduce protein degradation resultant from the pathway 
of ERAD. Yifat et al stated that MG132 upregulated the level of PrP
c
 in CHO-MHM2 
and N2a cells due to resistance of PrP
c
 to proteolysis by ERAD
14
. Other studies found 
that MG132 increased cytosolic 27-34 kDa of PrP
c
 in Hela-PrP, N2a-PrP and N2a cell 
lines. This has been associated with disruption of the proteasome function that results 
in the unfolded protein response (UPR) in a sequence to ER stress
259
.  
To summarise, despite the effect of MG132 on cell proliferation and apoptosis, its 
combination with TMZ showed that there is no accumulative effect on U87 cells. 
Therefore, it implies that the combination treatment of MG132 and TMZ may 
counteract the effect of TMZ. Furthermore, MG132 affected the metabolism of PrP
c
 
and then increased its level.  
Further investigations could be carried out to elucidate the exact effect on PrP in U87 
cells (cell surface and intracellular). For example, immunostaining using MG132 and 
other types of proteasome inhibitors could be used. In addition, pre-treatment with 
MG132 followed by treatment with different concentrations at various time points 
could be performed to sensitise U87 cells to TMZ treatment.   
8.4 Novel FAPi (FA pathway inhibitors) small molecules do not affect the level of 
PrP
c
 in U87 cells  
FA pathway is one of the DNA repair pathways that is activated through DNA 
replication or in response to DNA lesion
295
. This pathway is induced in glioblastoma 
cells treated with TMZ and BCNU by upregulating FANCD2, the key part of this 
pathway
16
. Previous work from our group (Drs. Matthew Sellwood and Peng HUA) 
showed that FAPi compounds inhibit the FA pathway in U87 cells (induced by TMZ 
or BCNU) by reducing the expression of FANCD2 (unpublished data). These 
Chapter 8: General discussion, Conclusions and Future perspectives 
- 209 - 
 
compounds, which have an amide group with different substitution groups, may have 
an ability to hit PrP
c
 in glioblastoma cells
18
. Therefore, we speculated that these 
compounds may disrupt PrP
c
 pathway.    
In this work, we used ICC by ImageXpress Micro as high content small molecule 
screening method to evaluate PrP
c
 in treated cells. To our knowledge, this is the first 
time that this method was performed to evaluate the PrP
c
 level in glioblastoma cells. 
Therefore, it was validated using different concentrations of two types of prion protein 
antibodies (3F4 and 8H4) which are commonly used in immunofluorescent 
staining
273,184
. Our results showed that both of these antibodies are suitable for 
screening.   
The screening of FAPi compounds in combination with or without TMZ or BCNU 
did not show any reduction of PrP
c
 level in treated U87 cells after 48h (8h with FAPi 
compounds and 40h in combination with TMZ or BCNU). Michael et al. found that a 
group of some amide analogs and other molecules decreased the level of PrP
c
 in 
glioblastoma cells T98G and the hits that lower PrP
c
 level on cell surface were 
confirmed using ELISA
18
. Despite the negative results, ICC by ImageXpress Micro 
screening assay is a useful technique to examine many compounds that have a 
possible potential to lower the expression of PrP.  
To conclude, many compounds of benzimidazole derivatives (FAPi compounds) were 
synthesised and purified by previous members of the group. In a separate study, it was 
found by the other member of the group (Drs.  Matthew Sellwood and Peng HUA) 
that these small molecules inhibited the FA pathway by downregulation of FANCD2 
protein in treated U87 cells with TMZ or BCNU. In our work, PrP
c
 level was assessed 
in U87 cells treated with FAPi compounds, and in combination with TMZ or BCNU 
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using ICC by ImageXpress Micro. These compounds however did not show any 
significant changes.  
Further experiments could be performed to assess the effect of FAPi compounds on 
PrP
c
 level in glioblastoma cells. For instance, the duration of treatment could be 
extended. Other biochemical assays such as flow cytometry, western blot and ICC by 
confocal microscopy may be carried out to confirm the findings of this study.   
8.5 Novel small molecules are cytotoxic to U87 cells 
Heteroaromatic molecules are an important class of heterocyclic compounds, which 
have a wide range of biological activities such as anticancer
279
. The anticancer activity 
of several compounds is associated with their ability to activate some signalling 
pathways that promote cell death
280
. In this work, we examined groups of small 
molecules of heteroaromatic compounds (30 compounds) on U87 cells. According to 
previous work of the group, these molecules exhibit a cytotoxic effect on 
teratocarcinoma stem cells NT2. Therefore, we hypothesized that these compounds 
may have efficacy to induce cell death in U87 cells.  
Our results showed that 8 of these compounds exhibited a cytotoxic effect on U87 
cells. To further investigate the mechanism of toxicity, apoptosis assay using Annexin 
V and PI was employed. Only one compound (175) induced apoptosis of U87 cells. 
Besides, compound 175 inhibits the viability of U87 cells with an IC50 value of 10.9 
µM, according to MTT assay. This compound belongs to acridine 9-aminoacridine 





 and pancreatic cancer
288,289
. To our knowledge, 
these derivatives have not been tested against glioblastoma cells.  
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The effect of compound 175 on U87 cells was further studied. Cell cycle assay 
showed that this compound arrests the cells in G2/M, which supports the cell viability 
findings where the G2/M arrest decreases cell proliferation. The G2/M arrest may be 
ascribed to the interaction of compound 175 with DNA through intercalation. Several 
studies have previously shown that some acridine compounds intercalate with DNA 
by the amine group and this action may cause cytotoxicity
283,284
. Furthermore, several 
9-aminoacridine derivatives compounds were found to inhibit topoisomerase II (topo 
II) that participates in the over-winding or under-winding of DNA
283,290,291
. The 




Due to G2/M accumulation resulting from compound 175; p53 and p21 were 
evaluated in treated cells. Both of these proteins were upregulated, and this 
upregulation may be resultant of the toxicity to compound 175, where p53 and p21 
were induced in response to DNA damage. It has been found that p53 induced G2 
arrest in response to the inhibition of topo II
293
. Additionally, the induction of p53 in 
treated cells with compound 175 may induce apoptosis of U87 cells, and this effect 
was supported by the results from the Annexin V assay. Wang et al. found that 9-
aminoacridine derivatives increased the apoptosis rate in several cancer cells via 
upregulating p53 and Bax
286
. p53, as a tumour suppressor protein, is accumulated in 




On the other hand, it was expected that this compound may reduce PrP
c
 level due to 
its binding to prion protein as previously observed. Surprisingly, compound 175 did 
not change the expression of PrP
c
 in U87 cells. Other studies showed that 9-
aminoacridine derivatives bind to PrP
c
 through specific amino acid residues (Tyrosine 
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225, Tyrosine 226, and Glutamine 227)
294,281
. In addition, according to SPR assay, the 




To summarise, several novel heteroaromatic compounds from the libraries (30 
compounds) synthesised by the previous members in the group, were tested as new 
anti-glioblastoma agents. These compounds previously exhibited cytotoxicity effects 
on NT2 cells. In our work, 8 of these molecules induced toxicity in U87 cells. 
Compound 175 (acridine derivative) has the efficacy to reduce cell viability with an 
IC50 value of 10.9 μM and increased the apoptosis rate of U87 cells.  It also arrested 
the cells in G2/M and upregulated p53 and p21 levels.  
To our knowledge, this is the first study concerning the effect of the acridine 
compounds on glioblastoma cells. Therefore, further studies are required to 
investigate other acridine derivatives as potential anti-glioblastoma agents. Many 
biological tests may be applied to investigate the apoptotic pathway of these 
compounds. For example, caspase 3 is a useful biomarker to determine the apoptosis 
of treated cells. Pro-apoptotic factors such as Bax, Bak and Bcl-X or anti-apoptotic 
factors such as Bcl-2 and Bcl-XL can also be estimated using western blot.
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